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DEVELOPMENT OF A HIERARCHICAL ELECTROSPUN SCAFFOLD FOR LIGAMENT 
REPLACEMENT 
 
The anterior cruciate ligament (ACL) is a dense collagenous structure that connects the femur to 
the tibia and is vital for joint stability. The ACL possesses complex time-dependent viscoelastic 
properties and functions primarily to prevent excessive translations and rotations of the tibia 
relative to the femur. It is estimated that 400,000 ACL tears occur in the United States annually 
and the monetary burden of these injuries and their subsequent treatment is approximately $1 
billion annually. After injury allografts and autografts are commonly implanted to reconstruct the 
torn ACL in an attempt to restore joint stability, prevent pain, and limit damage to surrounding 
tissues. However surgical reconstructions fail to completely restore knee functionality or prevent 
additional injury and regardless of intervention technique radiographic osteoarthritis is present in 
13% of patients 10 years after ACL rupture. 
 
Drawbacks to traditional treatments for ACL ruptures motivate the development of a synthetic 
ACL replacement. Tissue engineering is the use of a scaffold, cells, and signaling molecules to 
create a replacement for damaged tissue. The goal of this work is to develop a polymer scaffold 
that can be utilized as a replacement for the ACL. A tissue engineered ACL replacement should 
replicate the hierarchical structure of the native ACL, possess reasonable time zero mechanical 
properties, and promote the deposition of de novo collagenous tissue in vitro. Additionally, the 
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scaffold should be implantable using standard surgical techniques and should maintain in situ 
tibiofemoral contact mechanics. Thus, four specific aims are proposed: 
 
1) Fabricate and characterize an aligned 3-dimensional electrospun scaffold for ACL 
replacement. 
2) Assess the in vitro behavior of ovine bone marrow-derived stems cells seeded on the 
scaffold in the presence of conjugated growth factor. 
3) Evaluate the performance of the electrospun scaffold using uniaxial mechanical testing. 
4) Assess the effect of the electrospun scaffold on ovine stifle joint contact mechanics. 
 
Development of a tissue engineered ACL replacement that mimics the structure and function of 
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1.1 ACL Anatomy and Structure 
The knee joint consists of three major bones: the femur, the tibia and the fibula1 (Figure 1.1). The 
anterior cruciate ligament (ACL) of the knee is a dense collagenous structure that connects the 
femur to the tibia. Along with the posterior cruciate ligament (PCL), the medial collateral lateral 
ligament (MCL), and the lateral collateral ligament (LCL), the ACL is one of the major 
stabilizing ligaments of the knee and it functions primarily to prevent excessive translations and 
rotations of the tibia relative to the femur2. The integrity of the ACL is vital for proper joint 
function. 
Figure 1.1: General knee anatomy. Reprinted with permission from Makris et al. 20111. 
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1.1.1 Anatomy and Physiology 
The attachment sites of the ACL to the femur and tibia fan out over a broad flattened area. The 
femoral attachment of the ACL is found on the posterior-lateral condyle of the femur. In humans, 
the attachment site is ovular and covers an area of approximately 2cm2 3. From the femur, the 
ACL spirals towards the tibia where it inserts at the anterior-medial aspect of the tibia over an 
area of approximately 3cm2 3. In humans, some of the fibers of the tibial attachment may blend 
with the anterior horn of the lateral meniscus4,5. Odensten et al. reported the total length of the 
ACL in humans to be 31±3 mm with a thickness of 5±1 mm and a width of 10±2 mm6.  
 
The ACL has been characterized as consisting of two bundles: an anteromedial bundle and a 
posterolateral bundle4. The fibers of the anteromedial bundle begin at the proximal portion of the 
femoral attachment and attach to the anteromedial portion of the tibial attachment. The 
posterolateral bundle begins more distally on the femoral attachment and attaches to the 
posterolateral portion of the tibial attachment. When the knee undergoes flexion and extension 
during normal joint movement the tensioned portion of the ligament changes5. When the knee is 
extended the posterolateral bundle is taut and the anteromedial bundle is relatively lax (Figure 
1.2a). However, as the knee is flexed the posterolateral bundle loosens and the anteromedial 




The ACL attaches to the femur and tibia at graded attachment sites where the collagen fibers of 
the ligament transition into the subchondral bone, often called an enthesis. Entheses exhibit 
gradients in tissue composition, structure and mechanical properties which allow forces to be 
effectively transferred between the compliant ligament tissue and stiff bone tissue without the 
development of stress concentrations7. Four distinct tissue zones are present in the ACL 
entheses: ligament, uncalcified fibrocartilage, calcified fibrocartilage, and finally subchondral 
bone. Collagen fibers that compose the ligament transition first to uncalcified fibrocartilage. The 
tidemark represents the point of calcification after which there is a much higher mineral content 
present in the calcified fibrocartilage. The calcified fibrocartilage finally attaches to the 
underlying subchondral bone at an interdigitated cement line. The transition from ligament to 
subchondral bone occurs over a region of ~200 µm and the structural organization of the enthesis 
Figure 1.2: Tension of the ACL anteromedial bundle (A-A’) and posterolateral bundles (B-B’) 










allows for the effective transfer of stresses between the compliant ligament tissue and the relative 
stiff subchondral bone8. 
 
1.1.2 Composition and Hierarchical Structure 
The ACL is primarily composed of collagen fibers that are arranged in a complex hierarchical 
structure (Figure 1.3). The smallest functional unit of the ACL is collagen fibrils that vary in size 
from 50-500 nm9. Similar to other tendons and ligaments, the collagen fibrils of the ACL have a 
characteristic crimped structure which contributes to the tissue biomechanics. Although the 
majority of collagen fibrils are oriented parallel to the long axis of the ligament, there are some 
fibrils running in the transverse direction. Many collagen fibrils are grouped together to form 
collagen fascicles with are generally 100-500 µm in size and are surrounded by epitenon, a loose 
connective tissue9. Finally, ~20 collagen fascicles are grouped together to form the entire 
ligament2. A thicker connective tissue, called paratenon, surrounds the entire ligament and 
blends with the epitenon. The hierarchical structure of the ACL is thought to be vital for its 
proper mechanical function3. Type I collagen is the major type of collagen found in the ACL and 
it is largely responsible for the tensile strength of the ligament10. Type II collagen, characteristic 
of cartilage, is only present in the fibrocartilage of the ACL enthesis. Type III collagen is present 




Although the ACL is not a highly cellularized ligament there are some cells present throughout 
the tissue. The most proximal portion of the ligament contains many round ovoid cells and some 
fusiform fibroblasts10 (Figure 1.4A). The central portion of the ACL, also called the fusiform 
zone, contains a low density of fusiform and spindle-shaped fibroblasts among the high-density 
collagen fibers12 (Figure 1.4B). These spindle-shaped fibroblasts possess an elongated 
morphology and are closely attached to the surrounding collagen. The distal portion of the 
ligament contains chondroblasts, which closely resemble cartilage cells, ovoid fibroblasts, and a 
lower density of collagen fibers (Figure 1.4C).  






Figure 1.4: Histological images of the ACL showing the cellularity of the proximal portion 




There are very few vessels that supply blood to the ACL, which contributes to its low healing 
capacity after injury. The ligament is surrounded by a synovial membrane which is vascularized 
by small periligamentous vessels. These vessels primarily originate from the middle genicular 
artery and extend into the ACL with a transverse orientation before branching into a network of 
vessels that lie parallel to the collagen fibers of the ACL4,10. The ACL also possesses some nerve 
innervation, specifically from branches of the tibial nerve13. These fibers are primarily blended 
with the periligamentous blood vessels and are similarly oriented parallel to the collagen fibers. 
It is hypothesized that some of the mechanoreceptive nerve fibers in the ACL may have 
proprioceptive and sensory functions14. Very few free nerve endings have been identified in the 
ACL, which may account for the lack of pain experienced by individuals immediately after a 
rupture of the ACL13. 
 
1.1.3 Mechanical Function and Material Properties 
The ACL functions primarily to prevent excessive movement of the tibia relative to the femur 
during knee motion15. Under normal conditions, the ACL prevents the tibia from displacing 
anteriorly relative to the femur. In a knee with a ruptured ACL, the anterior translation in 
response to an applied load is four times greater than in normal knees16,17. Clinically, an “anterior 
drawer test”, where an anterior force is applied to the tibia, is used to test for the presence of an 
ACL tear18,19. The secondary function of the ACL is to prevent internal rotation of the tibia 
relative to the femur, particularly when the knee is fully extended. Additionally, the ACL 
functions to prevent a combination of external tibial rotation and varus-valgus motion under 
weight-bearing conditions. Clinically, a “pivot shift test”, where internal rotation and valgus 
torque is applied to the tibia, is also used to test for an ACL rupture18,19. During normal gait, the 
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force experienced by the ACL varies depending on the point of the gait cycle. Based on 
musculoskeletal modeling the peak force in the human ACL occurs at the beginning of the single 
leg stance and is ~300 N and the ACL remains loaded throughout the entire gait cycle20. The 
strain behavior of the ACL also varies throughout the gait cycle but has been shown to not 
exceed strains of 4%21. 
 
Based on the importance of the ACL during knee movement a number of studies have been 
conducted to assess its tensile properties. Noyes and Grood performed tensile pull to failure tests 
of the ACL with the attached tibial and femoral bone blocks and found that in young cadaveric 
samples (aged 22-35) the average modulus was 111±26 MPa and the average maximum stress at 
failure was 37.8±9.3 MPa22. Interestingly in older adults, the modulus and failure stress were 
significantly reduced to 65.3+24 MPa and 13.3±5 MPa respectively, suggesting that age-related 
degenerative changes may influence ACL material properties. To investigate the effect of sex on 
ACL material properties Chandrashekar et al. assessed the material properties of femur-ACL-
tibia complexes from middle-aged (average age 38 years) men and women23. The ACLs from 
male cadavers were found to be significantly stiffer and have a higher failure load than ACLs 
from female cadavers. These differences in material properties could explain the injury 
discrepancies that have been reported between males and females, with females experiencing 
ACL ruptures nearly three times as often as males24. Work has also been done to characterize the 
material properties of the sub-structures that compose the ACL by conducting tensile testing on 
individual ACL fascicles as well as the separate ACL bundles25,26. The substructures of the ACL 
were found to be, for the most part, stiffer than the ACL as a whole, suggesting that the 
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interactions between the substructures during whole tissue movement may alter the whole tissue 
material properties25,26. 
 
Similar to many other ligaments, the ACL possesses complex time-dependent viscoelastic 
properties that are dependent on the collagen fibers and matrix materials, primarily elastin, that 
compose the tissue27. The first region of the load-elongation curve is a linear region of low 
stiffness where the elastin fibers are loaded and the collagen fibers are not yet engaged (Figure 
1.5). The second region consists of a non-linear toe region where the collagen fibers are 
beginning to undergo reversible un-crimping. In the third region of the loading curve the 
collagen fibers are completely un-crimped and taut, which results in a constant higher stiffness28. 
Finally, in the fourth region, the collagen fibers have ruptured and thus the stiffness increases 
prior to complete failure. The time-dependent response of the ACL often manifests as creep, 
change in the length of the ACL when exposed to a constant load, stress relaxation, a decrease in 
measured load experienced by the ACL at a constant level of strain, and hysteresis, energy 
dissipation with continual loading and unloading29,30. These viscoelastic properties are important 
to take into consideration when assessing an appropriate replacement for a ruptured ACL since 




1.2 ACL Injuries and Treatments 
1.2.1 Epidemiology 
It is estimated that up to 400,000 ACL tears occur in the US each year32.  There is a higher 
incidence of ACL tears in females compared to males, and nearly 3 times as many women tear 
their ACLs as men24. Hypothesized risk factors for this difference include decreased femoral 
intercondylar notch size, which may cause ACL impingement and excessively valgus (knock-
kneed) anatomy33. Many ACL tears occur in athletes, particularly those participating in alpine 
skiing, soccer, basketball, and football34. The incidence of ACL injuries decreases with as a 
person ages, potentially because of a decrease in sports participation35. 
 
About 70% of ACL ruptures occur due to “non-contact” scenarios where there is no direct insult 
to the knee joint. These injuries can occur when a person experiences a jump landing or a lateral 
cutting maneuver which are both common during sports such as soccer and basketball36 (Figure 




















1.6). During a jump landing, a rupture of the ACL may occur when the knee is in a shallow state 
of flexion and the tibia translates too far anteriorly, allowing the femur to begin to slide 
posteriorly off the tibial plateau, rupturing the ACL (Figure 1.6A). Additionally, if a knee 
undergoes simultaneous valgus and internal rotation of the tibia, such as during a cutting motion, 
the combined loading mechanism could cause the ACL to rupture (Figure 1.6B). ACL ruptures 
typically occur in conjunction with damage to the surrounding tissues, including the menisci, 




Figure 1.6: Examples of motions that frequently cause ACL ruptures: jump landing (A) 




Each year in the US between 100,000 and 400,000 patients undergo ACL surgeries32. 
Additionally, because only one-third of ACL tears occur with no concomitant injuries, an ACL 
rupture surgery often involves additional procedures38. For example, a study of patients in New 
York State reported that 32% of all patients who underwent surgery for an ACL rupture also 
required treatment of a meniscal injury, which increases surgical time and costs35. The cost of an 
ACL surgery depends on a number of factors including the type of graft used, the source of the 
graft, and graft processing. An ACL reconstruction using an autograft, where the graft is 
harvested from the patient’s own body, typically costs $5,000-$6,000 and an ACL allograft, 
where the graft is obtained from a donor, costs $6,000-$7,00039. Should a primary ACL graft 
fail, a revision surgery is often even more expensive and can cost roughly $20,00040. Including 
all surgical and rehabilitation costs, the estimate for treating ACL injuries in the use is $1.7 
billion annually33. 
 
1.2.2 Treatments and Outcomes 
Rupture of the ACL results in significant alterations to knee joint kinematics. During normal 
activities, a joint with a ruptured ACL often has an increased anterior translation of the tibia as 
well as more internal tibial rotation15,16. Because the ACL is one of the primary joint stabilizers, 
when it is ruptured the stabilizing role is transferred to the surrounding joint structures, including 
the bone, cartilage, menisci, and other major ligaments such as the MCL and PCL41. The 
alteration of knee kinematics and transition of load to surrounding tissues may cause the tissues 
to be more susceptible to damage and degradation42. Thus, if left untreated, ACL ruptures often 
lead to pain, feelings of instability, bone bruising and occult tissue damage. The prevalence of 
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radiographic knee osteoarthritis has been reported to be 60%-90% at 10-15 years after injury for 
patients who receive conservative (i.e. non-surgical) treatment43–45. 
 
 The standard surgical treatment for an ACL rupture is to remove any remaining tissue and 
reconstruct the ACL with a free tendon graft. The tendon graft is put in place through bone 
tunnels in the femur and tibia and anchored at the bone ends. A number of factors associated 
with the ACL reconstruction surgery including the placement of bone tunnels, the pre-tensioning 
of the graft, the fixation method, and the fixation strength can vary among patients and may 
significantly affect surgical outcomes46. The two most common types of ACL grafts are 
autografts, where tissue is harvested from the patient, and allografts, where donor tissue is used. 
For autografts, the most common choices are the patellar tendon with attached bone blocks or 
semitendinosus-gracilis tendons. Bone-patellar tendon-bone grafts are advantageous because the 
attached bone blocks allow for graft fixation within tibial and femoral bone tunnels which can 
improve healing and stability47. However, meta-analyses have reported no significant differences 
in clinical outcomes between patellar tendon and semitendinosus-gracilis tendon grafts48,49. The 
major drawback to autografts is that the tissue must be harvested from the patients’ own body 
which necessitates a second surgical site and can result in donor site morbidity, pain and muscle 
weakness. In contrast, ACL allografts are tissues that are obtained from donor cadavers. Tendons 
used for allografts include the semitendinosus tendon,  the gracilis tendon, and the Achilles 
tendon50 (Figure 1.7). The major drawback to allografts is that the physical and chemical 
processing techniques used to sterilize and store the donor tissue may affect tissue integrity and 
alter the material properties51. A meta-analysis found that when autograft and allograft bone-
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patellar-bone grafts were compared, patients who received an allograft were more likely to 
rupture the graft and score lower on functional tests52.  
 
Regardless of reconstruction technique, at 10 years follow up, up to 13% of ACL reconstruction 
patients display signs of radiographic knee osteoarthritis53. The prevalence of radiographic knee 
osteoarthritis increases to 21%-48% if the ACL tear occurs in combination with an injury to the 
meniscus54. Poor outcomes of ACL reconstruction may be attributed to failure to match the 
material properties of the ACL, failure to restore normal joint kinematics or a lack of a biological 
healing cascade55. Undesirable outcomes of traditional ACL surgical reconstruction techniques 
have motivated research on alternative ACL repair and replacement strategies33.  
 
1.3 ACL Tissue Engineering 
Based on the drawbacks to traditional ACL allografts there has been interest in developing a 
synthetic ACL replacement since the early 1970s. However, there are currently no FDA 
Figure 1.7: Examples of ACL allografts: Semitendinosus tendon (top), gracilis tendon 




approved synthetic devices for primary ACL repair on the US market. Recent advancements in 
our understanding of the life sciences have motivated researchers to focus on the development a 
tissue engineered ACL replacement. Tissue engineering is a multidisciplinary field that 
incorporates aspects of engineering, biology, chemistry, and materials science technique to create 
replacements for damaged tissues56. The most common paradigm of tissue engineering is the use 
of a scaffold, cells, and signaling molecules in combination to encourage the regeneration of new 
tissue. Tissue engineering offers a unique opportunity to not repair damaged tissue but instead 
engineer new, or de novo, tissue. 
 
1.3.1 Scaffolds 
The scaffolds utilized for tissue engineering applications provide mechanical stability and act as 
a substrate for cell growth. When assessing scaffolds for use in ACL tissue engineering it is 
important to consider the type of material as well as its mechanical and biochemical properties. 
Due to the important mechanical function of the native ACL, a successful ACL scaffold must 
have material properties that are comparable to the native ACL. Additionally, an appropriate 
scaffold should have the ability to promote cellular attachment and encourage ligament tissue 
growth and remodeling, while being compatible with the surrounding tissue and not provoking 
an immune response. Finally, the degradation rate of the scaffold must be considered. Ideally, the 
scaffold degradation rate should match the rate of new tissue formation. 
 
Both xenogeneic materials, as well as other natural materials, have been considered for tissue 
engineering scaffolds of ligamentous materials. Collagen, the primary component of the native 
ACL, has been a popular choice for the creation of ACL scaffolds based on its biocompatibility 
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and the wide availability of xenogeneic (bovine) collagen. Despite promoting fibroblast 
adhesion, collagen lacks mechanical strength and xenogeneic collagen can provoke an immune 
response57,58.  Silk is another natural polymer that has been investigated, primarily because of its 
superior tensile strength. However in its natural state silk does not promote cell adhesion, and 
chemical modification to increase cell attachment can modify the morphology and mechanical 
properties of the scaffolds59,60. Challenges with the use of naturally occurring polymers have led 
researchers to focus on scaffolds fabricated from synthetic biodegradable polymers. Depending 
on the type of polymer chosen it is possible to tailor the scaffold mechanical properties, 
degradation rate, and cellular response. Materials such as poly(glycolic acid), poly(ʟ-lactic acid) 
and poly(lactic-co-glycolic acid) are common FDA approved materials that can be manufactured 
into various configurations and promote cell adhesion, however, the degradation products are 
highly acidic and there are issues with poor mechanical strength61–63. 
 
Recently polycaprolactone (PCL) has received significant attention as a suitable scaffold 
material. PCL is a semi-crystalline polyester that is composed of repeating subunits of the 
monomer ε-caprolactone64. Several PCL based medical devices have received US Food and Drug 
Administration approval, including sutures and drug delivery devices65,66. PCL has also been 
thoroughly investigated as a tissue engineering substrate and has been used for tissue engineering 
of skin, knee menisci, nerves, and bone67–70. 
 
PCL degrades via a hydrolytic degradation process due to the presence of hydrolytically labile 
aliphatic ester linkages. The degradation of PCL happens slowly (over a period of ~2-3 years) 
and the degradation products are readily metabolized via the citric acid cycle64. The degradation 
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rate of PCL is affected by a number of factors including the surface area to volume ratio of the 
scaffold, the molecular weight of the PCL, and the degradation environment64. Higher molecular 
weight PCL degrades slower because there are more ester bonds to be cleaved in order to 
generate the water-soluble monomers and oligomers enable the hydrolytic degradation. In a 
biological environment, the PCL degradation rate is also increased by the presence of biological 
enzymes. Additionally scaffolds that possess a high surface area to volume ratio, such as 
electrospun nanofibers, degrade more quickly due to the exposed polymer surface area. 
However, in general, the relatively slow degradation rate and lack of harmful byproducts make 
PCL a popular choice for biomedical materials.  
 
Another benefit of PCL is the large number of techniques that can be used to process it into 
various formulations. PCL has been woven, 3D printed, solvent cast, and extruded to form 
various types of scaffolds. Electrospinning is a versatile polymer fabrication technique that can 
be used to create a non-woven mat of nanofibers71,72. One of the major benefits of 
electrospinning is that the size scale of the nanofibers mimics the natural extracellular matrix 
which promotes cell adhesion, proliferation, and de novo extracellular matrix production73. 
Particularly important for ACL tissue engineering, the structure of aligned electrospun 
nanofibers mimics the size and structure of the collagen fibrils that compose the native 
ligament74,75. The electrospinning process can be readily modified to achieve tunable 
characteristics such as fiber size, fiber alignment, and porosity76–79 (Figure 1.8). Electrospun 
materials can be used in conjunction with chemical cues and mechanical cues to induce cell 
growth and differentiation80,81. Despite the promise of electrospun scaffolds for tissue 
engineering, sheets of electrospinning are fragile and difficult to handle, making clinical 
17 
 
translation difficult, and the mechanical properties are far inferior to the properties of native 
ligaments. In an attempt to overcome these challenges several research groups are investigating 
methods for creating more robust electrospun scaffolds using techniques such as braiding, 
lamination and the inclusion of hydrogels82–84. With more complex scaffolds, encouraging cell 
adhesion and proliferation while simultaneously achieving more robust mechanical properties 
can be challenging. 
 
1.3.2 Cells and Signaling Molecules 
Another important consideration for ACL tissue engineering is the type of cell that is seeded 
onto the scaffold. The ideal cell source is one that is readily available, has a high capacity for 
proliferation, and has the ability to secrete de novo extracellular matrix material that mimics the 
composition of the native ligament. In early tissue engineering attempts, primary ACL 
Figure 1.8: Modifications of electrospun scaffolds: Altering nanofiber diameter (A, B), 
increasing pore spaces between fibers (C, D), and altering nanofiber alignment (E, F). 
Reprinted with permission from Balguid et al. 2009 (A, B)76, Baker et al. 2008 (C, D)77, and 
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fibroblasts were investigated as a cell source, since fibroblasts are the cells found in the native 
ligament10. However, ACL fibroblasts are challenging to harvest and obtaining an adequate 
number can be difficult. Once seeded on a scaffold ACL fibroblasts do produce collagen, 
however, their low proliferative capacity limits usefulness85,86. More recent ACL tissue 
engineering attempts have turned to pluripotent and multipotent stem cells. Bone marrow-
derived mesenchymal stems cells (BMSCs) are multipotent cells that can be derived from bone 
marrow that has been harvested from long bones. BMSCs avoid the ethical challenges of 
embryonic stems cells and can be directed to differentiate into a number of different types of 
cells including chondrocytes, osteoblasts, and adipocytes87–89. In vitro and in vivo BMSCs have a 
robust ability to proliferate and they are able to differentiate into fibroblasts and produce 
collagen, which is vital for ligament tissue engineering applications85,90,91. Additionally, the use 
of autologous BMSCs can eliminate potential issues with immune response after implantation.  
 
Growth factors are chemical signaling molecules that are commonly used to influence cellular 
activity. For ligament tissue engineering, growth factors are employed to increase cell 
proliferation and extracellular matrix production. A number of growth factors, including 
transforming growth factor beta (TGF-β), insulin-like growth factor (IGF), fibroblast growth 
factor (FGF), and platelet-derived growth factor (PDGF), and have been shown to increase the 
proliferative capacity and matrix production of ACL fibroblasts92–94. However, fewer studies 
have been done to investigate the effects of ligament-related growth factors on BMSCs. In vitro, 
FGF has been shown to increase BMSC proliferation, upregulate collagen production, and 
encourage fibroblastic differentiation, however, the exact signaling pathway is unknown95,96. 
Connective tissue growth factor (CTGF) is a heparin-binding protein that has also been shown to 
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encourage fibroblastic differentiation of stem cells as evidenced by increased cell proliferation, 
alterations in gene expression, and increased ligament matrix deposition97,98. 
 
When considering the type of growth factor to utilize for tissue engineering applications it is also 
important to consider the method of growth factor delivery. The most common way to deliver 
growth factors to cells is by including the growth factor in the in vitro cell culture media. 
However, growth factors have a relatively short half-life in media and become rapidly 
inactivated99. Sustained growth factor delivery is often necessary to influence cell behavior and 
presents a challenge for creating functional scaffolds. Several strategies have been developed to 
prolong the influence of growth factors on cells including physically incorporating the growth 
factors into the bulk material of the scaffold and covalently conjugating growth factors onto 
scaffold surfaces99. Covalent conjugation is a surface modification technique that utilizes 
chemical bonds to immobilize growth factors to exposed functional groups on scaffold surfaces. 
Typically, a chemical treatment is used to functionalize the nanofibers by the addition of 
functional groups, and then a subsequent chemical treatment is used to covalently attach growth 
factors (Figure 1.9). Growth factors conjugated to the surface scaffolds composed of electrospun 
nanofibers have been utilized to encourage neuronal differentiation, enhance wound healing, and 
stimulate osteogenic cellular activity80,100–102. Chemical conjugation of growth factors presents a 
promising technique to allow growth factors to have a more extended influence on cells, 






1.4 Ovine Stifle Model 
When assessing potential tissue engineered ligament replacements animal models are often used 
for experimentation prior to human models. It is important to use an animal model that has 
anatomical features comparable to those of the human knee joint. The sheep stifle joint anatomy 
is similar to the anatomy of the human knee and prior work has shown that it is a valid surgical 
model for the human knee104,105 (Figure 1.10). Additionally, sheep are relatively large compared 
with most other animal models and the size of the stifle joint allows there to be adequate tissue 
for mechanical, histological, and biochemical testing of the same joint. Previous groups have 
successfully utilized the ovine stifle joint to study various orthopedic conditions and treatments 


















Due to the rising popularity of the ovine stifle joint as an orthopedic model, several research 
groups have worked to thoroughly characterize the biomechanics of the joint. In ovine cadaver 
stifles, tensile pull to failure tests have been conducted to assess the structural properties of the 
native ACL. The mechanical properties of the native ovine ACL, including modulus, stiffness, 
and load at failure, are comparable to the mechanical properties of the human ACL (Table 
1)22,23,108,113. Compressive testing has been conducted to assess contact pressures and contact 
areas on the tibial plateau of sheep during simulated gait and have shown that the tibiofemoral 
contact pressures mimic what has been measured in the human knee110,112,114,115. In live sheep, 
surgically implanted bone markers have been used to track the motion of the ovine stifle joint 
during normal gait to assess the three-dimensional kinematics. During gait the ovine stifle 
experiences flexion-extension angles between ~40º and ~80º which is a more narrow range of 
angles and an overall more flexed position than what is observed during human gait115–118 
(Figure 1.11). However, the peak tibiofemoral contact force during gait in sheep is ~2.12 times 
Figure 1.10: Comparative anatomy of the human knee joint and the sheep stifle joint anterior 





bodyweight, which is similar to the loads experienced by the human knee during gait115,119. The 
anatomic similarity between the human knee joint and the ovine stifle joint and the thorough 
characterization of the ovine stifle biomechanical properties make it an appropriate model for 
investigating ACL replacements. Most notably the ovine stifle joint models offer an opportunity 
to assess the ability of tissue engineered ACL scaffolds to mimic the hierarchal ACL structure, 
encourage in vivo collagen deposition, possess appropriate tensile properties, and restore native 
joint contact mechanics. A tissue-engineered scaffold that accomplishes these goals in the ovine 








Figure 1.11: Knee angle during ovine gait (A) and human gait (B) from heel strike (HS) to 
toe off (TO). Reprinted with permission from Tapper et al. 2008 (A)116 and Lafortune et al. 
1992 (B)118. 
A B




1.5 Specific Aims 
The aim of this work is to develop a polymer scaffold to use as a replacement for the anterior 
cruciate ligament (ACL). The scaffold should replicate the hierarchical structure of the native 
ACL while possessing reasonable time-zero mechanical properties. In an in vitro environment, 
the scaffold should encourage stem cell adhesion and proliferation and promote the deposition of 
de novo ligament tissue, specifically collagen. Finally, the scaffold should be able to be 
implanted in situ in an ovine stifle joint with standard surgical techniques and once implanted it 
should adequately maintain tibiofemoral contact mecahnics during simulated joint loading.  
 
Specific Aim 1: Fabricate and characterize an aligned 3-dimensional electrospun scaffold for 
ACL replacement. 
In order to provide a suitable replacement for a ruptured ligament, a scaffold should closely 
match the structural and material properties of the native ACL. Based on the hierarchical 
arrangement of collagen in the ACL a scaffold will be created to mimic the ligament structure 
using the polymer polycaprolactone and the nanofiber fabrication technique electrospinning. The 
subcomponents of the scaffold, flat sheets of electrospun nanofibers and rolled nanofiber bundles 
will be tested via uniaxial tensile testing to determine the material properties. Adipose-derived 
stem cells will be seeded on the scaffold subcomponents to assess the effect of the nanofiber 
materials on cell adhesion, proliferation, and morphology. 
 
Specific Aim 2: Assess the in vitro behavior of ovine bone marrow-derived stem cells seeded on 
the scaffold in the presence of conjugated growth factor. 
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Once a scaffold has been created and characterized it is necessary to determine the in vitro cell 
behavior in the presence of growth factors, signaling molecules used to induce the deposition of 
collagen. Using a chemical conjugation technique connective tissue growth factor (CTGF) will 
be covalently conjugated to the surface of nanofiber bundles and assessed for the conjugation 
efficiency, growth factor release dynamics, conjugation efficiency, and the short-term response 
of ovine bone-marrow derived stem cells (OBMSCs). The long-term response of OBMSCs will 
be assessed using groups of ~20 nanofiber bundles conjugated with CTGF assembled together to 
form a scaffold. Scaffolds will be evaluated for collagen production via histology, biochemical 
assays, and immunohistochemistry. 
 
Specific Aim 3: Evaluate the performance of the electrospun scaffold using uniaxial mechanical 
testing. 
A suitable ACL replacement must be surgically implantable and once implanted should mimic 
the tensile properties of the intact ligament. First, a complete scaffold will be fabricated by 
securing the ends of ~100 nanofiber bundles together with cylindrical solvent cast blocks of 
PCL. The structural properties of the complete scaffold will be assessed via tensile mechanical 
testing. Standard surgical techniques will be used to implant the scaffold into ovine cadaver stifle 
joints in place of the native ACL. After scaffold implantation, the ovine cadaver stifle will be 
assessed via tensile mechanical testing and a clinically relevant test of ACL integrity. 
Mechanical behavior of the cadaver stifles with the implanted scaffold will be compared to knees 




Specific Aim 4: Assess the effect of the electrospun scaffold on ovine stifle joint contact 
mechanics. 
One of the primary functions of the ACL is to provide stability to the knee joint and thus 
maintain a normal distribution of contact pressure between the femur and tibia. The tibiofemoral 
contact mechanics of cadaver ovine stifle joints will be assessed during simulated gait angles 
using thin film pressure sensors. Contact mechanics from four conditions will be assessed: (1) 
the native ACL intact, (2) the native ACL transected, (3) the electrospun scaffold implanted, and 
(4) a soft tissue graft implanted to determine if presence of the electrospun scaffold allows for 
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MECHANICAL PROPERTIES AND CELLULAR RESPONSE OF NOVEL 
ELECTROSPUN NANOFIBERS FOR LIGAMENT TISSUE ENGINEERING: EFFECTS 





The high incidence of tendon and ligament injuries necessitates the need for an efficient repair 
strategy. The anterior cruciate ligament (ACL) is frequently ruptured due to traumatic loading, 
and in the United States alone up to 200,000 ACL tears occur annually 1,2. The most commonly 
injured tendons include the flexor/extensor tendons of the hand (incidence of 4.83 and 
18/100,000 per year respectively) and the Achilles tendon (12/100,000) 3.  Following injury, 
tendons and ligaments have a low intrinsic healing capacity due to limited vascularization and 
thus surgery is required to repair or replace the injured tissue 4,5. The most common surgical 
treatment options for tendon and ligament injuries are tissue replacement with allografts or 
autografts. Although autografts have been historically successful, the primary drawback 
associated with the technique is donor site morbidity that can result in pain, tendonitis, and 
weakness 6,7. To avoid the complications associated with donor site morbidity, cadaver allografts 
have been used as a primary repair technique; however, limited tissue supply and a risk of 
disease transmission remain problematic 8. Regardless of the type of surgical intervention, 
traumatic and degenerative tendon and ligament injuries still often lead to the development of 
osteoarthritis 9,10.  
 
                                                        
1 This chapter has been published as a Research Paper in the Journal of the Mechanical Behavior 
of Biomedical Materials (61, 2016). All content has been adapted with permission from Elsevier. 
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In order to improve surgical outcomes of tendon and ligament repairs, the field of tissue 
engineering has attempted to recapitulate the structure and function of the tendons and ligaments 
to create an artificial replacement tissue. However, there are currently no FDA approved tissue 
engineered tendon and ligament replacements 11.  To successfully replace native tendons and 
ligaments, biocompatibility and mechanical properties of the replacement should be considered 
12. Collagen scaffolds are advantageous because collagen is a major component of the native 
tendons and ligaments, however, these scaffolds lack sufficient mechanical strength and may 
elicit an immune response 13,14. Silk scaffolds have superior mechanical properties but suffer 
from limited cell attachment without extensive chemical modification 15,16. Synthetic polymers 
are a popular option for scaffolds since many have already been FDA approved for other 
applications 11. Biodegradable polymers can be utilized with a variety of fabrication techniques 
and the characteristics of the resulting scaffold, including degradation rate, cell compatibility, 
and mechanical properties, can be altered depending on the type of polymer used 12.  
 
Tissue-engineered replacements should take into account the unique structure and mechanical 
functions of tendons and ligaments which enables them to bear loads throughout complex joint 
loading regimes. The smallest structural unit of tendons and ligaments are aligned collagen 
fibrils, which range from 50-500 nm in diameter 4,17. Collagen fibrils are organized into fibers 
approximately 10-50 μm in diameter. Groups of fibers are then organized into fascicles, 
approximately 50-500 μm in size, which are combined to compose the whole tendon or ligament. 
This hierarchical structure is likely important for the proper mechanical function of the tissue. It 
is generally thought that tissue engineering strategies employed to recreate tendons and 
38 
 
ligaments must be able to accurately recapitulate complex the micro- and nano-scale structure in 
order to achieve proper function 18,19. 
 
Electrospinning is a versatile tissue engineering technique that results in a non-woven mat of 
polymeric nanofibers 20,21. One of the major benefits of electrospinning is the ability to produce 
nanofibers that may mimic the natural extracellular matrix of tissues, and thus can support cell 
adhesion, proliferation, and extracellular matrix production 22. Furthermore, the structure of 
aligned electrospun nanofibers mimic the dimensionality of collagen fibrils that comprise native 
tendons and ligaments 23,24. Electrospinning can be readily modified to achieve tunable 
characteristics such as fiber size, fiber alignment, and porosity 25–28. Despite the promise of 
electrospun scaffolds in the field of tissue engineering, there are a number of factors that have 
thus far limited their clinical applicability. Primarily, sheets of electrospun fibers are fragile and 
difficult to handle, making them difficult to use in a clinical setting despite architectural 
modifications in an attempt to improve handleability. Braided electrospun scaffolds seeded with 
human bone marrow-derived stem cells have been shown to support cell adhesion and the 
upregulation of tenogenic markers 29,30, and stacked electrospun scaffolds with laser cut pores 
have successfully encouraged cell infiltration 31, but both demonstrated inferior mechanical 
strength compared to native ligaments.  
 
Since previous attempts have been unable to achieve the cellular and mechanical behavior 
required for tendon and ligament replacement, it has become necessary to develop a more robust 
electrospun construct, while still maintaining the complex structure and the cellular 
compatibility. The hierarchical structure of tendons and ligaments has motivated the 
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development of micro-scale bundles of nanofibers, which mimic the fascicles that compose 
native connective tissues. The objective of the following study was to assess the influence of 
nanofiber orientation on mechanical properties and cellular response of nanofiber bundles that 
have been designed to mimic the hierarchical organization of native tendons and ligaments. The 
overarching goal of this work is to create a more robust tissue engineered tendon and ligament 
replacement that closely replicates the native tissue structure. 
 
2.2 Experimental Materials and Methods 
2.2.1 Fabrication of nanofiber sheet and bundles 
Poly(ε-caprolactone) (PCL) nanofiber sheets were fabricated using an electrospinning technique. 
The solution for electrospinning was prepared by dissolving PCL pellets (Mw = 80,000, Sigma 
440744, St. Louis, MO) in chloroform and mixing the polymer solution with oleic acid sodium 
salt (OLA, TCI America O0057, Portland, OR) dissolved in methanol to ensure uniform fiber 
diameter. The final 10% PCL electrospinning solution was a homogenous mixture with a 3:1 
chloroform to methanol volume ratio and a 97:3 PCL to OLA ratio of the solid portion. For 
electrospinning, a glass syringe (Cadence Scientific Micro-Mate, Staunton, VA) outfitted with an 
18 gauge luer-lock blunt tip syringe needle (Hamilton 90134, Reno, NV) was filled with polymer 
solution and situated within an adjustable flow syringe pump (Genie Touch, Kent Scientific, 
Torrington, CT). The positive lead of a high voltage power supply (Acopian P030HP2, Easton, 
PA) was connected to the needle tip with an alligator clip. The collector consisted of an 
aluminum drum (NaBond, Shenzhen, China) 75 mm in diameter positioned 10 cm from the tip of 
the syringe needle and covered in aluminum foil. To create a randomly oriented flat sheet of 
nanofibers (Figure 2.1a) the collector drum was rotated at a speed of 300 rpm (linear velocity of 
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0.785 m/s), and to create a longitudinally aligned flat sheet of nanofibers (Figure 2.1b) the drum 
was rotated at a speed of 3000 rpm (linear velocity of 23.6 m/s). The volumetric flow rate of the 
PCL solution from the needle was 2.5 mL/h and the applied voltage was 15 kV. After fabricating 
a flat nanofiber sheet, nanofiber bundles were created by excising a rectangular section 
(approximately 5 cm x 10 cm) of either the random or aligned nanofiber sheet and rolling it into 
a cylindrical bundle composed of nanofibers (Figure 2.1c). The fabrication of nanofiber bundles 
required no special tools and was analogous to tightly rolling up a sheet of paper into a tube. 
However, because the nanofiber sheets were very thin the center of the nanofiber bundle was not 
hollow. This fabrication technique allowed for the fiber architecture and the pores between the 
fibers to remain intact. After fabrication, the nanofiber sheets and bundles were soaked in 




Figure 2.1: Nanofiber sheets with random (a) and aligned (b) nanofibers were used to 
fabricate nanofiber bundles (c). The diameters of nanofibers which compose random and 
aligned nanofiber sheets are significantly different (d, * indicates p<0.05) however the 
diameter of random and aligned nanofiber bundles (NFB) are not significantly different e). 
Randomly oriented nanofiber sheets have a wider spread of nanofiber angles (f) compared to 
aligned nanofiber sheets (g). 
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2.2.2 Characterization of nanofiber sheets and bundles 
Nanofiber sheets and bundles were mounted on stubs using carbon tape, sputter coated with a 10 
nm thick gold coating, and imaged using a field emission scanning electron microscope (SEM, 
JEOL JSM-6500F, Peabody, MA) operating at 10 kV to examine nanofiber architecture. To 
quantify nanofiber diameter using SEM images, 5000x magnification images (n=6) were taken 
from different samples of random and aligned nanofibers. Using Image J v1.48 (NIH, Bethesda, 
MD), the diameter of 20 nanofibers in each image was manually (LG) measured. Diameters of 
random and aligned nanofiber bundles (n=15) were quantified by imaging samples with a CCD 
camera (Flea3, Point Grey Research, Richmond, BC, Canada) and measured manually. 
 
The same 20 nanofibers used for diameter measurement were assessed for angular orientation to 
quantify nanofiber alignment 32. A reference line was drawn along the horizontal plane and the 
angle of each fiber was measured relative to the reference line. To account for initial rotation of 
aligned samples the angles were normalized to the primary direction of sample rotation. The 
analysis yielded a distribution of fiber angles ranging from -90° to 90° where 0° was defined as 
the horizontal. Histograms were created from all angle measurements for both random and 
aligned samples. Angular deviation was calculated using the MATLAB circular statistics toolbox 
33. 
 
Cross-sectional area of nanofiber sheets and bundles was determined two ways - via 
measurements of “as-spun” nanofiber sheets and bundles with pores spaces left intact (Figure 
2.2a, 2.2b), and of “compressed” nanofiber sheets and bundles with pores spaces removed 
(Figure 2.2c, 2.2d). As-spun nanofiber sheets are highly porous and using sample width and 
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thickness to calculate cross-sectional area overestimates the true amount of material present in 
the sample since the pores contribute significantly to the sample thickness. For nanofiber 
bundles, using the outer diameter to calculate cross-sectional area does not take into account pore 
space between nanofibers and additionally does not take into account any gaps between the 
rolled “layers” of nanofiber sheets. 
 
As-spun thickness of nanofiber sheets (n=5) was determined by measuring the thickness at 10 
locations on each sample from transverse SEM images (Figure 2.2a). As-spun cross-sectional 
area of nanofiber bundles was determined by manually measuring the diameter of nanofiber 
bundle and assuming a cylindrical shape (Figure 2.2b). To determine the compressed cross-
sectional area nanofiber sheets (n=5) and nanofiber bundles (n=20) were compressed under a 10 
lb weight for 10 min in order to eliminate pore space between nanofibers. Transverse sections of 
compressed nanofiber sheets and bundles were imaged via SEM to visualize true cross-sectional 
area of each sample after pore space had been eliminated. Thickness of nanofiber sheets was 
determined by measuring the thickness of 10 locations of each sample (Figure 2.2c). For 
nanofiber bundles, the diameter of each nanofiber bundle was measured prior to compression and 
then cross-sectional area was determined by outlining the area of the transverse cross-section in 
Image J v1.48 (NIH, Bethesda, MD) (Figure 2.2d). This allowed for the determination of a 
relationship between measured nanofiber bundle diameter and true cross-sectional area. 
Compression of nanofiber sheets and bundles was only conducted to assess true material cross-
sectional area for calculation of material properties. All mechanical tests and cell culture 





2.2.3 Mechanical Testing 
Uniaxial tensile testing was performed on random and aligned nanofiber sheets and nanofiber 
bundles. Samples (n=5) for testing from each group were culled from different nanofiber sheets 
to account for any batch-to-batch variability. Each sample was preloaded to 0.1 N before being 
Figure 2.2: Transverse section of as-spun nanofiber sheet (a) nanofiber bundle (b). Transverse 
section of compressed nanofiber sheet (c) and nanofiber bundle (d). Linear relationship between 
measured nanofiber bundle diameter and compressed cross-sectional area (e). 
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strained at a set strain rate until mid-substance failure. Three strain rates were examined: 1%/s, 
5%/s, and 25%/s to simulate approximate normal walking speeds, normal running speeds, and 
traumatic loading speeds respectively 34–36. Prior to mechanical testing nanofiber sheets were 
punched into dog-bone shapes (Figure 2.3a) with a central width of 3.17 mm (ASTM standard 
#D638-05, Qualitest USA, Plantation, FL). Thin film grips covered in 100 grit sandpaper were 
utilized to clamp each specimen with a gauge length of approximately 4 cm. A servo-hydraulic 
mechanical test system (Bionic Model 370.02 MTS Systems Corporation, Eden Prairie, MN) 
equipped with an 8.9 N load cell (Futek LSB200, Irvine, CA) was used to test nanofiber sheets. 
Samples were speckle coated with India ink and surface images were captured during testing 
with a CCD camera (Flea3, Point Grey Research, Richmond, BC, Canada) at a rate of 15 frames 
per second. To calculate strain, images were analyzed using a Matlab-based Digital Image 
Correlation code to track the displacement of the speckle pattern in the central region of each 
dog-bone shaped sample 37.  
 
For tensile testing of the nanofiber bundles, a custom fabricated testing fixture was used to 
secure each sample without creating stress concentrations (Figure 2.3b). The servo-hydraulic 
mechanical test system was equipped with a 44.5 N load cell (Futek LSB303, Irvine, CA) and 
prior to testing the diameter of each nanofiber bundle was measured to allow for calculation of 




Strain values for nanofiber bundles were calculated by dividing the crosshead displacement by 
the original gauge length. For all samples, stress was calculated by dividing force values by 
either the as-spun or compressed cross-sectional area of each sample. Tensile modulus was 
Figure 2.3: Nanofiber sheets (a) and nanofiber bundles (b) during mechanical testing. 
Representative load displacement curves (c). Results of mechanical testing: scaffold elastic 
modulus (d, g), yield stress (c, h), and yield strain (d, i) for random nanofiber sheets (rNFS), 
aligned nanofiber sheets (aNFS), random nanofiber bundles (rNFB) and aligned nanofiber bundles 
(aNFB). Results were calculated using either as-spun (d, e, f) or compressed cross-sectional area 
(g, h, i). Due to a lack of strain rate dependence data from the tests at the three strain rates were 
combined for statistical analyses. * Indicates significant difference between random and aligned 
scaffolds with same geometry (p<0.05). # Indicates significant difference between nanofiber 
sheets and nanofiber bundles with same nanofiber orientation (p<0.05).   
46 
 
determined by measuring the slope of the linear region of each stress-strain curve, with excellent 
agreement to the data (r2 = 0.98 ± 0.02). Yield stress and strain values were calculated based on 
the intersection of a 0.2% offset line. 
 
2.2.4 Cell Culture 
Adult human adipose-derived stem cells (Zen-Bio ACS-F, Research Triangle Park, NC) at 
passage 2 were expanded using standard cell culture techniques. The cell growth media consisted 
of Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal bovine serum and 1% 
penicillin/streptomycin. Nanofiber sheets and bundles were sterilized by soaking in 70% ethanol 
for one hour followed by exposure to ultra-violet light for 30 min prior to cell culture. Following 
expansion, cells in passage 4 were seeded on nanofiber sheets and nanofiber bundles at a density 
of 10,000 cells/cm2 and growth media was changed every 2-3 days. After 1 and 7 days of culture 
cell, cellular response to nanofiber sheets and bundles was assessed by examining cell viability, 
cell adhesion, and cell morphology.  
 
Cell viability was determined by a CellTiter-Blue Cell Viability Assay (Promega G808A, 
Madison, WI), which was used according to the manufacturer’s instructions. 20 µL of CellTiter-
Blue dye was added to scaffolds (n=6) for every 100 µL of culture media and samples were 
incubated for 4 h at 37°C and 5% CO2. Blank scaffolds were also included as controls. Sample 
fluorescence was read in a microplate reader (Molecular Devices SpectraMax M3, Sunnyvale, 




At each time point cell adhesion was assessed by staining the cells with 5-
Chloromethylfluorescein Diacetate (CMFDA, Life Technologies C2925, Carlsbad, CA), 
rhodamine-phalloidin (Cytoskeleton, Inc, Denver, CO), and 4’,6-diamidino-2-phenylindole 
(DAPI, Life Technologies D1306, Carlsbad, CA). Nanofiber sheets and bundles were incubated 
in PBS and CMFDA stain at a concentration of 10 µM for 45 min in a 37°C and 5% CO2 
incubator. Nanofiber sheets and bundles were then incubated in warm culture media for 30 min 
and fixed in 3.7% formaldehyde for 50 min at ambient temperature. All samples were rinsed 
with PBS between subsequent steps and protected from light exposure. Nanofiber sheets and 
bundles were exposed to 1% Triton-X 100 for 3 min to permeabilize cells. Samples were 
incubated at room temperature in a 5 µL/mL solution of rhodamine-phalloidin for 25 min and 
DAPI was added for the final 5 min of the incubation period at a concentration of 300 nM. 
Samples were imaged using a Zeiss Axioplan 2 fluorescence microscope. Cell count and cell 
shape factor for each aligned and random nanofiber sheets and bundles (n=15) were determined 
from five images at 10x magnification. For cell counts, DAPI stained cell nuclei were counted 
(Particle count tool, Image J v1.48 NIH, Bethesda, MD) and cell shape factor was quantified 
using a ratio of cell length to cell width based on rhodamine-phalloidin stained cells 38,39. Cell 
length was defined as the diameter of the smallest circle that would fit around the outer edge of a 
cell and cell width was defined as the diameter of the largest circle that would fit entirely within 
the cell.  
 
SEM was used to visualize cell morphology and cell-nanofiber interactions. Cells and nanofibers 
were fixed for imaging in a solution of 3% glutaraldehyde, 0.1 M sodium cacodylate, and 0.1 M 
sucrose for 45 min. Scaffolds were then soaked for 10 min in a buffer solution of 0.1 M sodium 
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cacodylate and 0.1 M sucrose. Nanofiber surface and cells were processed in serial ethanol 
dehydrations for 10 min each and dehydrated in hexamethyldisilazane before being stored in a 
desiccator until SEM imaging. 
 
2.2.5 Statistics 
Data are presented as mean ± standard error of the mean. Data analysis was performed using 
Minitab (Minitab, Inc., State College, PA). For all quantitative measures, comparisons were 
performed using a two-way analysis of variance (ANOVA) models with Tukey’s post-hoc test. 




2.3.1 Fabrication and characterization of nanofiber sheets and bundles 
Using the electrospinning methods described above, a non-woven nanofiber sheet was 
successfully created in a repeatable manner. Based on SEM images, the diameter of random and 
aligned nanofibers was significantly different (p=.002, Figure 2.1d). The mean fiber diameter of 
random nanofiber sheets and bundles was 334 nm ± 20 nm and the mean fiber diameter of the 
aligned samples was 289 nm ± 19 nm. This size scale mimics the size of collagen fibers found in 
native tendons and ligaments. There was no significant difference in the average diameter of as-
spun nanofiber bundles with random and aligned nanofibers (490 ± 60 µm and 474 ± 57 µm 
respectively, Figure 2.1e). This size scale mimics the size of fascicles that compose native 
tendons and ligaments. As seen in the histograms of nanofiber angle, a collector drum rotating at 
a linear velocity of 0.78 m/s resulted in a wider spread of fiber angles (Figure 2.1f), while a 
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collector drum rotating at 23.6 m/s induced nanofiber alignment and decreased the spread of 
nanofiber angles (Figure 2.1g). The angular deviation of random nanofiber sheets and bundles 
was 40.33° and the angular deviation of aligned samples was 17.31°. The as-spun thickness of 
nanofiber sheets was found to be 20.4 ± 1.13 µm and the compressed thickness of these same 
nanofiber sheets was found to be 5.6 ± 0.41 µm. The cross-sectional area of compressed 
nanofiber bundles was found to be linearly related to the measured diameter (r=0.95) (Figure 
2.2e). 
 
2.3.2 Mechanical Testing 
All samples of nanofiber sheets and nanofiber bundles exhibited a linear elastic region followed 
by a larger region of plastic deformation (Figure 2.3c). Nanofiber sheets and bundles composed 
of aligned nanofibers displayed a slight toe region prior to the linear elastic region. Results are 
presented as material properties calculated using both the as-spun and compressed cross-
sectional area measurements (Figure 2.3). Elastic modulus, yield stress, and yield strain results 
presented no strain rate dependence, thus data from the tests at the three strain rates were 
combined for statistical analyses. 
 
The orientation of nanofibers within the scaffolds had a significant effect on elastic modulus 
(Figure 2.3d, 2.3g). Sheets composed of aligned nanofibers had an elastic modulus 125% greater 
than sheets composed of random nanofibers (p<0.0005), and aligned nanofiber bundles had a 
modulus 105% greater than random nanofiber bundles (p<0.0005). Geometry, whether the 
electrospinning was a sheet or a bundle, only had a significant effect on elastic modulus for 
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nanofiber sheets and bundles that consisted of aligned nanofibers; aligned nanofiber sheets had a 
significantly higher elastic modulus than aligned nanofiber bundles (p<0.0005). 
 
Yield stress of all scaffolds (Figure 2.3e, 2.3h) was significantly different depending on the 
orientation of nanofibers composing the scaffolds. Yield stress of aligned nanofiber sheets was 
130% greater than yield stress of random nanofiber sheets (p=0.006). Similarly, aligned 
nanofiber bundles yielded at stresses 130% higher than the yield stress of random nanofiber 
bundles (p<0.0005). Geometry only significantly affected yield stress for scaffolds with aligned 
fibers: the yield stress of aligned nanofiber bundles was 95% greater than that of nanofiber sheets 
(p<0.001). Both fiber orientation and scaffold geometry influenced scaffold yield strain (Figure 
2.3f, 2.3g). Aligned nanofiber bundles yielded at strains 30% higher than random nanofiber 
bundles p<0.0005). Additionally, nanofiber bundles had significantly higher yield strains than 
flat sheets of the same alignment (aligned: p<0.0005, random: p<0.0005). 
 
2.3.3 Cell Culture 
The CellTiter-Blue cell viability assay revealed that cells proliferated and remained viable on 
nanofiber sheets and bundles for up to 7 days of culture (Figure 2.4a). Initially, cells appeared to 
adhere more readily to nanofiber bundles, as demonstrated by higher levels of viability at day 
one on nanofiber bundles compared to nanofiber sheets (aligned: p=0.02, random: p<0.0005). 
However, by day 7, only random nanofiber bundles showed greater levels of cell viability 
compared to random nanofiber sheets (p=0.004) and no other other significant differences 




Fluorescence microscopy images revealed that nanofiber sheets and bundles were all able to 
support cell adhesion and proliferation for up to 7 days of culture (Figure 2.5). Results of cell 
counts indicate that neither nanofiber orientation nor geometry had a significant effect on the 
number of cells present, however for all nanofiber sheets and bundles cell number increased 
(random nanofiber sheet: p=0.005, aligned nanofiber sheet: p=0.008, random nanofiber bundle: 
p=0.04, aligned nanofiber bundle: p=0.04) over the 7 day culture period (Figure 2.4b). 
Figure 2.4: Quantification of cell viability, proliferation and morphology on random nanofiber 
sheets (rNFS), aligned nanofiber sheets (aNFS), random nanofiber bundles (rNFB) and aligned 
nanofiber bundles (aNFB) after 1 and 7 days of culture. CellTiter-Blue fluorescence (a), cell 
counts (b), and cell shape factor (c). * Indicates significant difference between random and 
aligned scaffolds with same geometry (p<0.05). # Indicates significant difference between 
nanofiber sheets and nanofiber bundles with same nanofiber orientation (p<0.05). & Indicates 





To determine the influence of nanofiber orientation and geometry on cell morphology, cell shape 
factor (the ratio of cell length to cell width) was quantified via 10x magnification rhodamine-
phalloidin stained images (Figure 2.4c). A lower shape factor indicates that the cell is more 
spherical and a higher shape factor indicates that a cell is more elongated. After 1 day of cell 
culture, cells on random nanofiber bundles were significantly more elongated than cells on 
Figure 2.5: Representative fluorescent images of cells random nanofiber sheets (rNFS), aligned 
nanofiber sheets (aNFS), random nanofiber bundles (rNFB) and aligned nanofiber bundles 
(aNFB) after 1 and 7 days of culture.  
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random nanofiber sheets (p=0.04). Over the course of the 7 day, culture period cells on aligned 
nanofiber sheets and nanofiber bundles continued to elongate while cells on random nanofiber 
sheets remained more spherical. At Day 7, cells on scaffolds (both flat sheets and nanofiber 
bundles) with aligned nanofibers were significantly more elongated than cells on corresponding 
scaffolds with random nanofibers (aligned: p<0.0005 and random: p=0.002). Geometry of 
nanofiber sheets significantly affected cell shape factor only for random samples; random 
nanofiber bundles had more elongated cells compared to random nanofiber sheets (p<0.005).  
 
The results of cell shape factor quantification were supported by SEM images, which were used 
to visualize cell morphology on nanofiber sheets and bundles (Figure 2.6). In addition to 
visualization of morphology, SEM shows the interaction of cell extensions with the nanofiber 
surfaces. SEM results demonstrated that cells adhered and proliferated on nanofiber sheets and 
bundles after 7 days in culture and cells and were evenly distributed on the nanofiber surfaces. 
Cells were noticeably elongated on aligned nanofiber sheets and random and aligned nanofiber 
bundles, while on random nanofiber sheets cells maintained a more distributed morphology. 
Based on high magnification SEM images, cells on nanofiber sheets and bundles appeared to be 
interacting with nanofibers and neighboring cells via cellular extensions even after only one day 
of culture. Additionally, after 7 days of culture, cellular extensions appeared to be longer and the 






Electrospinning is a simple polymer fabrication technique that allows for the creation of porous 
nanofiber sheets with controllable nanofiber size and alignment. Although flat electrospun sheets 
Figure 2.6: Representative SEM images of cells on random nanofiber sheets (rNFS), aligned 
nanofiber sheets (aNFS), random nanofiber bundles (rNFB) and aligned nanofiber bundles 
(aNFB)after 1 and 7 days of culture. 
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are suitable for cell growth, inherent limitations impede their use in tendon and ligament 
regeneration. It is challenging to produce flat sheets of electrospinning that are more than 1mm 
thick due to electrostatic repulsion properties that prevent excessive fiber deposition 40. Although 
some research groups have attempted to laminate flat sheets of electrospinning and incorporate 
hydrogels to create more robust scaffolds, the mechanical properties are still relatively low 31,41–
44. In order to make electrospun scaffolds more applicable for large-scale tissue engineering 
purposes, it is necessary to modify the geometry of flat sheets to better mimic the structure and 
mechanical properties of target tissues, in this case, tendons and ligaments, both load bearing 
orthopedic connective tissues.  
 
In the present study, we have investigated how to vary the structure of nanofiber sheets by 
modifying both the geometry and nanofiber orientation in order to better replicate the form and 
function of tendons and ligaments and improve mechanical properties. We present a novel 
technique for improving the mechanical properties of nanofiber scaffolds while maintaining the 
complex underlying fiber architecture. The electrospinning process was conducted using a 
rotating mandrel, which allowed for modulation of the nanofiber orientation. The parallel 
alignment of PCL nanofibers in aligned nanofiber sheets closely mimicked the size scale and 
structure of collagen fibers within the ACL 45,46.  Although the aligned nanofibers mimic the 
orientation of collagen fibers in the native ACL, the pores between the nanofibers are much 
larger than the spaces between the densely packed ACL collagen fibers. These larger pores in the 
electrospun scaffold are necessary for encouraging cell infiltration and production of 
extracellular matrix. In addition to modifying the orientation of electrospun nanofibers, this study 
reports a method for modifying flat nanofiber sheets into a three-dimensional bundle of 
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nanofibers. The size of the nanofiber bundles (400-500 µm) mimics the size of collagen fascicles 
(50-500 µm) found in load-bearing orthopedic tissues 4,45. Modifying the geometry of 
electrospun sheets to create nanofiber bundles results in a novel cylindrical scaffold that is 
remarkably robust, suggesting that it may be more feasible for clinical use. By fabricating 
nanofiber bundles from random or aligned nanofiber sheets we were able to modulate the 
mechanical properties as well as the cellular response. 
 
In order for a tissue-engineered scaffold to provide a suitable replacement for native human 
tendons and ligaments, it is desirable for the scaffold to possess mechanical properties that are 
similar to native ACL. An important consideration in the calculation of material properties is 
how sample cross-sectional area is determined. Since electrospun sheets are highly porous, 
simply utilizing the width and the “as-spun” thickness of the nanofiber sheet to calculate the 
cross-sectional area overestimates the amount of material that is actually present and 
consequently underestimates the mechanical properties. To overcome this problem, in addition to 
calculating the as-spun cross-sectional area of nanofiber sheets and bundles, we compressed 
nanofiber sheets and bundles to eliminate pore space and used additional SEM images to 
determine true material area. In this way, it is possible to determine both the apparent properties 
of the bulk scaffold, as well as the inherent properties of the electrospun material. A limitation to 
this method was the difficulty in verifying if all pore space had been completely eliminated using 
only visual inspection of SEM images; however this work is still the first to calculate the 





Firstly, altering nanofiber orientation so nanofiber sheets consisted of primarily aligned 
nanofibers increased the elastic modulus by ~125% and the yield stress by ~150%. These 
differences in mechanical properties are possibly due to more fibers being present in parallel 
over which to distribute the applied loads, thus requiring more force to cause elastic deformation. 
Previous studies of the mechanical behavior of aligned nanofiber sheets of electrospun PCL have 
reported the elastic modulus to range from 20-40 MPa and the yield stress to range from 2-4 
MPa 23,24,47,48. Despite some expected variation due to spinning technique and duration, these 
previously reported values are relatively similar to values calculated in this study utilizing the as-
spun cross-sectional area but are up to an order of magnitude lower than the values calculated 
utilizing the compressed cross-sectional area. Similar to our findings, previous studies assessing 
the moduli of nanofiber sheets have shown aligned nanofiber sheets to have moduli 75-140% 
higher than the random nanofiber sheets (23,47,48). 
 
In addition to altering nanofiber orientation, altering the geometry of nanofiber sheets 
significantly affected the mechanical properties. When random nanofiber sheets were used to 
create randomly oriented nanofiber bundles there was no significant difference in elastic 
modulus, however, the elastic modulus of aligned nanofiber bundles was observed to be ~55% 
lower than the elastic modulus of aligned nanofiber sheets. The decrease in elastic modulus of 
aligned nanofiber bundles may be due to the extent of nanofibers that were engaged during the 
tensile test and bearing the applied load. However, it is difficult to speculate exactly why 
scaffolds with similar nanofiber alignment but different geometries possess different material 
properties. We hypothesize that these differing material properties may be due to interactions 
between the fiber layers and varying recruitment of the nanofibers to bear the applied loads. 
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Based on the low standard errors of the measured material properties, we feel confident that 
sample preparation and testing techniques are not responsible for the differing properties. Further 
experiments will be necessary to elucidate the exact reasons for the variation in material 
properties with altered scaffold geometry. 
 
One limitation of the mechanical testing techniques used in this study, which could limit the 
interpretation of the results was the different techniques used to measure the strain of flat sheets 
and nanofiber bundles. Speckle tracking of India ink dots was used to measure strain in the 
central region of the dog-bone shaped flat sheets, however, due to the small size of the nanofiber 
bundles (~0.5 mm) and limited resolution of the camera used to track the samples the speckle 
coating technique could not be used. Instead, strain for nanofiber bundles was measured using 
grip-to-grip displacement from the servo-hydraulic mechanical test system (Bionic Model 370.02 
MTS Systems Corporation, Eden Prairie, MN). 
 
Previous studies have assessed the effects of modifying the geometry of electrospun scaffolds. 
Computational work conducted by Nerurkar et al. found that any modulus reinforcement effects 
from stacking layers of electrospun fibers only occurred when layers were oriented in opposing 
directions and fibers were forced to undergo rotation under tensile loading to align along the axis 
of the load, generating additional shear forces 49. Similarly, Fisher et al., reported that when 
assessing the mechanical properties of stacks of sheets of electrospinning, only layers with “non-
orthogonal” orientations showed evidence for a mechanical reinforcement effect compared to 
individual sheets 41. Previous groups investigating the effects of twisting or braiding electrospun 
nanofibers have observed trends of increasing elastic modulus with more complex geometry, 
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however, this could be attributed to variation in the calculation of scaffold cross-sectional area 
29,30,50. Nerurkar et al. showed that layers of electrospun fibers stiffened after extended cell 
culture, likely due to cell matrix deposition between layers, which suggests that aligned 
nanofiber bundles may develop a higher elastic modulus over time in culture 51. 
 
Modifying geometry also resulted in significant differences in yield stress and strain of the 
resultant scaffolds, particularly when nanofibers were aligned. Aligned nanofiber bundles had an  
average yield stress 90% higher than aligned nanofiber sheets and an average yield strain 130% 
higher than aligned nanofiber sheets. This is promising for the proposed ligament tissue 
engineering applications because although ligaments typically only undergo less than 10% strain 
during normal loading, it would be valuable for scaffolds to be able to sustain higher stresses and 
strains prior to plastic deformation 36. Overall, modifying both geometry and nanofiber 
orientation to create a nanofiber bundle composed of aligned nanofibers resulted in a scaffold 
with modulus and yield stress and strain values within the range of the native human ACL (Table 
2-1). Previous research has also assessed the mechanical properties of the sub-structures of the 
native human ACL, including the anteromedial, anterolateral, and posterior bundles as well as 
individual fascicles 52,53. The anteromedial and anterolateral bundle and individual fascicles have 
moduli that are higher than that of the entire ACL and higher than that of aligned nanofiber 
bundles. This presents a limitation of the described scaffold since it does not precisely match the 
material properties of the structures that compose the native human ACL. However, the modulus  
of aligned nanofiber bundles does closely match the modulus of the posterolateral bundle. 
Additionally, the yield stress and yield strain of aligned nanofiber bundles are within in the range 
of the tensile strength and yield strain of ACL bundles as well as ACL fascicles. In the context of  
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ACL replacement scaffolds, yield stress, and strain are comparable to tensile strength and failure 
strain since a scaffold that has plastically deformed has essentially “failed” as it is no longer able 
to properly fulfill the role of the ACL. Notably, the results of the present study suggest that 
aligned nanofiber bundles may be suitable for use as a tissue-engineered scaffold, since the 
modulus and the yield properties of the scaffold meet the mechanical demands of the native 
ACL, and potentially other tendons and ligaments as well. Additional modification, such as 
combining multiple nanofiber bundles into a single construct may further alter scaffold 
mechanical properties. Preliminary work has suggested that securing together the ends of ~100 
nanofiber bundles using solvent cast solid PCL produces a structure with significantly higher 
stiffness and failure load.  
 
 
 Modulus (MPa) Yield Stress (MPa) Yield Strain 
Aligned nanofiber bundle 154 ± 28 54 ± 12 0.38 ± 0.03 
     




Noyes & Grood 54 ACL, Old 65 ± 24 13 ± 5 0.49 ± 0.12 
ACL, Young 111 ± 26 38 ± 9 0.60 ± 0.07 
Chandrashekar 55 ACL, Male 128 ± 35 26 ± 10 0.30  ± 0.06 
ACL, Female 99  ± 50 23  ± 9 0.27  ± 0.08 
Butler 52 ACL fascicle 345 ± 22 36 ± 3  0.15 ±0.008 
Butler 53 ACL 
anteromedial 
bundle 








154 ± 119.5  15 ± 10 0.15 ± 0.05 
Table 2.1: Material properties of aligned nanofiber bundles compared to properties of human 
ACL from previous studies. 
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All nanofiber sheets and bundles were able to support cell adhesion and proliferation, which was 
expected since electrospun PCL nanofibers have previously been shown to support a variety of 
cell types 27,56,57. However, quantitative measures indicated that there were some differences in 
both cell viability and cell morphology between nanofiber sheets and bundles. Higher 
fluorescence from CellTiter-Blue viability assays on nanofiber bundles may be due to the larger 
surface area of nanofiber bundles compared to nanofiber sheets. The results of cell counts based 
on DAPI stained nuclei indicated no differences in cell number on any nanofiber sheets and 
bundles at the Day 1 or Day 7 time points. Any discrepancies between CellTiter-Blue viability 
assay results and cell count results may be because cells proliferated around the curved edges of 
the nanofiber bundles or migrated into the center of the nanofibers where they could not be 
imaged. The quantification of cell shape showed interesting effects of both geometry and 
nanofiber orientation on cell morphology. Similar to reports from other groups, after 7 days in 
culture cells on aligned nanofiber sheets were significantly more elongated along the primary 
nanofiber direction compared to cells on random sheets 23,27,58. However, on nanofiber bundles, 
cells were more elongated compared to nanofiber sheets regardless of fiber alignment. It is 
hypothesized that the cells may have detected the convex curvature of the cylindrical nanofiber 
bundles, regardless of fiber alignment, and consequently aligned along the length of the 
nanofiber bundle. This novel finding suggests that the micro-scale geometry of nanofiber 
bundles has a separate and significant impact on cell morphology. It has also been previously 
shown that substrate stiffness has important effects on cell development and differentiation 59,60. 
Specifically, the modulus of the substrate influences cytoskeleton assembly and; on less stiff 
surfaces cells have reduced spreading and increased rates of motility 61. Additionally, 
mesenchymal stem cells differentiation response has been shown to be acutely sensitive to the 
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elasticity of the underlying substrate 62. Because the scaffolds in this study demonstrate 
significantly different levels of stiffness and this may play a role in altering cell morphology. The 
ability to modulate cell morphology is important for tissue engineering applications because cell 
shape affects numerous cell processes, including cell migration and communication as well as 
cellular differentiation 63. A limitation of the current nanofiber sheets and bundles is the low 
porosity (pore sizes of approximately 5 µm), which could potentially limit cell infiltration into 
the interior of the scaffolds. Cell infiltration could be encouraged by modifying the 
electrospinning technique to include sacrificial fibers/porogens or increasing the nanofiber 
diameter in order to increase overall porosity 64–66. 
 
2.5 Conclusions 
This work presents a novel cylindrical electrospun scaffold with robust mechanical properties 
and a complex underlying nanofiber structure. Nanofiber orientation and geometry of 
electrospun PCL were modified to mimic the fascicles of native tendon and ligament. Aligned 
nanofiber bundles had the highest yield stresses and strains, while still maintaining a relatively 
high elastic modulus. Remarkably, these mechanical properties are within the range of the native 
human ACL. For the first time in this work, the mechanical properties of electrospun scaffolds 
were calculated using a true material cross-sectional area, with pore space between nanofibers 
eliminated to prevent an underestimation of properties. Additionally all nanofiber sheets and 
bundles were able to support cell adhesion and proliferation for up to 7 days in culture; however, 
nanofiber bundles are preferable for encouraging the parallel elongation of adipose-derived stem 
cells. The mechanical properties and cell response of aligned electrospun nanofiber bundles 
suggest they are a promising scaffold for orthopedic tissue engineering applications. Future 
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studies will investigate the utilization of growth factors to promote cell differentiation into a 
ligamentous phenotype and the effect of combining multiple nanofiber bundles into a more 
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The anterior cruciate ligament (ACL) is located in the knee and runs from the lateral posterior 
aspect of the femoral condyle to the medial anterior aspect of the tibial plateau1. The ACL is vital 
for joint stability and it functions primarily as a restraint to excessive translations of the tibia 
relative to the femur 2,3. The ACL is primarily composed of collagen fibers arranged in a unique 
hierarchical structure and a lack of vascularization means that the ligament has a low intrinsic 
healing capacity4,5. It is estimated that up to 200,000 ACL injuries occur in the United States 
annually and the monetary burden of these injuries and subsequent treatment is estimated to be 
$1 billion each year6,7. Untreated tears of the ACL can cause knee pain, bone bruising, excessive 
joint laxity, and damage to the surrounding cartilage and menisci of the knee. Following an ACL 
injury, surgical replacement of the ACL with an autograft or allograft is typically attempted to 
restore function and stability to the injured knee. However, drawbacks exist to both intervention 
techniques. Although allografts have been historically successful, morbidity at the site of tissue 
donation can result in pain, tendonitis, and weakness8,9. Allograft tissue obtained from cadavers 
can also be used to replace the ACL however tissue supply is limited and disease transmission 
can be problematic10. Thus there is interest in developing a tissue-engineered replacement ACL 
that can overcome the limitations of traditional allografts and autografts.  
                                                        
2 This chapter has been published as a Research Paper in Tissue Engineering Part A (23, 2017). 




The field of tissue engineering aims to combine scaffolds, cells, and signaling molecules to 
create a replacement for damaged biological tissue.  Electrospinning is a versatile scaffold 
fabrication technique which uses biodegradable polymers to create a nanoscale structure that 
mimics the structure of the extracellular matrix11,12. Braided electrospun scaffolds have been 
shown to encourage cell proliferation and upregulation of tenogenic markers13,14 whereas 
laminated electrospun sheets have successfully encouraged cell infiltration15. However, both of 
these approaches have demonstrated inferior mechanical properties12-14. A tissue engineered 
ACL that matches the hierarchical structure of the native ligament, has sufficient mechanical 
properties and encourages the production of ligamentous tissue deposition in vitro and in vivo 
will likely improve the clinical treatment of ACL injury.  
 
Our group has previously developed a technique for modifying flat sheets of aligned electrospun 
polycaprolactone (PCL) nanofibers to create a more robust structure16. These cylindrical 
“nanofiber bundles” are approximately 500 µm in diameter and are composed of nanofibers 
aligned along the longitudinal axis that mimic the native ACL structure. Nanofiber bundles are 
able to support short-term cell growth and elongated cell morphology and have material 
properties that are comparable to that of the native human ACL16–18. The smallest functional 
units of the ACL are collagen fibrils that range in size from 50-500 nm and are primarily 
oriented parallel to the longitudinal axis19,20. The individual PCL nanofibers that compose the 
electrospun sheets used in this study mimic this size scale16. Collagen fibrils of the ACL are 
organized into fibers and numerous collagen fibers are grouped into fascicles, approximately 
100-500 µm in size. The size of these collagen fascicles is similar to the size of one nanofiber 
bundles. In the native ACL, multiple collagen fascicles are grouped together to form the entire 
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ligament. Thus, in an effort to mimic the hierarchical ACL structure, multiple nanofiber bundles 
were combined together to form a 3D scaffold for this study. 
 
Growth factors are chemical signaling molecules that can be used to direct cell behavior. In the 
context of ligament tissue engineering, it would be beneficial to utilize a growth factor that 
encourages cell proliferation as well as the deposition of extracellular matrix material 
characteristic of native ligaments21. Connective tissue growth factor (CTGF) is a 36-38 kDa 
heparin-binding protein characterized by multiple conserved cysteine-rich domains22. CTGF is 
involved in a variety of physiological processes including angiogenesis, embryo development, 
and would healing23. CTGF has been previously shown to encourage fibroblastic differentiation 
of stem cells, as evidenced by cell proliferation, gene expression changes, and increased matrix 
deposition22,24. The most common way to expose cells to growth factors is by introducing the 
growth factor to the cells in vitro in the cell growth media. The major drawback to this technique 
is that growth factors have a relatively short half-life in cell growth media and are rapidly 
inactivated, thus making it necessary to introduce fresh growth factor during each media 
change25. Additionally, sustained growth factor delivery in an in vivo setting is a challenge that 
needs to be addressed to facilitate the development of functionalized scaffolds. One strategy to 
address these challenges is to conjugate growth factors to the scaffold surface using a covalent 
chemical conjugation procedure26. This surface modification-technique utilizes chemical bonds 
to immobilize the growth factors to exposed functional groups on a scaffold. Chemical 
conjugation of growth factors to a scaffold creates functionalized nanofiber scaffolds with 
tunable growth factor release and a prolonged influence on cell behavior25,26. Previously, 
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electrospun scaffolds with chemically conjugated growth factors have been used to encourage 
neuronal differentiation, enhance wound healing, and stimulate osteogenic cellular activity27–29. 
 
Previously, we have shown that individual PCL nanofiber bundles support short-term in vitro 
cell growth and proliferation16,  hence, this study is aimed at assessing long-term cell behavior 
on a 3D scaffold with multiple nanofiber bundles and chemically conjugated CTGF, both in vitro 
and in vivo. It is hypothesized that the combination of the unique hierarchical structure and the 
presence of CTGF will induce the deposition of tissue that is characteristic of ligaments, 
primarily collagen type I and type III.  
 
3.2 Methods 
3.2.1 Scaffold fabrication 
Flat sheets of aligned nanofibers were fabricated using an electrospinning technique as detailed 
previously16. A 10% w/v solution of polycaprolactone (PCL, Mw = 80,000, Sigma 440744, St. 
Louis, MO) was prepared in a 3:1 v/v mixture of chloroform and methanol. The electrospinning 
solution was ejected horizontally from a glass syringe outfitted with an 18-gauge blunt tipped 
needle at a rate of 2 mL/hr for 15 min. To create sheets of aligned nanofibers (Figure 3.1A), the 
collector surface was a rotating aluminum drum located 10 cm from the needle tip and rotating 
with a linear velocity of approximately 12 m/s. These sheets were further used to create 
cylindrical bundles of nanofibers (Figure 3.1B) by excising a rectangular portion of the sheet 
(approximately 5 cm x 175 cm) and rolling it up tightly into a cylinder16. This resulted in 
nanofiber bundles that were approximately 0.5 mm in diameter and 175 mm length, with 
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nanofibers aligned along the longitudinal axis. For further studies, nanofiber bundles were cut to 
20 mm in length 
 
3.2.2 Growth factor conjugation 
CTGF (Sigma SRP4702, St. Louis, MO) was covalently bound to nanofiber bundles (n=3) using 
a multi-step chemical conjugation technique (Figure 3.2A). First amines were added by 
incubating nanofiber bundles in a 5% v/v aqueous solution of polyallylamine (Sigma 479136, St. 
Louis, MO) with simultaneous ultraviolet radiation for 25 min. Next nanofiber bundles were 
incubated on a shaker plate in a solution 10% w/w solution of N-succinimidyl-3-
Figure 3.1: Aligned nanofibers (A), nanofiber bundle (B), scaffold composed of ~20 




maleimidoproprionate (TCI America SO427, Portland, OR) N,N-dimethylformamide (Sigma 
227056, St. Louis, MO) for 1 hr to add on maleimide terminals. In the final step, the nanofiber 
bundles were incubated in a 50 ng/mL solution of CTGF for 2 hr. Between subsequent steps, the 
nanofiber bundles were rinsed in triplicate using deionized water (dH2O), incubated in distilled 
dH2O for 2 hr, and then rinsed an additional 3 times in dH2O to ensure all excess chemicals had 
been leached from the nanofibers.  
 
Figure 3.2: Chemical conjugation procedure (A), XPS survey spectra showing increasing 
nitrogen peak (B), immunofluorescence staining of conjugated CTGF (C), amount of CTGF 
conjugated (D),  and CTGF release over a 14 day period (E). 
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CTGF conjugation efficiency was assessed using X-ray photoelectron spectroscopy (XPS, PE-
5800, Physical Electronics, Chanhassen, MN). XPS was conducted after each subsequent 
modification step to assess the surface composition of nitrogen, which is indicative of successful 
conjugation of each linker component as well as CTGF. Survey spectra were collected from 0 to 
1100eV with a pass energy of 187.85 and data for the percent elemental composition were 
calculated using the instrument specific software (PHI MultiPak, Physical Electronics, 
Chanhassen, MN). 
 
Distribution of CTGF was assessed using immunofluorescence labeling. To 
immunofluorescently label the conjugated CTGF, nanofiber bundles were first rinsed with 
phosphate-buffered saline (PBS) and then incubated with 10% donkey serum (Santa Cruz 
Biotechnology sc-2044, Santa Cruz, CA) in PBS for 20 min. After rinsing again in PBS, 
nanofiber bundles were incubated in the primary antibody against CTGF (goat, Santa Cruz 
Biotechnology sc-14939, Santa Cruz, CA) prepared in 1.5% donkey serum at a concentration of 
4 µg/mL in PBS for 1 hr. Nanofiber bundles were then rinsed in PBS in triplicate for 5 min each. 
Next, nanofiber bundles were incubated in the secondary antibody labeled with fluorescein 
isothiocyanate (FITC, donkey anti-goat, Santa Cruz Biotechnology sc-2024, Santa Cruz, CA) 
prepared in 1.5% donkey serum at a concentration of 4 µg/mL in PBS for 1 hr. Nanofiber 
bundles were rinsed again in PBS prior to imaging with a fluorescent microscope (Olympus 
IX70, Center Valley, PA). 
 
An enzyme-linked immunosorbent assay (ELISA, PeproTech 900-m317, Rocky Hill, NJ) was 
used to characterize the amount of CTGF initially conjugated to each nanofiber bundle as well as 
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the cumulative release of CTGF from nanofiber bundles over a 2 week time period. After the 
final conjugation step, the CTGF solution was used to measure the amount of growth factor that 
remained unconjugated.  Then nanofiber bundles with conjugated CTGF were incubated in dH2O 
at 37º C and 5% CO2. DH2O was collected from the nanofiber bundles at Days 1, 2, 5, 7, 10, and 
14 and the amount of CTGF in the solution was measured following the manufacturer 
instructions provided with the ELISA kit. This provided a cumulative measure of the percentage 
of conjugated CTGF that was released from the nanofiber bundles. 
 
3.2.3 Harvest of bone marrow-derived stem cells 
Ovine bone marrow-derived mesenchymal stem cells (OBMSCs) for the in vitro experiments 
were aseptically harvested from the bone marrow of the femurs of 4 skeletally mature sheep that 
were euthanized for unrelated purposes. After disarticulating the leg, the muscle and fascia were 
removed and the femur was sawn open close to the femoral head.  Bone marrow (~5 mL from 
each femur) was removed from the medullary canal and transferred to a 50 mL tube containing 
cell growth media. The cell growth media consisted of Dulbecco’s Modified Eagle Medium with 
10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 2.5 µg/mL amphotericin B. 
Bone marrow was gently aspirated to break up tissue aggregates prior to centrifugation at 650 g 
for 5 min. The separated fatty layer was discarded and the cell pellet was resuspended in 20 mL 
of cell growth media, triturated through a 16 gauge needle and filtered through a 40 µm nylon 
cell strainer. Red blood cells were lysed using 4% acetic acid and mononuclear cells were 
counted using an automatic cell counter (Scepter 2.0, MilliporeSigma, Billerica, MA). Isolated 
OBMSC from the 4 animals were pooled, seeded at a density of 5,000 cells/cm2 in 75 cm2 flasks 
and expanded until passage 4. Passage 4 OBMSCs were used for the in vitro experiments. 
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Porcine bone marrow-derived mesenchymal stem cells (PBMSCs) for the in vivo experiments 
were isolated and expanded as previously described30. Briefly, mononuclear cells were isolated 
from the femora of 4-month-old pigs as described above and seeded at a density of 5,000 
cells/cm2 in 75 cm2 flasks. PBMSCs were maintained in cell growth media consisting of high 
glucose Dulbecco’s modified Eagle’s medium GlutaMAX, 10% FBS, 1% 
penicillin/streptomycin and 2.5 μg/mL amphotericin B and were expanded until passage 2. 
Passage 2 PBMSCs were used for the in vivo experiments. 
   
3.2.4 Short-term in vitro cell culture 
To assess the short-term effects of the conjugated CTGF on nanofiber bundles, OMBSCs were 
seeded on individual nanofiber bundles (n = 6, Figure 3.1B) both with and without conjugated 
CTGF. After CTGF conjugation samples were sterilized using 70% ethanol and exposure to 
ultra-violet light. OBMSCs at passage 4 were seeded on nanofiber bundles at a concentration of 
approximately 200 cells/µL. Nanofiber bundles seeded with OBMSCs were maintained at 37º C 
and 5% CO2 for 1 week and the cell growth media was changed every 2-3 days. Cell viability 
(n=6) was measured after 1, 4, and 7, days of culture using a CellTiter-Blue Cell Viability Assay 
(Promega G808A, Madison, WI) according to the manufacturer’s instructions. 
 
After 7 days in culture, cell adhesion was assessed by staining the cells on nanofiber bundles 
(n=3) with 5-Chloromethylfluorescein Diacetate (CMFDA, Life Technologies C2925, Carlsbad, 
CA), rhodamine-phalloidin (Cytoskeleton, Inc, Denver, CO) and 4’,6-diamidino-2-phenylindole 
(DAPI, Life Technologies D1306, Carlbad, CA).  The cytoplasm of live cells was stained green 
with CMFDA followed by fixation in 3.7% formaldehyde for 50 min and permeabilization with 
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1% Triton-X 100 for 3 min. After permeabilization rhodamine-phalloidin was used to stain the 
actin cytoskeleton of cells red and DAPI was used to stain the cell nuclei blue. Nanofiber 
bundles were imaged with a Zeiss Axioplan 2 fluorescence microscope. Additionally, scanning 
electron microscopy (SEM) was used to assess the morphology and spatial organization of cells 
on nanofiber bundles (n=3) as previously described16. Briefly, cells were fixed for imaging in a 
solution of 3% glutaraldehyde, 0.1 M sodium cacodylate, and 0.1 M sucrose for 45 min, then 
serially dehydrated and stored in a desiccator until imaged with an SEM (JSM-6500F, JOEL, 
Peabody, MA) operating at 10kV. 
 
3.2.5 Long-term in vitro cell culture 
 A scaled-up scaffold (n = 12) composed of multiple nanofiber bundles was used to assess the 
long-term influence of conjugated CTGF on cells grown in vitro. This scaled-up scaffold was ~3 
mm in diameter and consisted of ~20 nanofiber bundles cut to 20mm in length tied together at 
the ends with suture wire (Figure 3.1C). After fabrication scaffolds were either conjugated with 
CTGF (as previously described) or left unconjugated to serve as a control. OBMSCs at passage 4 
were seeded on scaffolds at a concentration of approximately 600 cells/µL. Scaffolds were 
maintained in standard cell culture conditions for 21 days. Cell viability of scaffolds (n=12) was 
measured at days 1, 7, 14, and 21 using a CellTiter-Blue viability assay. 
 
At the end of the 21 day culture period scaffolds were assessed using histological and 
immunohistochemical staining and biochemical assays. To assess the biochemical content 
scaffolds (n=8) were cut in half and rinsed in PBS and immediately frozen at -80 ºC. After 
thawing, scaffolds were digested with papain (125 µg/mL) in 0.1 M sodium acetate, 5 mM L-
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cysteine-HCL, and 0.05 M ethylenediaminetetraacetic acid (EDTA) under constant rotation for 
18 hr. Immediately after the papain digestion DNA content was analyzed using a PicoGreen 
DNA assay (Thermo Fisher Scientific P11496, Waltham, MA). Total collagen content was 
determined by measuring the hydroxyproline content, after acidic hydrolysis of samples (110º C 
for 18 hr) in concentrated hydrochloric acid (38%)31. Samples were assayed using a chloramine-
T assay assuming a hydroxyproline-to-collagen ratio of 1:7.6932. The amount of sulphated 
glycosaminoglycans (sGAG) was quantified using a dimethylmethylene blue dye-binding 
(DMMB) assay as previously reported31.   
 
Additional halves of scaffolds (n=8) were used for histology and immunohistochemistry. 
Scaffolds were fixed for 24 hr in 10% formalin, infiltrated with a graded series of sucrose 
solutions, embedded in optimum cutting temperature medium (Tissue-Tek, Sakura Finetek, 
Torrance, CA), and flash frozen in liquid nitrogen. Embedded scaffolds were cryosectioned 
axially through the center to obtain 10 µm slices which were fixed to microscope slides. Sections 
were stained with picrosirius red to assess collagen deposition, 1% alizarin red to assess calcium 
accumulation, and hematoxylin and safraninO/fast green to assess sulfated glycosaminoglycan 
content. Stained sections from day 1 were included as controls. Immunohistochemical analysis of 
collagen types I and III was performed using a standard immunohistochemical technique to 
evaluate the collagen types deposited by cells. Briefly, sections were pre-treated with pronase 
(Sigma-Aldrich PRON-RO, St Louis, MO) in a humidified environment at 37 °C for 5 min for 
antigen retrieval. Then, sections were blocked with goat-serum (Sigma-Aldrich G9023, St Louis, 
MO) for 1 hr and incubated with primary antibodies specific to collagens type I and III overnight 
at 4 °C. For in vivo samples primary antibodies, anti-collagen I antibody [Col-1] (mouse 
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monoclonal ab90395) or anti-collagen III antibody [1E7-D7/Col-3] (mouse monoclonal 
ab23445) were used. For in vitro samples primary antibodies, anti-collagen I antibody [5D8-G9] 
(mouse monoclonal ab23446) or anti-collagen III antibody (rabbit polyclonal ab7778) were used 
(all Abcam, Cambridge, UK). After overnight incubation, sections were washed in PBS and 
incubated with the secondary antibody, goat anti-mouse IgG (B7151, Sigma) or goat anti-rabbit 
IgG (20019, Biotium) for 1 h. Color was developed using the Vectastain ABC reagent kit 
(Vectastain ABC kit, Vector Laboratories, UK) followed by exposure to peroxidase DAB 
peroxidase substrate (DAB Peroxidase (HRP) Substrate Kit, Vector Laboratories, UK ). Reaction 
was stopped when color was visible and sections were washed, dehydrated through an alcohol 
gradient and mounted using Vectashield (Vector Laboratories, UK). 
 
3.2.6 In vivo subcutaneous implantation 
A smaller scaffold (n = 8) consisting of 4 nanofiber bundles secured together at one end was 
implanted subcutaneously into the back of a nude mouse (Figure 3.1D). The size of the scaffold 
was adjusted so that it could be used with the nude mouse. CTGF was conjugated to the small 
scaffold surface as described above and control scaffolds were also included with no growth 
factors. PBMSCs at passage 2 were seeded on small scaffolds at a concentration of 
approximately 2000 cells/µL 
 
All animal experiments were approved by the Ethics Committee of Trinity College Dublin 
(Republic of Ireland) and the Irish Medicines Board (IMB, Republic of Ireland). Control and 
CTGF conjugated small scaffolds (n=8 per group) were implanted into the subcutaneous space of 
Balb/C nude mice (Harlan, UK) using a previously described surgical procedure33  Briefly, 2 
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subcutaneous pockets were created on both flanks of the mice under aseptic conditions through 
an incision made on the dorsal side of the mouse. Then, one small scaffold was implanted in 
each subcutaneous pocket (2 small scaffolds per animal). All small scaffolds were harvested at 6 
weeks of in vivo implantation. Small scaffolds were analyzed for gross appearance and 




Data are presented as mean ± standard error of the mean. Data analysis was performed using 
Minitab (Minitab, Inc., State College, PA). For all quantitative measures, comparisons were 
performed using a two-way analysis of variance (ANOVA) with Tukey’s post-hoc test. 




3.3.1 Growth factor conjugation 
The covalent chemical conjugation of CTGF to electrospun nanofibers was verified using XPS 
analysis after modification of the nanofiber bundles with the linker molecules and CTGF. 
Initially, since unmodified PCL consists only of carbon and oxygen atoms there is no nitrogen 
present. After modifying with polyallylamine to add amines groups on the surface of the 
nanofiber bundles, the surface elemental nitrogen composition was 1.5%. The addition of 
maleimides terminals using N-succinimidyl-3-maleimidoproprionate resulted in a 0.8% increase 
in the nitrogen composition of the surface. Finally, after adding the growth factor CTGF, which 
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consists of multiple conserved cysteine-rich domains, the final nitrogen composition was 3.5%. 
The increase in nitrogen could be seen visually by inspecting the nitrogen peak of the XPS 
survey before and after CTGF conjugation (Figure 3.2B). This increase in elemental nitrogen 
percentage after each subsequent modification step indicates successful conjugation. 
 
Immunofluorescence labeling demonstrated that the conjugated CTGF was distributed uniformly 
across the surface of nanofiber bundles, as intended (Figure 3.2C). A CTGF ELISA was used to 
determine how much CTGF did not conjugate on to the nanofiber surfaces, as a quantitative 
measure of conjugation efficiency. During the conjugation procedure, each sample was exposed 
to 10 ng of CTGF in dH2O. After the 2 hr incubation period, an average of only 0.466 (± 0.028) 
ng of CTGF remained in the dH2O (Figure 3.2D). This demonstrates that 95% of the CTGF was 
successfully conjugated to the nanofiber bundles. The same ELISA was also used to assess how 
much of CTGF was released from nanofiber bundles over a 2 week time period. The results 
showed that over the 2 week time period less the 6% of conjugated CTGF was released from the 
samples (Figure 3.2E). In the first 5 days, there was a slight burst release where ~ 5% of CTGF 
was released, however, in the following 9 days only an additional 1% of the CTGF was released 
 
3.3.2 Short-term in vitro cell culture 
The CellTiter-Blue metabolic assay revealed that cells attached and remained viable on 
individual nanofiber bundles both with and without conjugated CTGF for up to 7 days in culture 
(Figure 3.3A). There were no differences in metabolic activity level of the cells on nanofiber 
bundles with or without CTGF, and the metabolic activity level of cells on all nanofiber bundles 
remained relatively constant over time. SEM images showed that cells adhered, spread, and 
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colonized on all nanofiber bundles (Figure 3.3B, 3.3D). Additionally, cells appeared to have 
adopted an elongated morphology along the direction of the nanofibers (along the longitudinal 
axis of the nanofiber bundle) for all nanofiber bundles. Similarly, after 7 days of culture, 
fluorescence microscopy images showed elongated cells covering the surfaces of all nanofiber 
bundles (Figure 3.3C, 3.3E). 
 
Figure 3.3: 7 day in vitro nanofiber bundle CellTiter Blue assay results (A), representative 
SEM (B,D) and fluorescence (C,E) images of cells on control (B,C) and CTGF conjugated 
(D,E) nanofiber bundles. 
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3.3.3 Long-term in vitro cell culture 
The CellTiter-Blue assay revealed significant differences in the metabolic activity of cells on 
control and CTGF scaffolds consisting of ~20 nanofiber bundles. At each time point investigated 
the metabolic activity of cells on CTGF scaffolds was significantly higher than the metabolic 
activity of cells grown on control scaffolds (Figure 3.4A). Additionally, the metabolic activity of 
cells on scaffolds conjugated with CTGF was increased significantly from Day 1 to Day 21 
(p=0.002). In contrast, the metabolic activity of cells on control scaffolds did not significantly 
change from Day 1 to Day 21 (p=0.142). Similarly, the PicoGreen Assay to measure DNA 
content of the scaffolds showed that after 1 day in culture the DNA content of cells on CTGF 
scaffolds was significantly higher DNA content of control scaffolds (p=0.01, Figure 3.4B). By 
Day 21 the DNA content of cells on CTGF scaffolds had increased significantly from Day 1 




Biochemical analysis revealed that by Day 21 the amount of accumulated collagen (normalized 
to µg of DNA) in CTGF conjugated scaffolds was significantly higher than the collagen 
accumulated in control scaffolds (p=0.031, Figure 3.4C). The DMMB assay to determine sGAG 
accumulation within the scaffolds showed that by Day 21 of culture the sGAG content 
(normalized to µg of DNA) of CTGF scaffolds was significantly lower than the sGAG content of 
control scaffolds (p=0.0008, Figure 3.4D). 
 
Figure 3.4: 21 day in vitro scaffold CellTiter Blue assay results (A), PicoGreen assay for 
DNA content (B), Day 21 hydroxyproline assay for collagen content (C), and Day 21 
DMMB assay for sGAG content (D). * Indicates significant difference between control and 




Histology performed using a picrosirius red stain after 21 days of culture showed that there was 
notable collagen deposition by cells grown on CTGF scaffolds compared to control scaffolds 
(Figure 3.5A, 3.5B). The collagen was deposited primarily around nanofiber bundles that were 
on the exterior of the scaffold, which some deposition reaching towards the interior. There was 
no notable deposition of glycosaminoglycans (red/pink stain) or calcium (bright red), based on 
safraninO/fast green and alizarin red stains respectively, on either control or CTGF scaffolds 
(Figure 3.5C-F).  Immunohistochemical analysis showed that there was no apparent labeling of 
collagen on control scaffolds (Figure 3.5G, 3.5I). The collagen deposited on the CTGF scaffolds 




3.3.4 In vivo subcutaneous implantation 
CTGF conjugated scaffolds implanted in vivo showed more homogenous collagen coverage 
around the nanofiber bundles whereas the control in vivo small scaffolds showed uneven 
Figure 3.5: Representative 21 day in vitro scaffold histology staining with picrosirius red for 
collagen (A,B), safraninO/fast green for sGAG (C,D), and alizarin red for calcium (E,F) in 
control (A,C,E) and CTGF conjugated (B,D,F) scaffolds. Immunohistochemical staining for 




covering of collagen with different staining intensity in some places around the nanofiber 
bundles (Figure 3.6A, 3.6B). The collagen type I and III immunohistochemistry showed uniform 
staining around the CTGF conjugated nanofiber bundles indicating the even distribution of 
ligament specific tissue in presence of CTGF (Figure 3.6D, 3.6F). The periphery of control 
nanofiber bundles stained intensely for collagen type I staining and relatively weakly for 
collagen type III (Figure 3.6C, 3.6E). This could indicate that non-specific fibrous tissue is 
forming on the unconjugated nanofiber bundles. 
 
  
Figure 3.6: Representative 6 week in vivo histology staining with picrosirius red for collagen 
(A,B) in control (A) and CTGF conjugated (B) scaffolds. Immunohistochemical staining for 





The key requirements for a tissue engineered ligament scaffold have been well described 
previously21,34. The scaffold must be made from a biocompatible material and closely match the 
structural and mechanical properties of the native tissue. The scaffolds investigated in this work 
represent a hierarchal construct that mimics the structure of the native human ACL using sheets 
of aligned nanofibers prepared using a standard electrospinning technique. By rolling rectangular 
sections of the electrospun nanofiber sheets to create nanofiber bundles it creates a robust 
structure which supports cell growth and proliferation, cell elongation, and has material 
properties that are comparable to the properties of the native human ACL16–18.  Others have 
attempted to use stacked PCL sheets for ACL replacement and while transient immune responses 
were noted15, they subsided and the potential for heparin-mediated growth factor release was 
noted, as a technique for further encouraging de novo extracellular matrix deposition35,36. 
Similarly, Bosworth et al. reported that tightly wound PCL yarn could be utilized as a substrate 
for tendon fibroblast adhesion and proliferation37. Modifications to traditional PCL have also 
been investigated as materials for ligament scaffolds, particularly ultra-high molecular weight 
PCL (UHMWPCL) and PCL with the addition of L-lactic acid (PCLC) with promising 
results38,39. In the current study, a scaffold composed of multiple nanofiber bundles was created 
to better mimic the hierarchal structure of the collagen in the native ACL on macro, micro, and 
nano-size scales, and provide space for matrix deposition between and around the nanofiber 
bundles. 
 
In addition to scaffold material, it is also important to consider the structure of the scaffold. The 
native ACL possess a complex hierarchical structure with collagen fibrils primarily oriented 
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along the longitudinal axis of the ligament20 and then organized into fascicles5. The primarily 
parallel orientation is thought to lend tensile strength and stability to the ligament4. The scaffold 
presented in this work was fabricated to attempt to mimic this hierarchical structure. The 
electrospun PCL nanofibers which mimic the collagen fibrils are tightly rolled upon themselves 
to create nanofiber bundles which mimic the collagen fascicles. Previous work showed that these 
individual nanofiber bundles promoted cell adhesion and proliferation16. In order to provide a 
suitable ligament replacement, a scaffold must also be able to withstand the repeated tensile 
loading experienced by native ligaments.  Previous mechanical testing revealed that when pulled 
to failure at a physiologically relevant strain rate the modulus, yield stress, and yield stress and 
yield strain of nanofiber bundles mimic the material properties of the native human ACL, 
suggesting this scaffold has the potential to meet the mechanical demands of the ligament16. To 
better mimic the overall ACL structure multiple nanofiber bundles were grouped together by 
tying the ends together, which allows the nanofiber bundles to lie parallel to one another. 
Although the native collagen fascicles of ACL are not perfectly parallel to one another, 
particularly when comparing fascicles in the in the anteromedial and posterolateral bundles of 
the ligament, this scaffold structure represents a first step at mimicking the hierarchical ACL 
structure. Other groups have attempted to recreate the hierarchical ACL structure with various 
techniques.  Two popular techniques are utilizing braided or twisted strands of material to 
increase stiffness and tensile strength, however encouraging cell infiltration can be 
challenging13,39–42. A recent study comparing braided electrospun PCL sheets to stacked 
electrospun PCL sheets showed that the braided scaffolds possessed improved tensile strength 
which better mimicked the native ACL, however, cell infiltration and proliferation was superior 
in stacked constructs43. 
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In order to encourage cell adhesion and proliferation as well as the deposition of native ligament 
ECM by the cells, we investigated the chemical conjugation of growth factors on the surface of 
the scaffold. The chemical conjugation technique used in this study resulted in a 95% 
conjugation efficiency, which suggests a secure covalent bond between the PCL, linker 
molecules, and the CTGF. After an initial burst release, over a two week time period only ~6% 
of the conjugated CTGF was released from the scaffold. Previous studies using similar 
techniques to covalently immobilize growth factors on scaffold surfaces have shown similar 
release profiles28,44. The initial burst release of CTGF into the surrounding media could be due to 
the release of some unconjugated CTGF that was physically trapped within the porous network 
of nanofibers and required multiple days to diffuse out into the surrounding solution. The CTGF 
that remains covalently conjugated to the nanofiber bundles is thought to influence cells that 
adhere to the scaffold via juxtacrine signal transduction45. When cells are in contact with the 
conjugated growth factors, signal transduction pathways are initiated which lead to cellular 
adaptation and upregulation of collagen I and III production29. 
 
After one week of in vitro culture, there was no difference in cell metabolic activity on nanofiber 
bundles with and without conjugated with CTGF. Thus, for early time points, the presence of the 
CTGF likely has no impact on cell proliferation and viability.  Other groups that have utilized 
growth factors for ligament tissue engineering have found differences in cell proliferation as 
early as 7 days in vitro. Notably, after 1 week of culture Sahoo et al. demonstrated significantly 
higher viability when cells were grown on knitted silk scaffolds that had been with electrospun 
nanofibers made of a PLGA/basic fibroblastic growth factor (bFGF) blend, compared to the 
same scaffolds without bFGF46. However, this response could be due to the release profile of the 
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bFGF since nearly 60% was released into the surrounding media in the first 7 days47. Similarly, 
Hankemeier et al. showed that after 7 days of culture higher doses of bFGF results in a higher 
density of cells48. On our scaffolds, no apparent differences in cell coverage on nanofiber bundle 
surfaces were noted, and cells became elongated along the long-axis of the nanofiber bundle 
regardless of CTGF presence. This is somewhat surprising since previous studies have shown 
that the presence of CTGF induces a more elongated cell shape22,24 however it could be that the 
aligned PCL nanofibers present in our scaffold encourage cell elongation regardless of growth 
factor presence. The shape and morphology of cells, as dictated by the structure of the scaffold, 
influence cell migration, and communication as well as cellular differentiation49. In the context 
of ligament tissue engineering, an elongated spindle-shaped cell morphology mimics the 
structure of native fibroblasts and is thought to be important for fibroblastic cellular 
differentiation50,51.  
 
In contrast to the cell proliferation seen on individual nanofiber bundles, when scaffolds 
consisting of ~20 nanofiber bundles were cultured in vitro, there were significant differences in 
cell proliferation in the presence of conjugated CTGF. As early as 1 day after cell seeding, DNA 
content and cellular metabolic activity on scaffolds with conjugated CTGF were both nearly 
double that of control scaffolds. This suggests that initially, the cells had a greater affinity for 
attaching to scaffolds with conjugated CTGF. However, on individual nanofiber bundles, cells 
adhered at equal levels regardless of CTGF presence. This could be due to the differences in the 
macro-scale architecture of the scaffold.  Since the 3D scaffold consisted of multiple nanofiber 
bundles, each conjugated with CTGF, the larger area of exposed surface area for growth factor 
could encourage more cell attachment. It is difficult to compare our initial cell attachment results 
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to those of other groups since typically cell behavior is not investigated after only one day of in 
vitro culture. However, in the future, it will be necessary to better understand what chemical and 
structural properties of scaffolds influence initial cell attachment. The trend for higher DNA 
content and higher metabolic activity on CTGF scaffolds persisted through day 21 of in vitro 
culture. Additionally, after 21 days of in vitro culture, the cell metabolic activity and the DNA 
content on CTGF conjugated scaffolds was higher than it had been at day 1, suggesting robust 
cellular proliferation throughout the 3 week culture period. These results closely match those of 
other research groups who have assessed the proliferation of cells both in the presence of other 
ligament-related growth factors35,46,48,52 and specifically in the presence of CTGF22,24.   
 
In addition to influencing cell adhesion and proliferation, conjugated CTGF had an effect on the 
matrix material deposited by cells in vitro. Collagen is the predominant extracellular matrix 
material in ligaments and its presence is crucial for repair and regeneration of fibrous tissues53. 
Robust deposition of collagen is vital for a successful tissue engineered ligament so that as the 
scaffold gradually degrades, de novo tissue remains in its place. Cells on all scaffolds deposited 
collagen around the nanofiber bundles. The collagen deposition was mostly observed around the 
outside of the scaffold where it bridged the gaps between nanofiber bundles, however, some 
collagen deposition was also present toward the interior of the scaffold. Similarly, Copper et al. 
implanted braided scaffolds composed of PLLA fibers in a rabbit ACL reconstruction model and 
noted robust deposition of cells and dense connective tissue surrounding all polymer fibers54. 
The 21 day in vitro culture period investigated in the present study was chosen based on 
measurable changes in collagen deposition between the groups of control and CTGF conjugated 
scaffolds. Additionally, other research groups who have investigated the effects of growth factors 
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on nanofibrous scaffolds in vitro have used similar 3 week time points to investigate cell 
behavior13,24,46,52,55. In order to further encourage more robust deposition of collagen around and 
between the individual nanofiber bundles that compose the 3D scaffold it may be necessary to 
incorporate mechanical stimulation. Previous groups have shown that compared to static culture, 
tensile loading of polymer scaffolds during culture encourages more cellular deposition of highly 
aligned collagen fibers similar to those observed in ligaments56,57.  Additionally, nano-scale 
alterations such as modifying the nanofibers to have a crimp-like microarchitecture may 
encourage ECM deposition and cell differentiation58,59. On the scaffolds presented in this study, 
collagen deposition was notably more pronounced on scaffolds with conjugated CTGF. 
Quantitatively, the measured amount of accumulated collagen (normalized for DNA content) 
was nearly 4 times higher on CTGF scaffolds compared to control scaffolds. CTGF presence has 
been previously shown to stimulate the robust production of collagen in vitro in both fibroblasts 
and mesenchymal stem cells based on assessment of mRNA levels and histological staining of 
tissues22,23.  
 
Ideally, the extracellular matrix produced by cells on a tissue-engineered ligament should mimic 
the structure and biological function of the native ligament ECM as much as possible. Thus, 
when considering collagen deposition on a scaffold it is important to not only note the presence 
of collagen, but also the specific types of collagen. Collagen type I is the major collagen found in 
ligaments however collagen type III is also present5. Type III collagen is found throughout the 
ACL as a component of reticular fibers, a loose connective tissue that divides type I collagen 
bundles. Immunohistochemistry after 3 weeks in vitro showed that on scaffolds with conjugated 
CTGF the collagen that was deposited on the surface of the nanofiber bundles was primarily 
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types I and III. In contrast, on the control scaffolds, there was essentially no evidence of either 
collagen I or III staining. There has been some evidence to suggest that the levels of different 
types of collagen fluctuate during tendon development, where type III collagen is deposited 
initially and later replaced by type I collagen60. Similarly, during the connective tissue healing 
process, some groups have found an initial increase in type III collagen followed by additional 
type I collagen deposition61,62. Thus in future work, it may be beneficial to quantify the types of 
collagen present to assess early recapitulation of the ligament development and healing process. 
Additionally, notable deposition of collagen types I and III could suggest that the OBMSCs 
seeded on the scaffolds are beginning to differentiate into fibroblasts, cells characteristic of 
ligaments63,64. In future studies, gene expression changes will be investigated to further confirm 
cell differentiation.  
 
There was no apparent deposition of calcium or sGAG on any scaffolds. The absence of calcium 
is appropriate since no calcium is present in native ligaments. By Day 21 the amount of sGAG 
accumulated on CTGF scaffolds was lower than the accumulated sGAG on control scaffolds.  
Because high sGAG production is typically associated with chondrogenic differentiation, less 
accumulation of sGAG further suggests that the OBMSCs seeded on the scaffolds conjugated 
with CTGF may be differentiating into fibroblasts65. The ACL does have a small amount of 
sGAG, about 9% of the weight of the dry tissue, which is thought to be important for the 
viscoelastic mechanical behavior5,66. In future studies, it may be necessary to optimize the 




In an effort to better understand the in vivo response of cells to the scaffold and conjugated 
growth factor at a long time point, a nude mouse model was utilized. The smaller size of the 
scaffolds implanted in vivo permitted the assessment of matrix deposition between nanofiber 
bundles while conserving space and resources. The 6 week implantation period was chosen in 
order to be an extension of the in vitro time point and to get an initial indication of longer term in 
vivo cell behavior. After 6 weeks of in vivo implantation, collagen deposition was observed 
around all fibers of the scaffolds. The stacked electrospun PCL scaffold implanted in vitro by 
Petrigliano et al. in a rat model of ACL reconstruction showed that cells did not start producing a 
collagen matrix until 6 weeks after implantation, and this collagen matrix matured through week 
1215. Thus it is possible that the collagen observed on our scaffolds in vitro would continue to 
increase and mature with additional implantation time. For the scaffolds presented in this study, 
in vivo collagen deposition appeared similar for both control and CTGF scaffolds. Differences in 
the influence of CTGF on collagen deposition in vitro and in vivo could be due to the longer time 
point, the presence of host cells in vivo, or the influence of other in vivo environmental cues. 
Additionally, the collagen deposited on all scaffolds (control and CTGF conjugated) in vivo was 
identified as collagen types I and III. This is a slightly different from what was observed in vitro, 
where types I and III collagen were only identified on CTGF conjugated scaffolds. This 
difference could be based on culture times, and potentially with longer in vitro, culture times 
collagen I and III accumulation would increase on control scaffolds, similar to what was seen in 
vivo. Similarly, a knitted silk scaffold implanted in a porcine ACL reconstruction model was 
found to support robust deposition of collagen I and III and tenasin-C in vivo67. One limitation of 
the in vivo results presented is a lack of quantification of collagen content of the scaffolds. Non-
specific fibrous tissue that can form around scaffolds during subcutaneous implantation can 
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interfere with the hydroxyproline assay which is commonly used to measure collagen content. 
Thus we chose to only utilize histology and immunohistochemical staining for the specific types 
of collagen found in ligaments. An additional limitation of the in vivo work is that in the in vivo 
environment it is challenging to separate the activities of the cells seeded on the scaffold prior to 
implantation from host cells found within the animal. For example, Spalazzi et al implanted a 
triphasic polymer scaffold subcutaneously in an athymic rat and found thorough host cell 
infiltration which led to the deposition of de novo tissue within the scaffold68,69.  Future studies 
will explore implanting cell-free and cell-laden scaffolds in more challenging orthotopic 
locations.  
 
Overall the results of this study have demonstrated that it is possible to utilize CTGF conjugation 
and novel biofabrication strategies to create a bioactive scaffold that mimics the hierarchal 
structure of the native ACL. During in vitro and in vivo culture the presence of CTGF 
encourages cell adhesion, proliferation, and robust deposition of collagen which is specific for 
ligament tissue.  This suggests that the presence of CTGF may be influencing the seeded stem 
cells to differentiate into ligamentous cells. Therefore the scaffold developed in this study, in 
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MECHANICAL PROPERTIES OF A HIERARCHICAL ELECTROSPUN SCAFFOLD 
FOR OVINE ANTERIOR CRUCIATE LIGAMENT REPLACEMENT 
 
4. 1 Introduction 
The anterior cruciate ligament (ACL) is a complex hierarchical structure that connects the femur 
to the tibia and is composed primarily of collagen. The primary function of the ACL is to restrict 
translations and rotations of the tibia and thus stabilize the knee throughout the functional range 
of motion1. When the ACL is intact it prevents the tibia from displacing anteriorly relative to the 
femur as well as undergoing excessive internal and varus-valgus tibial rotations2. When anterior 
force is applied to the tibia of an ACL deficient knee, the anterior tibial translation is four times 
greater than in an intact knee3,4. Clinically, functional stability is assessed using an anterior 
drawer test5,6. The ACL is loaded throughout the gait cycle and musculoskeletal modeling has 
shown that in human knees the ACL experiences peak loads of ~300 N and maximum strains of 
approximately 3%7,8. 
 
Similar to other tendons and ligaments, the ACL is characterized by nonlinear behavior in 
response to applied tensile loads9. Under initial tensile loads, the force-displacement curve of the 
ACL displays a characteristic low stiffness linear region where the collagen fibers of the 
ligament are not yet loaded whereas the elastin component is loaded. Next, a non-linear toe 
region is evident from the reversible un-crimping of collagen fibers, followed by a linear elastic 
region of loading where the collagen fibers are completely un-crimped and taut10. The ACL also 
exhibits time-dependent viscoelastic properties, where the elongation of the ligament depends 
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not only on the magnitude of the force but also on the application rate11. This time dependence is 
often manifested as stress relaxation where the tissue shows a decrease in load under constant 
elongation. These time-dependent material properties enable to ACL to contribute to knee 
stability12. 
 
Tears of the ACL are common and frequently occur during non-contact sports injuries13,14. In an 
ACL deficient knee,  altered joint kinematics can limit normal activities15. Following rupture of 
the ACL, significant pain, bone bruising, joint instability, and damage to surrounding soft tissues 
will occur16. ACL reconstruction aims to restore a connection between the femur and tibia to 
restore stability to the joint17. Both allografts and autografts are commonly used to replace the 
torn ACL15,18. Commonly used grafts include the semitendinosus tendon, the gracilis tendon, the 
Achilles tendon, or patellar tendon with attached bone plugs19–21. Regardless of tissue type or 
tissue source no definitive evidence has demonstrated the ability of ACL reconstructions to fully 
restore knee functionally or prevent re-tears of the reconstruction or the contralateral ACL22–24. 
Poor outcomes after ACL reconstruction may be attributed to a failure to match the mechanical 
property of the native ACL and an inability of the reconstruction to restore knee kinematics25. 
Additionally surgeons typically fail to treat occult damage that has occurred to surrounding 
tissues, including tears of the menisci and damage to articular cartilage and subchondral bone, 
which can result in accelerated osteoarthritis progression23. 
 
Based on the limitations of traditional ACL allografts and autografts, our group has developed a 
polycaprolactone (PCL) scaffold for use as a tissue-engineered ACL replacement that mimics the 
hierarchical structure of the native ACL. PCL has a slow degradation rate and does not generate 
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harmful byproducts, making it a popular choice for tissue engineered scaffolds26. The scaffold 
structure mimics a bone-patellar tendon-bone ACL graft with electrospun nanofiber bundles 
connecting two solid cylindrical blocks intended to be inserted into bone tunnels. We have 
previously shown that the sub-structural components of the scaffold mimic the hierarchical 
structure and material properties of the native ACL27. Additionally, we have shown that ovine 
bone marrow-derived stem cells seeded on the scaffold deposit collagen in vitro, and 
implantation into the ovine stifle joint is clinically feasible28. Taken together, these advances 
suggest that the novel scaffold could perform well as a tissue engineered ACL replacement.  
 
Prior to an in vivo study, assessment of the scaffold ex vivo (prior to implantation) as well as in 
situ (after implantation into a cadaver stifle joint) is necessary. Additionally, comparing the 
performance of the implanted scaffold to an implanted soft tissue graft which mimics a “gold 
standard” allograft or autograft would be beneficial. If the in situ performance of the implanted 
scaffold is comparable to the performance of a traditional soft tissue graft, it would suggest that 
the novel scaffold developed in this study can provide a similar amount of stabilization to the 
knee as a current gold standard repair. Thus, the goal of this work was to evaluate the 
performance of the novel scaffold as an ACL replacement. 
 
4.2 Methods 
4.2.1 Electrospun Scaffold Fabrication 
The base material for the scaffolds (Figure 4.1A) was flat sheets of aligned electrospun 
polycaprolactone (PCL) nanofibers created using a previously detailed electrospinning 
technique27,28. Briefly, a 10% w/v solution of PCL (MW=80,000; Sigma 440744, St. Louis, MO) 
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was dissolved in a 3:1 v/v mixture of chloroform and methanol and was ejected from a glass 
syringe outfitted with an 18 gauge blunt-tip needle at a rate of 2 mL/hr. To create sheets with 
nanofibers primarily aligned along one axis, an aluminum drum rotating at a linear velocity of 
approximately 12 m/s was placed 10 cm from the needle tip and used as the collector surface. 
The electrospinning procedure was carried out for 15 minutes and then sheets of nanofibers were 
dried for 24 hours. Nanofiber bundles approximately 0.5 mm in diameter and 175 mm in length 
were created from sheets of nanofibers by excising a rectangular section (5 x 175 mm) and 
rolling it into a tight cylinder27,28 (Figure 4.1B). The nanofibers composing the nanofiber bundles 
were primarily aligned along the long axis of each nanofiber bundle27 (Figure 4.1C). 
 
Figure 4.1: Electrospun scaffold (A), individual nanofiber bundle (B) and electrospun 
nanofibers (C). Silicone tubing with solvent cast PCL (D), solidified PCL with voids cut off 
and remainder inserted into silicone tubing (E), nanofiber bundles inserted into solvent cast 
PCL (F), and PCL block technique repeated on other end of nanofiber bundles (G). 
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A solvent casting technique was used to combine together multiple nanofiber bundles to create a 
complete scaffold (Figure 4.1D-G)  Groups of approximately 50 nanofiber bundles with an 
overall diameter of approximately 4 mm were cut to 35 mm in length and tied together with 
sutures. The solvent solution was created by dissolving 3.5 mg PCL (Mw=50,000; Perstorp Capa 
6506, Malmo, Sweden) in 5 mL of dichloromethane (Fisher Chemical D37-1) to create a 70% 
w/v PCL solution. To create PCL blocks with diameter 6 mm and length 30 mm, 850 mL of the 
PCL solution was cast into a segment of silicone tubing (Figure 4.1D) and the solvent was 
allowed to evaporate off overnight. The upper 15 mm of each PCL block was cut off and 
discarded due to the presence of voids formed from bubbles during solvent evaporation (Figure 
4.1E). The remaining 15 mm of each PCL block was inserted into the bottom of a new segment 
of silicone tubing (20 mm in length, Figure 4.1E) and 140 mL of 70% PCL solution was cast 
onto the top of the PCL block. Immediately after casting the solution on top of the PCL block, 
one end of the nanofiber bundle group was inserted into the solution (Figure 4.1F). The solvent 
was allowed to evaporate overnight before repeating the procedure on the other end of the 
nanofiber bundle group (Figure 4.1G). This procedure created scaffolds with a fiber region 4 mm 
in diameter and 20 mm in length held together at each end with PCL blocks 6mm in diameter 
and 20 mm in length (Figure 4.1A). The fiber region mimics the length of the native ovine ACL 
to extend through the intraarticular space and the PCL blocks will be inserted into bone tunnels 
in the femur and tibia. 
 
4.2.2 Surgical technique 
Ovine cadaver stifle joints were used for the study, and either a soft tissue allograft or a novel 
electrospun scaffold was implanted for ACL reconstruction. “Gold standard” soft tissue grafts 
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were obtained by harvesting the lateral digital extensor (LDE) tendons from the hind limbs of 
sheep (Ovis aris Rambouillet X Columbian ewes) that had been euthanized for unrelated 
purposes. Hind limbs underwent one freeze thaw cycle prior to tendon harvest. Surgical 
procedures were performed by trained veterinary surgeons. The LDE tendon was first isolated at 
the metatarsal and then transected from the tibia. Harvested tendons were doubled looped and the 
ends were augmented with sutures (Covidien, Polysorb 2-0). Soft tissue grafts were 
approximately 6 mm in diameter and 120 mm in length and remained hydrated with phosphate 
buffered saline solution (PBS) until use.  
 
Prior to ACL reconstruction, the native ACL was transected and all remnant tissue was removed 
so the femoral and tibial ACL footprints could be visualized. With the stifle joint flexed to 
approximately 110º, the tibial bone tunnel was created such that the tunnel originated at the tibial 
footprint of the ACL and emerged on the distal medial tibia. A 2.4 mm guide wire (Arthrex AR-
1250SB) was first drilled “inside-out” through the tibia and then a 7 mm tunnel was drilled over 
the guide wire with an acorn reamer (Arthrex AR-1407-LP) to create a tibial bone tunnel 
approximately 35 mm in length. With the joint still partially flexed the femoral bone tunnel was 
drilled originating at the femoral footprint of the ACL and emerging on the proximal lateral 
femur. A similar process was used to create a femoral bone tunnel approximately 30 mm in 
length. Both bone tunnels were notched on the anterior margin and tapped with a 7mm tap to aid 
interference screw insertion. Care was taken to avoid damaging any surrounding ligaments, 
particularly the PCL and the intermeniscal ligament, as well as the anterior lateral meniscal root 




For implantation of the soft tissue allograft, the graft was first delivered into the femoral bone 
tunnel using a passing pin. With the joint in high flexion, a 7 mm stainless steel interference 
screw (Arthrex AR-1370H-25) was inserted “inside-out” into the posterior-medial aspect of the 
femoral tunnel while the graft was tensioned on the posterio-lateral aspect of the tunnel. The free 
end of the graft was then delivered into the tibial bone tunnel and care was taken to ensure the 
graft did not twist in the intraarticular space. With the joint at approximately 90º of flexion and 
the graft tensioned along the postero-lateral aspect of the tibial bone tunnel, a 7 mm interference 
screw was inserted “inside-out” into the antero-medial aspect of the tibial bone tunnel. 
 
For implantation of electrospun scaffold, fishing line was inserted through each PCL block to 
serve as passing sutures. A passing pin was used to draw the scaffold “outside-in” through the 
tibial bone tunnel so that the one PCL block remained in the tibial tunnel. The second PCL block 
was drawn “inside-out” through the femoral tunnel with the passing pin and care was taken to 
ensure that the fibers were not twisted in the intraarticular space. With the joint in high flexion 
and tension on the scaffold via the tibial passing sutures, a 6 mm stainless steel interference 
screw (Arthrex AR-1360E) was inserted “inside-out” into the antero-medial aspect of the 
femoral bone tunnel. Finally with the joint at approximately 90º of flexion and the graft 
tensioned via the tibial passing sutures, a 6 mm interference screw was inserted “inside-out” into 
the antero-medial aspect of the tibial bone tunnel. 
 
4.2.3 Ovine stifle joint mechanical testing 
Ovine cadaver stifle joints were obtained from sheep (Ovis aris Rambouillet X Columbian ewes) 
that had been euthanized for unrelated studies. Stifle joints were tested under four conditions: 
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ACL intact (ACL), ACL transected (ACLX), soft tissue graft implanted (Graft), and electrospun 
scaffold implanted (Scaffold in situ). Surgical techniques for soft tissue graft and electrospun 
scaffold implantation are described above. Prior to mechanical testing, the femur and tibia were 
cut to approximately 135 mm from the stifle joint line and the proximal 70 mm of the femur and 
the distal 70 mm of the tibia were cleared of all tissue. Wood screws were drilled into the 
proximal femur and distal tibia to increase surface area and the ends of the bones were potted in 
resin (Smooth-Cast 321) in cylindrical cardboard molds (50 mm diameter, 70 mm length).  
 
Stifle joints were tested using a servo-hydraulic material test system (MTS, Bionic Model 370.02 
MTS Systems Corporation, Eden Prairie, MN). Anterior drawer testing was simulated for four 
conditions: ACL intact (n=5), ACL transected (n=5), soft tissue graft implanted (n=6), and 
electrospun scaffold implanted (n=6). Major stifle ligaments and the menisci were left intact 
while all musculature was removed. The MTS was equipped with a 2000 lb load cell (Interface 
1210AF-2k, Scottsdale, AZ) and a custom-built testing fixture was used to hold the joint at 90º 
of flexion with the tibia positioned horizontally and the femur positioned vertically (Figure 
4.2A). Following the application of a 5 N pre-load the femur was displaced upward at a rate of 1 






Joints were then tested under stress relaxation followed by pull to failure testing for ACL intact 
(n=5), soft tissue graft implanted (n=4), and electrospun scaffold implanted (n=5). Joints were 
dissected of all soft tissue leaving only the ACL, soft tissue graft, or electrospun scaffold 
attached at both the femoral and tibial insertions. With the stifle joint in full extension, calipers 
were used on the posterior aspect of the joint to measure the length of the ACL, soft tissue graft, 
or electrospun scaffold based on the distance from the center of the femoral insertion to the 
center of the tibial insertion. The MTS was equipped with a 2000 lb load cell and a custom-built 
testing fixture was used to hold the joint at 60º of flexion with the tibia positioned vertically to 
ensure that the longitudinal axis of the ACL was aligned with the axis of loading29 (Figure 4.2B). 
Joints were pre-loaded and then strained to 3% strain at a rate of 2mm/s, and held for 20 minutes 
to record stress relaxation behavior. Preliminary testing showed that after 15 minutes the 
Figure 4.2: Mechanical testing setup for simulated anterior drawer test (A), and stress 
relaxation and pull to failure tests (B). 
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observed load changed less than 0.1% over 1 minute indicating full relaxation had occurred. 
Following stress relaxation testing, and a 10 minute rest period, a 5 N preload was applied and 
the tibia was displaced upwards at a strain rate of 1%/sec until failure, which mimics the strain 
rate of the native ACL during gait8,32. 
 
4.2.4 Electrospun scaffold mechanical testing 
Uniaxial tensile testing was performed on ex vivo electrospun scaffolds using a servo-hydraulic 
material test system (MTS, Bionic Model 370.02 MTS Systems Corporation, Eden Prairie, MN) 
equipped with a 100 lb load cell (Interface 1500ASK-100, Scottsdale, AZ). Hydraulic wedge 
grips (Model 647 MTS Systems Corporation, Eden Prairie, MN) set to 500 psi were utilized to 
clamp the PCL blocks at the base of the nanofiber bundles such that all strain occurred in the 
fiber region. Sample gauge length was measured using a CCD camera (Flea3, Point Gray 
Research, Richmond, BC, Canada). Stress relaxation and pull to failure tests were completed on 
these samples under the same conditions described above for in situ testing.  
 
4.2.5 Data analysis 
Custom Matlab (R2016b Mathworks Inc., Natick, MA) codes were used to analyze the data. The 
amount of displacement necessary to reach a load of 50 N was calculated as a measure of joint 
laxity under the anterior drawer tests. Peak force was determined from the stress relaxation tests 
as the maximum force reached during the test and the relaxation force was an average of the 
force readings from 18 minutes – 20 minutes. Percent relaxation was calculated as the difference 
between the peak force and relaxation force as a percent of the peak force. With the Matlab 
Curve Fitting Toolbox, a second order power law fit of the force vs. time graph was used to fit 
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the relaxation curve. Equation 1 shows the equation used for fitting where y is equal to the force, 
x is equal to the time, and the coefficients A, B, and C are obtained from the curve fit33–35. 
Failure load and displacement values were determined from the pull to failure tests based on the 
point at which the sample reached the maximum force. Strains were determined using the 
original graft length. Using a least squares method, a bilinear curve fit was applied to the force-
displacement data to quantify the stiffness in the toe and linear regions, as well as force, 
displacement, and strain values corresponding to the transition point of the bilinear fit36–38.  
     = � � + �             (1) 
 
Data are presented as mean ± standard deviation. For all quantitative measures, comparisons 
were performed using multi-way analysis of variance (ANOVA) models with Tukey’s post-hoc 
test using Minitab (Minitab, Inc., State College, PA). Differences corresponding to a p-value of 
less than 0.05 were considered to be significant. 
 
4.3 Results 
4.3.1 Anterior drawer testing 
Ovine cadaver stifle joints with the native ACL intact underwent 2.3mm of displacement to 
reach an applied load of 50 N (Figure 4.3). After ACL transection, joint laxity increased 
significantly compared to the intact ACL condition. Implantation of the electrospun scaffold 
significantly reduced joint laxity compared to the ACLX condition and was not significantly 
different than the ACL intact condition.  In contrast, the soft tissue graft unable to restore joint 




4.3.2 Stress relaxation testing 
The native ACL relaxed on average 36% over the 20 minute hold period. The scaffold ex vivo, 
scaffold in situ, and the soft tissue graft relaxed 31%, 32%, and 63%, respectively, on average. 
There were no statistically significant differences in the peak force or relaxation forces of the 
native ACL and the scaffold ex vivo (Figure 4.4A). For the scaffold in situ, the peak force and 
relaxation force were significantly lower than the native ACL. The soft tissue graft had a 
relaxation force that was significantly lower than the native ACL. Using a second order power 
law, the average curve fit had an R2 value of 0.96 ± 0.04 for the native ACL, 0.99 ± 0.01 for the 
scaffold ex vivo, 0.97 ± 0.02 for the scaffold in situ, and 0.97 ± 0.03 for the soft tissue graft. No 
statistically significant differences were found between the fitted coefficients of the native ACL 
and the scaffolds ex vivo or in situ (Figures4.4B-D). However, all three of the fitted coefficients 
of the graft samples were significantly different than all other groups (Figures 4.4B-D). 
 
Figure 4.3: Anterior drawer laxity results. * Indicates significantly different from ACL 




Figure 4.4: Stress relaxation results including peak and relaxation force and second-order 
power law fitting coefficients. * Indicates significantly different from ACL (p<0.05), % 
indicates significantly different from scaffold ex vivo at (p<0.05), and $ indicates significantly 
different from scaffold in situ (p<0.05). 
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4.3.3 Pull to failure testing 
The failure load of the native ACL was significantly greater than the scaffold ex vivo, the 
scaffold in situ, and the soft tissue graft (Figure 4.5A, Figure 4.6), however, there were no 
significant differences in the failure strain and failure displacement of any groups (Figure 4.5B, 
4.5C). Bilinear fitting was applied to the native ACL and scaffold groups to quantify stiffness in 
the toe and linear regions. Graft samples did not display an obvious toe region and thus only a 
linear stiffness is reported. The toe region stiffness of the scaffold in situ was significantly lower 
than the native ACL (Figure 4.7A). The stiffness of the ACL in the linear region was 
significantly higher than the scaffold ex vivo, the scaffold in situ, and the graft (Figure 4.7A). 
The force corresponding to the transition point from the toe region to linear region was 
significantly higher for the native ACL compared to the scaffold ex vivo and in situ, however, 
there were no differences in the transition displacements or strains (Figure 4.7B-D). 
 
Figure 4.5: Pull to failure results including failure load (A), failure displacement (B), and 





Figure 4.6: Representative force displacement curves of native ACL, scaffold ex vivo, 
scaffold in situ, and soft tissue graft. 
 
Figure 4.7: Toe and linear stiffness (A), transition load (B), transition displacement (C), and 





In this study, we have developed a technique to simulate a clinical anterior drawer test which 
provides a functional assessment of joint laxity. Similar to other studies on ovine limbs, an intact 
ACL resulted in minimal displacement of the tibia relative to the femur and transection of the 
ACL nearly tripled the amount of joint laxity29–31. Implantation of the soft tissue graft that was 
used to mimic a “gold standard” tendon allograft failed to improve laxity levels and the joint 
laxity was no different than when the ACL was transected. Studies have shown that a variety of 
allograft materials are able to restore normal levels of joint laxity in cadaver knees during 
simulated anterior drawer tests39,40. The sustained joint laxity observed with soft tissue graft in 
the present study may be due to the graft fixation technique, or damage to the graft during 
implantation. Studies comparing soft tissue graft fixation techniques have shown that fixation 
with a transcondylar device or sutures secured over a button may provide a more robust repair 
and mitigate damage to the graft during insertion41–44. 
 
In contrast to the soft tissue graft, implantation of the electrospun scaffold improved joint laxity 
by 50% and returned it back to normal (ACL intact) levels.  It is likely that the secure attachment 
of the PCL blocks and stainless steel interference screws in the bone tunnels contributed to the 
reduced joint laxity. In an in vivo setting, this ability to decrease joint laxity will potentially 
improve joint stability, decrease the risk of repair failure, and mitigate damage to surrounding 
soft tissues16,45. Simulated anterior drawer testing has been previously used to assess the integrity 
of tissue engineered ovine ACL replacements and decreased laxity after reconstruction has been 




Stress relaxation experiments were utilized to compare the time-dependent properties of the 
native ACL as well as the scaffold and soft tissue graft ACL replacements and the scaffold ex 
vivo. Assessing the properties of the scaffold ex vivo provides a baseline measure of properties 
without effects of surgical implantation or the in situ environment. Although the peak and 
relaxation force of the native ACL and the scaffold ex vivo were in not significantly different, 
after in situ implantation the scaffold demonstrated significantly lower peak and relaxation forces 
than the native ACL. These differences in scaffold properties before and after implantation may 
suggest that the implantation procedure is damaging the scaffold. Placement of the scaffold into 
the bone tunnels requires significant physical manipulation which could be causing plastic 
deformation of the nanofibers, thus reducing stiffness and diminishing the ability to support 
applied loads. Additionally when the interference screws are inserted the sharp threads of the 
screw may slice through some nanofibers on the periphery of the scaffold which would change 
the structural properties. Future work should focus on optimizing the surgical procedure to 
ensure the structural integrity of the scaffold is not compromised during implantation 
 
The power-law fit of the stress relaxation curve demonstrated similar relaxation behavior 
between the native ACL and the electrospun scaffold, suggesting that in vivo the scaffold may 
mimic the time-dependent properties of the native ACL. In comparison, the fitted coefficients of 
the soft tissue graft stress relaxation curve suggest that the soft tissue graft relaxes more quickly 
than the native ACL. The graft also experienced nearly double the amount of relaxation as the 
ACL in the same time period. The stress relaxation response of the ACL is important for the 
ability of the ACL to prevent fatigue and stabilize the knee during prolonged joint motion and 
thus an ACL replacement should possess similar time-dependent properties46. 
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In order to choose a suitable replacement for a damaged ACL, other groups have investigated the 
time-dependent properties of soft tissue grafts via mechanical testing. Two variations of 
semitendinosus grafts were tested via stress relaxation and demonstrated approximately 55% 
relaxation47. This value closely matches the soft tissue graft in the present study however the 
semitendinosus grafts were tested ex vivo so it is difficult to estimate the relaxation after 
implantation. Donahue et al also performed testing on ex vivo soft tissue grafts from two species: 
bovine and human48. Double looped bovine digital extensor tendons and human semitendinosus 
and gracilis tendons demonstrated similar stress relaxation characteristics and relaxed 
approximately 20%.  This lower amount of relaxation may be due to the rigorous 
preconditioning regime or variations in testing setup. Clinically it has been shown that graft 
tension and stiffness achieved immediately following ACL reconstruction is not maintained post-
operatively due to stress relaxation, further emphasizing the importance of considering the stress 
relaxation response when choosing materials for ACL reconstructions49. 
 
Neither the electrospun scaffold (ex vivo or in vivo) nor the soft tissue graft was able to approach 
the failure load of the native ACL. This is similar to other research groups whose ovine ACL 
repair materials have been deficient in failure properties both before and after implantation50–53. 
However, assessing the properties of ACL replacements via pull to failure tests may not provide 
an accurate portrayal of in vivo behavior because the native ACL is not isolated and loaded in 
pure tension to the point of failure during normal activities of daily living. Because the ACL 
experiences strains of ~3% or ~1 mm during normal gait, investigating the behavior of ACL 
replacements in the region of more functionally applicable smaller strains may be more relevant 
for assessing the ability of replacements to mimic the native ACL. Hence, a bilinear fitting 
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approach was utilized to quantify two separate regions of the force-displacement curve: an initial 
non-linear toe region, followed by a stiffer linear region that occurred at higher strains9. Both the 
ACL and electrospun scaffold displayed the characteristic toe and linear regions. It is important 
to note that the toe region stiffness of the ex vivo scaffold was not significantly different than the 
toe region stiffness of the native ACL. This is promising as it suggests that in this lower strain 
functional toe region, the scaffold performs similarly to the native ACL. The lower toe region 
stiffness of the scaffold in situ may be due to rupture or plastic deformation of the nanofiber 
bundles during surgical implantation. The soft tissue graft did not display a characteristic toe and 
linear region which was surprising since tendon has been previously characterized as a 
hyperelastic material54.  
 
The bilinear fitting approach also permits identification of the transition point from the toe to 
linear region. Transition displacement and strain values for the native ACL and scaffolds were 
not different, and the transition strain is higher than the strains experienced by the native ACL in 
vivo, which is expected since in vivo loading of the ACL occurs primarily in the toe region of the 
force curve8,12. The transition force of the scaffold was significantly lower than the transition 
force of the native ACL, suggesting that the scaffold begins to undergo plastic deformation at 
lower loads. However, the transition force of the scaffold, as well as the toe region stiffness, are 
expected to increase with in vivo implantation time and de novo tissue deposition55–57.  
 
Overall the toe region and transition point similarities between the native ACL and the scaffold 
may be attributed to the materials’ similar hierarchical structures. The viscoelastic behavior of 
the ACL is thought to be due primarily to the crimped collagen fibers that make up the 
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ligament10. In the toe region of the force curve, the collagen fibers are experiencing reversible 
un-crimping and it’s not until the linear region of that force-displacement curve that the collagen 
fibers are fully un-crimped and directly loaded. Similarly, the electrospun scaffold is composed 
of electrospun PCL nanofibers that are primarily aligned along the longitudinal axis of the 
scaffold27. The initial toe region of the scaffold may be due to the rearrangement of the 
nanofibers during loading27. We have previously shown that the modulus of the nanofiber 
bundles that compose the scaffold is approximately 155 MPa which closely matches the modulus 
of the native ovine ACL, previously reported to be approximately 158 MPa 27,58. Finally, 
although the properties of the implanted electrospun scaffold do not perfectly match the native 
ACL at time zero after implantation it is hypothesized that mechanical properties may be altered 
with in vivo implantation time55–57. 
 
Overall this work has shown that prior to implantation the electrospun scaffold mimics the 
relaxation behavior of the native ACL and has a comparable toe region stiffness. After 
implantation in an ovine cadaver joint the scaffold demonstrates slightly diminished relaxation 
properties and toe region stiffness however under a simulated measure of joint laxity it is still 
able to restore joint laxity to normal levels better than a “gold standard” soft tissue graft. These 
results suggest that the electrospun scaffold is a suitable mechanical replacement for the ovine 
ACL. Future work will focus on characterizing the effect of the scaffold on force distribution 
within the tibiofemoral joint during simulated ovine gait. Thorough characterization of the in situ 
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EFFECT OF ANTERIOR CRUCIATE LIGAMENT TRANSECTION AND 
RECONSTRUCTION ON OVINE TIBIOFEMORAL CONTACT MECHANICS 
 
5.1 Introduction 
The anterior cruciate ligament is one of the primary knee stabilizers and its integrity is vital for 
joint functionality1. The ACL acts primarily to prevent anterior tibial translation while also 
reducing internal/external and varus/valgus tibial rotations2,3. It is estimated that up to 400,000 
ACL injuries occur each year in the US4. About 70% of ACL injuries occur due to “non-contact” 
loading scenarios where there is no direct impact to the knee joint5,6. Non-contact ACL injuries 
may occur due to excess anterior tibial translation while the knee is in shallow flexion or during 
a cutting motion, where the knee experiences simultaneous valgus and internal rotation of the 
tibia5. Tears of the ACL often result in long-term pain and instability and 10 years after ACL 
rupture up to 13% of patients have been found to display signs of radiographic knee 
osteoarthritis, a debilitating joint that is the leading cause of disability among adults in the US7–9. 
 
Ruptures of the ACL have been shown to result in significant changes to knee kinematics, most 
notably increases in tibial translation and rotation during normal activities2,10. Because the ACL 
is one of the primary joint stabilizers, when it is ruptured loads that were previously transduced 
through the ACL are transferred to the surrounding joint structures, including the bone, cartilage, 
menisci, and other ligaments such as the medial collateral ligament and posterior cruciate 
ligament11. The alteration of knee load distributions may cause those surrounding tissues to be 
more susceptible to damage12. Cadaveric and in vivo studies have observed that a ruptured ACL 
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alters tibiofemoral contact mechanics by shifting the contact point posteriorly in the joint, 
decreasing the overall contact area, and increasing the mean and peak contact pressures13–15. 
Studies assessing contact pressures and areas within the knee joint have previously utilized 
Tekscan thin-film pressure sensors to measure pressures in the joint under static and dynamic 
loading16–18. Alteration of contact pressures within the joint is thought to expedite cartilage 
degradation, which may exacerbate joint pain and progress the development of osteoarthritis19,20.  
 
After an ACL tear, surgical reconstruction is typically attempted in order to restore knee 
kinematics and mitigate damage to surrounding tissues. Typically during an ACL reconstruction 
surgery, a free tendon graft is inserted through bone tunnels in place of the native ACL21–23. The 
most common choices for graft materials are either a semitendinosus-gracilis tendon or the 
patellar tendon with attached bone blocks24,25. The sources for grafts can either be autografts, 
where the graft is harvested from the patients’ own body, or allografts, where the graft is harvest 
from a cadaver donor. However, both autografts and allografts have some drawbacks. Patients 
who receive autografts experience notable donor site morbidity, pain, and muscle weakness and 
the graft harvest necessitates a second surgical site. Allografts have a less robust physical 
performance likely due to the physical and chemical processing techniques required to sterilize 
the material, and the availability of donor tissue can be limited26,27. Additionally, there is a lack 
of evidence to suggest that currently available ACL graft options restore normal contact 
mechanics to the tibiofemoral joint and osteoarthritis progression has been shown to occur in 




Challenges with traditional ACL reconstructions have motivated the development of an 
alternative ACL replacement. The field of tissue engineering offers a unique opportunity to 
combine scaffolds, cells, and signaling molecules to encourage the regeneration of new ligament 
tissue. Scaffold material and biochemical properties can be optimized in order to mimic the 
structure and function of the native tissue while encouraging the deposition of new tissue as the 
scaffold degrades. Our group has previously developed an electrospun scaffold (Figure 5.1A) 
that mimics the hierarchical structure and the material properties of the native ovine ACL28. The 
scaffold has been shown to encourage collagen deposition in vitro and is implantable into an 
ovine cadaver stifle joint in place of the ACL using standard surgical techniques29. However, it is 
still unknown how well the ACL replacement electrospun scaffold can restore knee mechanics. 
While restoring knee mechanics to the native condition is ideal, a comparison to clinical “gold 
standard” ACL reconstruction is also important (Figure 5.1B). This study was designed to assess 
the ability of a traditional as well as a novel ACL reconstruction technique to restore knee 
contact mechanics19,20. The goal of this work was to determine the contact mechanics of the 
ovine cadaver stifle joint under four conditions: (1) the ACL intact, (2) the ACL transected, (3) 
our novel electrospun scaffold implanted in place of the ACL and (4) a gold standard soft tissue 
graft implanted in place of the ACL. 
 





5.2.1Tekscan sensor calibration 
Tekscan thin film pressure sensors (Model 4041, Tekscan, In., Boston, MA) were used to 
measure joint contact mechanics. Each sensor consisted of two prongs each with a sensing 
matrix with dimensions 31.4 mm x 12.6 mm (Figure 5.2A, 5.2B). Each sensing matrix was 
composed of 90 “sensels”, each with dimensions 2.1 mm x 2.1 mm which can sense pressures up 
to 13.79 MPa. Tekscan sensors function by measuring a “raw value” voltage reading (0 – 220 
RV) which can be related to a pressure value (0 – 13.79 MPa) based on a calibration curve. 
 
 
Prior to use, a 12-point calibration curve was created for each Tekscan sensor using a servo-
hydraulic material testing system (MTS, Bionix Model 370.02 Landmark Setup, MTS Systems 
Corporation, Eden Prairie, MN) with a 15,000 N load cell (Model 662.20D-04 MTS Systems 
Corporation, Eden Prairie, MN). The two prongs of the sensor were stacked on top of one 
another and sandwiched between aluminum plates with dimensions 40 mm x 20 mm. The 




surface of the aluminum plates was covered with a leather material to aid in pressure distribution. 
A load of 1.138 x 104 N was applied to the sensors using the MTS which corresponds to the 
maximum pressure of 13.79 MPa. The Tekscan software (iScan ver. 7.65-09I, Tekscan, In., 
Boston, MA) was utilized to maximize the sensitivity level while keeping the average raw 
pressure within an allowable range (50-200 raw value) and ensuring that less than 5% of the 
sensels were saturated (raw value of 220). The matrix was then loaded to the lowest possible 
load such that all sensels maintained a raw value. The MTS load cell and the average raw value 
were recorded and used to create the first point on the calibration curve. The sensor was then 
loaded sequentially from 445 – 1.111 x 104 N (100 – 2500 lb) in 890 N (200 lb) increments and 
the average raw value was recorded at each load. Pressures were calculated based on the applied 
loads, and linear interpolation fitting in Matlab (R2016b Mathworks Inc., Natick, MA) was used 
to generate a calibration curve of pressure vs average raw value (Figure 5.2C).  
 
5.2.2 Ovine stifle joint preparation 
Tekscan sensors were used to measure the contact mechanics of ovine stifle joints (n=12) from 
sheep (Ovis aris Rambouillet X Columbian ewes) that had been euthanized for unrelated 
purposes. Animals were approximately 3 years old and weighed between 65 – 90 kg. After 
harvesting the cadaver hind limb, the stifle joint was excised and all excess skin and soft tissue 
were removed with the stifle capsule left intact. The tibia was cut to a length of 135 mm and all 
tissue was removed from the distal 70 mm of the tibia. Stifle joints underwent a maximum of 
three freeze-thaw cycles prior to use. The joint was dissected in order to access to the medial and 
lateral hemijoints. The patella-patella tendon-quadriceps complex was retracted to expose the 
intraarticular joint space. Excess soft tissue was carefully removed to expose the lower edges of 
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the medial and lateral menisci. All major ligaments were left intact aside from the long digital 
extensor tendon which was sectioned at the femoral insertion and removed. Two horizontal holes 
were drilled through the femur to aid in positioning during mechanical testing. First, with the 
femur held at approximately 60º of flexion, a 10.5 mm hole was drilled through the femoral 
condyles just above the femoral attachment of the lateral collateral ligament, parallel with the 
tibial plateau. A second 10.5 mm hole was drilled through the femoral shaft 75 mm proximal to 
the first hole. The distal tibia was potted in resin (Smooth-Cast 321) in a cylindrical cardboard 
mold with a diameter of 50 mm and a length of 70 mm. 
 
Fishing line was used to insert Tekscan sensors in an anterior-to-posterior direction under the 
menisci on the tibial plateau such that one prong of a sensor was in the medial hemijoint and the 
other prong was in the lateral hemijoint. Each sensor was covered with clear tape to prevent 
contact with fluids during testing. 
 
5.2.3 Ovine stifle joint mechanical testing 
The MTS was equipped with an 8890 N load cell (Interface 1210AF-2k, Scottsdale, AZ) and 
used to apply compressive loads to the stifle joint at fixed flexion angles. Three testing 
conditions were assessed consecutively for each joint: ACL intact (Figure 5.3A), ACL transected 
(Figure 5.3B), and either a soft tissue allograft (n=6, Figure 5.3C) or an electrospun scaffold 
ACL reconstruction (n=6, Figure 5.3D), described below. A custom-built load frame was able to 
fix the stifle joint in flexion angles from 0-90º in 7.5º increments (Figure 5.4). The femur was 
held in the upper loading frame with two rods. The tibia was secured in a steel cup attached to a 
locking universal joint which allowed for control of tibial varus/valgus and internal/external 
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rotations. The universal joint could be moved laterally to ensure no excessive varus/valgus 
rotation and for each joint, the lateral position was recorded and maintained across all testing 
conditions. The amount of internal/external rotation was recorded for each flexion angle of each 
joint and then maintained for that joint and angle across all testing conditions. The patella-patella 






Figure 5.3: Ovine cadaver stifle joint test conditions: ACL intact (A), ACL transected (B) 






Three fixed flexion angles were assessed: 45º, 60º, and 75º flexion which mimics flexion angles 
of the ovine stifle joint during normal gait30. The MTS was used to apply a compressive force in 
222 N (50 lb) increments from 222 – 1778 N (50 – 400 lb), at each flexion angle which 
corresponds to the approximate force experienced on the ovine tibial plateau during gait. 
Tekscan sensor raw value readings were recorded for the medial and lateral hemijoint at each 
load and flexion angle. A custom Matlab code was used to generate pressure maps and calculate 
mean and peak contact pressures and contact areas based on the Teskcan sensor readings. 
 
  
Figure 5.4: Ovine cadaver stifle joint testing setup front view (A) and side view (B). 
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5.2.4 Electrospun scaffold fabrication 
Scaffolds were fabricated from sheets of polycaprolactone (PCL) nanofibers which were 
electrospun using a previously described technique28. Briefly, a 10% w/v solution of PCL 
(MW=80,000; Sigma 440744, St. Louis, MO) was dissolved in a 3:1 v/v mixture of chloroform 
and methanol. A negatively charged aluminum drum rotating at a linear velocity of 
approximately 12 m/s served as the collector surface to create sheets of aligned PCL nanofibers. 
Nanofibers were used to create nanofiber bundles by excising a rectangular portion of a flat sheet 
(approximately 5 x 175 mm) and rolling it up tightly into a cylinder28. Resulting nanofiber 
bundles were approximately 0.5 mm in diameter and 175 mm in length with nanofibers primarily 
aligned along the longitudinal axis. 
 
Nanofiber bundles were secured together using a solvent casting technique to create a complete 
ACL scaffold (Figure 5.1A). First, approximately 50 nanofiber bundles were cut to 35 mm in 
length and tied together with sutures such that the overall diameter was approximately 4 mm. A 
70% w/v PCL (Mw=50,000; Perstorp Capa 6506, Malmo, Sweden) solution was created by 
dissolving 3.5 mg PCL in 5 ml dichloromethane (Fisher Chemical D37-1) in an airtight glass 
container with 12 hours of rotation. 850 mL of the PCL solution was then cast into a segment of 
silicone tubing and after solvent evaporation, the resulting PCL block was 6 mm in diameter and 
30 mm in length. The upper half of the PCL block contained numerous voids due to the presence 
of bubbles during solvent evaporation and was thus cut off and discarded. The remaining PCL 
block was then inserted into a segment of silicone tubing 20 mm in length with an inner diameter 
of 6 mm such that the base of the PCL block was flush with the base of silicone tubing. 140 mL 
of 70% PCL solution was cast into the open space at the top of the silicone tubing and one end of 
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the nanofiber bundles was inserted into the solution. After allowing the solvent to evaporate 
overnight, the procedure was repeated on the other end of the nanofiber bundles. This procedure 
resulted in a scaffold with a PCL fiber region 4 mm in diameter and 20 mm in length, which 
mimics the length of the native ovine ACL. Each end of the scaffold fiber region was held 
together with PCL blocks 6 mm in diameter and 20 mm in length which are able to be inserted 
into bone tunnels.  
 
5.2.5 Surgical technique 
ACL reconstructions were conducted by implanting either a soft tissue allograft (n=6) or an 
electrospun scaffold (n=6) in place of the native ACL. Six lateral digital extensor (LDE) tendons 
were harvested from the hind limbs of sheep that had been euthanized for unrelated purpose. The 
LDE tendon was isolated at the junction of the metatarsal and a tendon stripper was used 
proximally to remove the tendon. Harvested grafts were doubled resulting in a free soft tissue 
graft approximately 6 mm in diameter and approximately 120 mm in length (Figure 5.1B). Each 
graft end was augmented with sutures (Covidien, Polysorb 2-0) and grafts were kept hydrated 
with phosphate buffered saline (PBS) solution until use. 
 
All remnant ACL tissue was removed to enable visualization of the tibial and femoral ACL 
footprints. With the stifle joint held at approximately 110º of flexion, a femoral bone tunnel was 
created originating at the femoral footprint of the ACL. A 2.4 mm guide wire (Arthrex AR-
1250SB) was drilled through the femur and then a 7 mm “inside-out tunnel” was drilled over the 
guide wire with an acorn reamer (Arthrex AR-1407-LP). The entire femoral bone tunnel was 
approximately 30 mm in length. Care was taken to avoid disrupting the PCL and any other 
ligaments. A tibial drill guide was used to create a tibial bone tunnel with a similar technique. 
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Care was taken to damage surrounding soft tissue during. A notch was created on the anterior 
margin of the femoral and tibial bone tunnels and each tunnel was tapped with a 7 mm tap. 
 
For implantation of the soft tissue allograft, a passing pin was used to pull the distal end of the 
graft into the femoral tunnel inside-out. The graft was tensioned on the posterio-lateral aspect of 
the femoral tunnel and a 7 mm stainless steel interference screw (Arthrex AR-1370H-25) was 
inserted “inside-out” into the posterior-medial aspect of the femoral tunnel. A passing pin was 
used to pull the free end of the graft into the tibial tunnel. Care was taken to ensure that there was 
no twisting of the graft within the joint space. The graft was tensioned along the posterio-lateral 
aspect of the tibial tunnel and a 7 mm stainless steel interference screw was inserted “inside-out” 
into the antero-medial aspect of the tunnel. 
 
For implantation of the electrospun scaffold, 3 mm holes were drilled in the ends of the PCL 
blocks and fishing line was inserted through the holes to serve as passing sutures. A passing pin 
was inserted first through the tibial bone tunnel and the scaffold was drawn into the joint space 
“outside-in” such that one PCL block remained in the tibial bone tunnel. The passing pin was 
then inserted through the femoral bone tunnel and used to draw the other PCL block “inside-out” 
into the femoral bone tunnel. Care was taken to ensure that the PCL fibers were not twisted in 
the joint space. While tensioning the scaffold via the tibial passing sutures and with the joint in 
high flexion, a 6 mm stainless steel interference screw (Arthrex AR-1360E) was inserted “inside-
out” into the antero-medial aspect of the femoral bone tunnel. A 6 mm stainless steel interference 





Data analysis was performed using Minitab (Minitab, Inc., State College, PA). Statistical 
significance was assessed for each combination of load and flexion angle for mean contact 
pressure, peak contact pressure, and contact area. For comparisons of mean and peak contact 
pressure and contact area between ACL and ACLX conditions, all samples were grouped (max 
n=12) and comparisons were made with a two-way repeated measures analysis of variance 
(ANOVA) model with Tukey’s post-hoc test. Comparisons were also made between ACL, 
ACLX, and scaffold conditions (max n=6) and ACL, ACLX, and graft conditions (max n=6) 
using a multi-way repeated measures ANOVA with Tukey’s post-hoc test. All measures of mean 
and peak contact area and contact pressure after scaffold or graft implantation were normalized 
to the corresponding control (ACL intact) value to make comparisons directly between the 
scaffold and graft groups. Means of scaffold and graft groups (max n=6) after normalization 
were compared using two-sample t-tests. Differences corresponding to a p-value of less than 




Not all stifle joints were able to withstand the higher load testing conditions due to instability 
that occurred because of the extensive joint dissection necessary for Tekscan sensor insertion. 
Based on a post-hoc power analysis, groups had to contain a minimum of 3 samples to achieve a 
power of 0.90. Thus, the higher load testing conditions (1334 N, 1556 N and 1778 N or 300 lb, 





First examining only the ACL intact condition, the mean pressure tended to increase with 
increasing load application up to a maximum mean pressure of approximately 1.5 MPa in the 
medial hemijoint and 1 MPa in the lateral hemijoint (Figure 5.5 and Figure 5.6A). Similarly, 
peak pressure increased with increasing load application up to a maximum peak pressure of 
approximately 4 MPa in the medial hemijoint and 2.5 MPa in the lateral hemijoint (Figure 5.6B). 
When the ACL was intact the contact area remained generally consistent with increasing load 
application, with a contact area in the medial hemijoint of approximately 250 mm2 and a contact 
area in lateral hemijoint of approximately 150 mm2 (Figure 5.6C). No differences were observed 
between the three different flexion angles and thus for the remaining results, the 60º flexion 
angle is presented as a representative case. Statistical comparisons were also assessed for contact 
parameters at all other angles (contact area: Table 5.2, mean contact pressure: Table 5.3, peak 
contact pressure: table 5.4). 









Figure 5.6: ACL intact measures of mean contact pressure (A), peak contact pressure (B), and 





Table 5.2: Contact area measurements. * Indicates significant different from ACL intact at 
p<0.05. ^ Indicates significant difference from ACLX at p<0.05. 
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  Table 5.3: Mean contact pressure measurements. * Indicates significant different from ACL 




  Table 5.4: Peak contact pressure measurements. * Indicates significant different from ACL 




After ACL transection, medial contact pressures (mean and peak) increased significantly at all 
applied loads (Figure 5.5 and Figure 5.7A). The mean and peak pressures in the ACL-deficient 
joint were approximately 1.5 and 3 times higher, respectively, than the mean and peak pressures 
in the ACL intact joint. Contact area in the ACL-deficient medial hemijoint significantly 
decreased at all applied loads and was approximately 0.6 times the contact area of the ACL intact 
joint (Figure 5.7A). In lateral hemijoint after ACL transection, significant changes were only 
observed in the contact area, which significantly decreased at all loading conditions and was 




Representative pressure maps from ACL, ACLX, scaffold, and graft conditions at 60º flexion 
and 890 N (200 lb) show that while the scaffold and graft implantations improve the joint contact 
mechanics compared to the ACLX group, they do not match the ACL intact condition (Figure 
5.8). Results were normalized to the respective intact condition for the ACLX, scaffold, and graft 
Figure 5.7: ACL-ACLX group comparisons for the medial hemijoint (A) and lateral hemijoint 





implantation groups (Figure 5.9, note: conditions normalized to intact ACL such that intact ACL 
=1). Contact pressures and area were not significantly different between the scaffold and graft 
groups for any applied load or flexion angle (Figure 5.9A, 5.9B). 
 
Figure 5.8 Representative pressure maps from ACL, ACL, scaffold, and graft conditions at 





Figure 5.9: ACLX, scaffold and graft results for the medial hemijoint (A) and lateral 
hemijoint (B) at 60º flexion and 445 and 890 N. Values are normalized to the respective intact 
condition such that intact ACL =  1. * Indicates significant different from ACL intact at 




Comparisons are presented below wherein first we compared the scaffold and graft replacements 
to the intact ACL condition, and then secondly compared the replacements to the ACLX 
condition. Medial and lateral mean pressures were not different from the ACL-intact condition 
after both scaffold and graft replacement at any load (Figure 5.9A, 5.9B).  Peak pressure in the 
medial hemijoint was however significantly greater after graft and scaffold at the higher applied 
loads (>=889 N) (Figure 5.9A).  At all applied loads, medial and lateral contact area was 
significantly lower than the ACL-intact condition after both scaffold and graft replacement 
(Figure 5.9A, 5.9B).  At lower loads (<667 N) the medial mean and peak pressures with the 
scaffold implanted were significantly lower than the ACL-deficient joint (Figure 5.9A). 
Surprisingly, implantation of the “gold-standard” graft did not significantly improve the contact 
pressures compared to the ACL-deficient joint (Figure 5.9A). Regardless of scaffold or graft 
implantation, contact area in the medial and lateral hemijoints was not significantly different than 
the ACL-deficient joint (Figure 5.9A, 5.9B). 
  
5.4 Discussion 
In the present study, we assessed the ability of a novel hierarchical electrospun scaffold to restore 
contact mechanics when implanted in place of the native ovine ACL. At low loads, implantation 
of the scaffold lowered medial mean and peak contact pressures from levels observed in the 
ACL-deficient knee. At all loads, medial mean pressure after scaffold implantation was not 
different from medial mean pressure in the ACL-intact knee. This suggests that scaffold 
implantation is able to normalize medial mean contact pressure and mitigate changes caused by 
ACL transection. Scaffold implantation was also able to normalize medial peak pressures at 
lower loads. However, at loads above approximately 890 N, the peak pressure remained 
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significantly higher than the ACL-intact peak pressure. Additionally, the point of highest 
pressure was shifted posteriorly on the medial tibial plateau, similar to what was observed in the 
ACL-deficient joint. Although the scaffold was not able to normalize contact pressures over the 
entire range of applied loads, its ability to mitigate some changes caused by ACL transection at 
low loads suggests it may be able to serve as a functional replacement. 
 
Implantation of the scaffold was not able to restore normal tibiofemoral contact area in the 
medial or lateral hemijoint. Contact area after scaffold implantation remained significantly lower 
than contact area in the ACL-intact knee. Higher peak pressures distributed over a lower contact 
area could result in long-term degradation of cartilage and damage to subchondral bone and 
meniscal tissue19,20. However, there was a trend for implantation of the scaffold to bring the 
contact areas slightly closer to intact levels suggesting that the scaffold may offer a slight 
improvement from the ACL-deficient joint. 
 
Changes in contact mechanics caused by implantation of the electrospun scaffold were compared 
to changes caused by implantation of a soft tissue graft. The soft tissue graft investigated 
represents a gold standard clinical ACL repair technique. Both repairs were implanted using 
similar surgical techniques and were fixed in the joint with stainless steel interference screws. At 
all loads and flexion angles normalized mean and peak contact pressures and contact areas were 
not different with the scaffold or graft implanted. Thus, at a time-zero time point (immediately 
after surgical implantation) the scaffold and graft are functionally equivalent in their ability to 
restore stifle joint contact mechanics. This suggests that the scaffold may serve as a novel 
alternative ACL reconstruction material that serves a similar mechanical function. 
154 
 
The inability of the scaffold to completely restore normal tibiofemoral contact pressures and 
areas may be due to the scaffold mechanical properties. We have previously shown that the 
modulus of the scaffold subcomponents is approximately 154 MPa which is comparable to the 
160 MPa modulus of the native ovine ACL, making the scaffold a suitable potential 
replacement28. However, in the toe region of the load-displacement curve the stiffness of the 
implanted scaffold is approximately 8 N/mm which is only 20% of the toe region stiffness of 
native ovine ACL. When load is applied to the ovine stifle joint the scaffold is loaded in tension 
as it functions to restrict anterior translations of the tibia relative to the femur. The lower 
stiffness may mean that the scaffold is not able to stabilize the joint since a less stiff material 
experiences more deformation under applied loads. This would also explain why the scaffold 
was less effective at restoring pressures at higher loads since under high loads the scaffold 
experiences greater deformations and is less able to restrict tibial translation. Additionally the 
surgical implantation procedure, particularly the drilling of the tibial and femoral bone tunnels, 
may have damaged the articular cartilage and the medial anterior meniscal attachment, which 
could account for some of the altered contact area. In future work, the surgical procedure should 
be optimized to minimize damage to surrounding tissues while still enabling a secure 
implantation. 
 
Although the scaffold does not completely restore contact mechanics immediately after 
implantation it is likely that the scaffold will stiffen and strengthen as it remodels in vivo. Bone 
marrow-derived stem cells deposited collagen on the scaffold surface when it was maintained in 
vitro for a three-week time period29. It is hypothesized that at longer time points in vivo collagen 
deposition and remodeling throughout the scaffold would result in increased stiffness, 
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particularly in the toe region of the force-displacement curve. Previous groups have similarly 
shown that tissue-engineered ligaments are able to stiffen and strengthen in vivo31,32. Because the 
scaffold is the least effective at restoring contact pressures at high loads, a postoperative 
reduction in weight bearing regime could be used to give the scaffold time to undergo 
remodeling and stiffen in vivo. Future studies should assess the rate of de novo tissue deposition 
and the longitudinal effect on tibiofemoral contact mechanics.  
 
In the present study, the ovine stifle joint is used as a model for the human knee joint. The ovine 
stifle joint has been previously established as an appropriate orthopedic model for the human 
knee and it has been utilized for the development of ligament reconstruction techniques33–37. 
Most notably for this work, the size, structure, and mechanical properties of the ovine ACL 
closely match the properties of the human ACL and the contact pressures on the tibial plateau are 
similar in ovine stifle joints and human knee joints15,38–40. In the present study transection of the 
ovine ACL resulted in increased tibiofemoral contact pressures and decreased contact area, 
which matches what has been previously observed in human ACL-deficient knees16,41. Thus the 
ovine stifle joint is an appropriate model for assessing ACL reconstruction techniques and the 
results obtained in the present study can likely be translated to the human knee joint. 
 
Although the results of this work are promising there are some limitations. A significant amount 
of stifle joint dissection was required to insert the Tekscan sensors, and the absence of 
surrounding tissue and musculature may have affected the accuracy of results. Although contact 
mechanics in the present study were measured under static uniaxial loads, in vivo loading is 
dynamic and multi-directional which should be better simulated in future work. Some challenges 
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associated with the Tekscan pressure sensors may have also affected results. The Tekscan 
sensors had a rectangular shape (Figure 5.1B) and did not entirely cover the tibial plateau and 
thus pressures in some regions of the medial and lateral hemijoints were not recorded. 
Additionally, sensor readings became saturated at high loads and sensor output may have been 
affected by liquid exposure and damaged sensing elements. 
 
Overall the results of this study suggest that our novel electrospun scaffold is a promising 
material for ACL reconstructions. The scaffold restores contact mechanics just as well as a gold 
standard soft tissue graft and, after remodeling time in vivo, may eventually stiffen and 
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CONCLUSIONS AND FUTURE WORK 
 
In summary, this work presents the development of a novel electrospun polymer scaffold for 
anterior cruciate ligament (ACL) replacement. Polycaprolactone (PCL) was chosen for this 
project based on its slow degradation rate and lack of harmful byproducts. The scaffold was 
composed of electrospun PCL nanofibers with a size and alignment that mimics the collagen 
fibers of the ACL. Sheets of aligned nanofibers were further modified into rolled nanofiber 
bundles which mimic the size and structure of collagen fascicles. This hierarchical structure 
likely enabled the nanofiber bundles to mimic the material properties, specifically the modulus, 
of the native ACL. However the stiffness and failure loads of nanofiber bundles were still 
notably lower than the collagenous components of the native ACL. Thus it may be useful to 
investigate other polymers that could be used to fabricate the scaffold to improve strength and 
stiffness. The mechanical properties could also be altered by modifying the diameter of 
individual nanofiber bundles and increasing the packing density of the nanofiber bundles used to 
compose the entire scaffold. Modifying the structure or the structure of the sub-components 
would potentially increase overall scaffold strength and stiffness. Additionally, it will be 
necessary to re-evaluate the mechanical properties of the scaffold after in vivo implantation since 
de novo tissue deposition and polymer degradation will eventually alter mechanical properties.  
 
In vitro, the scaffold encouraged the adhesion and proliferation of ovine bone marrow-derived 
stem cells and, in combination with conjugated growth factors, promoted the deposition of 
collagenous tissue. The 21-day time point investigated offers a short-term indication of in vitro 
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behavior, however, it would be valuable to conduct longer duration studies to assess long-term 
tissue deposition. Any longer term in vitro studies should incorporate mechanical stimulation to 
simulate in vivo loading conditions. Future work should also investigate in vitro and in vivo 
degradation rate. A common challenge of tissue engineering is to balance de novo tissue 
deposition with scaffold degradation to ensure degradation does happen too quickly, thus 
compromising the mechanical integrity of the scaffold. If the rate of tissue deposition is not 
sufficient to balance the rate of scaffold degradation it may be necessary optimize the spatial and 
temporal growth factor delivery or modify the types of growth factor used in order to accelerate 
de novo tissue deposition. 
 
In order to scale up the scaffold to make it implantable in place of the ACL in the knee joint, 
groups of nanofiber bundles were attached on each end with cylindrical solvent cast blocks of 
PCL. The PCL blocks were designed to be inserted into bone tunnels during surgical 
implantation to provide a secure fixation of the scaffold within the joint. Although other research 
groups have shown that solvent cast PCL is osteoinductive and promotes bone regeneration in 
tissue engineering applications, it is not known exactly how the PCL blocks will degrade and 
remodel within the femoral and tibial bone tunnels. Thus, future studies assessing the in vitro and 
in vivo behavior of the PCL blocks could be beneficial. Additionally, prior to clinical use, it will 
be necessary to consider how to modify the manufacturing process to reduce processing times 
associated with the solvent casting procedure. 
 
Implantation of the scaffold into an ovine cadaver stifle joint was shown to be clinically feasible 
however some modifications to the surgical procedure could be useful. Development of a 
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technique for determining the optimal length of the scaffold fibrous region would enable 
standard tensioning of the implanted scaffolds. If the fiber region was too short the scaffold was 
observed to be “tight” after implantation which could over constrain joint motion. Conversely, if 
the fiber region was too long the scaffold was “loose” which could fail to constrain joint motion. 
Thus it would be beneficial to decide optimal scaffold tension prior to surgery and determine 
how to implement it during surgery. In the present study, the implanted scaffold was compared 
to a tendon graft which was chosen as the gold standard comparison. However, a different graft 
type, such as a bone-patellar tendon-bone graft, could offer a gold standard comparison that 
better mimics the scaffold structure. Additionally, in the future, it would be beneficial to 
investigate a variety of surgical fixation techniques including Endobutton and bioresorbable 
interference screw, which have both demonstrated clinical success.  
 
After implantation, the presence of the scaffold restored joint laxity more effectively than a gold 
standard soft tissue graft ACL replacement. However the stress relaxation and pull to failure 
properties of the implanted scaffold were diminished compared to the scaffold prior to 
implantation. It is hypothesized that the implantation procedure may have damaged the scaffold 
nanofiber bundles either by cutting through them or straining to the point of plastic deformation. 
Any damage to the nanofiber bundles would diminish the ability of the scaffold to sustain 
applied loads. In the future scaffold structure and surgical procedure should be modified to 
ensure there is no damage to the scaffold during implantation.  
 
Finally, the implanted scaffold was able to mitigate some changes in tibiofemoral contact 
mechanics caused by ACL transection and was functionally similar to a gold standard soft tissue 
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graft. This suggests that the presence of the scaffold is able to restore contact mechanics to close 
to normal levels which could prevent damage to the menisci and articular cartilage. Failure of the 
scaffold to completely restore normal contact mechanics could be due to the stiffness of the 
scaffold, which is significantly lower than the stiffness of the native ovine ACL. However, the 
scaffold will likely undergo remodeling in vivo which could improve the strength and stiffness. 
Thus since the scaffold is functionally similar to a gold standard soft tissue graft and the 
mechanical properties may improve with implantation time, the scaffold may be a clinically 
useful ACL replacement. Future work should assess how in vivo tissue deposition affects long-
term changes in tibiofemoral contact mechanics. 
 
For a long-term in vivo setting, it will be important to consider the attachment of the ACL to the 
underlying subchondral bone. The ligament to bone attachment occurs over an area of ~200 µm 
and consists of a graded transition from the relatively compliant ligament to the stiffer 
subchondral bone. This graded attachment region is vital for transmitting tensile loads applied to 
the ligament to the bone and resisting mechanical failure. Typically ACL reconstruction 
techniques do not attempt to recreate this complex attachment. Recapitulating the native 
attachment region would enable a tissue engineered scaffold to fully replicate the structure of the 
native ligament. Potentially our scaffold could be incorporated with hydrogels, bone cements, 
and various cell types, to drive the in vivo formation of a graded attachment. 
 
While the present work has demonstrated the potential of this novel hierarchical polymer 
scaffold to act as a tissue engineered ACL replacement, there remains an opportunity to build 









A.1 Electrospinning and Scaffold Fabrication 
A.1.1 Electrospinning 
 
Product: Random OR aligned PCL nanofiber mat 
Solution: 5 ml 10% solid w/w PCL solution 
 97:3 PCL:oleic acid, 75:25 chloroform:methanol 
Item Source Location 
Polycaprolactone pellets MW=80,000 Sigma 440744 Shelf over scale 
Chloroform Chemistry stock room Flammables cabinet 
Oleic acid TCI America O0057 Fridge 
Methanol Chemistry stock room Flammables cabinet 
10ml glass syringe  Cadance Micro Mate Cabinet under espin setup 
Luer lock 18 gauge blunt tip needle Hamilton 90134 Cabinet under espin setup 












Make Polymer Solution 
1. Dissolve 0.5 g PCL in 3.75 ml chloroform by taping small glass vial to the rotator. 
a. Use only glass pipette to measure chloroform. Chloroform degrades plastic. 
b. Wrap Parafilm around lid to ensure no evaporation. 
c. Allow PCL to dissolve completely (~30min). Some small bubbles will form in dissolved 
solution. 
2. Dissolve 0.0152 g oleic acid in 1.25 ml methanol in small glass beaker covered with Parafilm. 
a. Takes less time to dissolve, but if necessary can stir with a small stir bar. 
3. When both separate solutions are completely dissolved add the oleic acid solution to the PCL 
solution and stir on the stir plate until well combined (~5 min). 
a. Again, always make sure to keep vial tightly capped and sealed with Parafilm 
4. Solution is usable for up to ~36 hours after making 
a. Wrap Parafilm around lid and store at room temperature overnight. 
Setup and Procedure 





2. Wrap the rotating mandrel in aluminum foil, ensure there aren’t wrinkles, and secure the edges 
with small pieces of tape. 
a. Use a new piece of tape every ~5 sheets or so, if tape wears out the foil will rip off during 
spinning. 
3. Carefully pour solution into glass syringe and attach needle. 
a. Ensure air bubbles are not present in the syringe. 
b. Depress the syringe plunger and make sure a drop of solution appears and the needle is 
not blocked. 
4. Turn on syringe pump and enter ejection rate of 2 ml/hr. Position syringe in the syringe pump. 
5. Attach positive (red) electrode to the base of the needle and the ground (green) electrode to the 
rotating mandrel collector. 
6. Position the collector so that it is directly perpendicular to the needle tip 10 cm away. Make sure 
that the spray ejected from the needle tip will be centered on the collector. If necessary place the 
syringe pump or the collector on the adjustable lab jack or other surfaces to elevate them. 
7. Hit “Run” on the syringe pump to begin ejecting the solution. Let it eject for ~30sec to make sure 
it is ejecting at a steady rate. Wipe excess off tip of needle as soon as possible before starting to 
spin. 
8. Turn on the rotating mandrel via the control box. Adjust rotation speed to either 300 rpm (random 
sheets) or 3000 rpm (aligned sheets). 
9. Slide the front of the enclosure over the box. If desired black paper can be taped on the back of 
the enclosure to aid in the visualization of the Taylor cone. 
10. Make sure voltage supply is initially at zero, and then turn on the voltage switch on. Gradually 
increase the voltage until it reaches 15 kV.  
a. Voltage supply can also be switched off with the voltage set at 15 kV, but when the 
voltage supply is turned back on expect the voltage to immediately be at 15 kV.  
11. After ~2 min, white deposits should be visible on the aluminum foil on the rotating mandrel. 




12. Turn off voltage supply and turn the voltage back down to zero. Turn off the rotating mandrel. 
Open the front of the enclosure. Carefully remove foil from the rotating mandrel. Wipe excess 
solution off the needle tip prior to beginning another sheet of electrospinning. 
a. ALWAYS TURN OFF VOLTAGE SUPPLY BEFORE TOUCHING ANY PART OF 
THE SETUP! OTHERWISE SEVERE ELECTRIC SHOCK WILL OCCUR! 
Troubleshooting 
1. If polymer isn’t spinning 
a. Are the electrodes hooked up correctly? 
i. Make sure the red lead is on the needle and the green lead is on the base of the 
rotating mandrel. 
b. Is the syringe pump on and running? 
i. Make sure to turn it on, program the correct ejection rate, and press Run. 
ii. If there was excessive arcing or sparking the pump may have shorted out. Turn it 
off and back on again. 
c. Is the needle clogged? (To check, try to manually push some solution out of the syringe. 
It should bead up at the tip of the needle.) 
i. If the needle is clogged, use a different needle and soak the clogged needle in a 
beaker of chloroform (covered in Parafilm) overnight to dissolve the clog. 
2. If the electrospinning looks weird on the aluminum foil 
a. Was the solution made correctly?  
i. Different concentrations will cause electrospinning to appear differently. 
b. Are the solution components fully dissolved and fully mixed? 
i. The solution should appear homogeneous within the syringe, sometimes small 
bubbles are present 
c. Are the spinning parameters correct? 
i. 10 cm tip-to-collector distance 
ii. 2 ml/hr flow rate 
iii. 15 kV 
3. If arcing or sparking is occurring 
a. Arcing is the term for the quiet “clicking” noise that is sometimes evident when 
increasing the voltage.  
i. Arcing is not ideal but electrospinning can be carried out despite arcing.  
ii. To decrease arcing make sure to increase the voltage very slowly. 
iii. Arcing is typically more evident with increased humidity. 
b. Sparking is when electric sparks can be seen between metal components of the 
electrospinning setup. 
i. Sparking is very dangerous. If sparking occurs turn the voltage supply off 
immediately. 
ii. The sparking components can be wrapped in extra electrical tape. However this 
is only a temporary fix as the excessive high voltages will still be present during 
spinning. 
4. If globs of solution or “streamers” collect at the tip of the needle during spinning. 
a. This is normal with some solutions (particularly PCL) so it can be ignored unless the 
excess solution is actively interfering with the spinning. 
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A.1.2 Nanofiber Bundle Fabrication 




Sheet of electrospun nanofibers on aluminum foil  Electrospinning cabinet 
Scalpel Dissection tools drawer 
Tweezers Dissection tools drawer 
 
1. Lay sheet of electrospun nanofibers on flat surface 
 
2. Beginning at one edge, gently use fingertips (wearing gloves) to begin to roll the sheet up on 
itself 
a. Usually works best initiate the roll at either the top or bottom edge and work towards the 
other direction 
b. If making aligned nanofiber bundles ensure that the direction of nanofiber alignment is 




3. When the nanofiber bundle is ~0.5 mm in diameter use a scalpel to slice close to the rolled edge. 
 
4. Use tweezers to pick up to pick up the nanofiber bundle and pull it away from the aluminum foil 
and onto the surrounding counter. Finish rolling up the nanofiber bundle. 
 
5. Repeat with remainder of the nanofiber sheet. If the final nanofiber bundle created with the last 
edge of the electrospun sheet is far too small in diameter (i.e. if it is similar in diameter to a strand 
of hair) then discard. 
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A.1.3 Electrospun Scaffold Fabrication 







Nanofiber bundles (SOP_NFB_HP) Hannah’s drawer 
String/suture wire Hannah’s drawer 
PCL (Perstorp Capa 6506) Chemical shelf 
Dichloromethane (CAS 75-09-2) Flammables cabinet 
Silicone tubing, 6 mm inner diameter Hannah’s drawer 
Dremel with thin cutoff wheel attachment  
 
1. Gather together ~50 nanofiber bundles (each ~75 cm in length) to create a group that is ~4 mm in 
diameter. Use string to tie together the nanofiber bundles in segments. 
a. Each cut segment should be ~35 cm in length with suture wires tied ~7 mm from the ends 
 
 
b. Guide should be used to determine placement of suture wires and cuts. 
c. Usually it’s easiest to tie on each of the pieces of suture wire for entire length of the 
nanofiber bundles, and then cut the segments apart. 
2. Make solvent cast PCL block ~15 mm in length and ~6 mm in diameter 
a. Make a 5 ml 70% PCL solution using powdered PCL 
i. Dissolving 3.5 mg PCL in 5 ml of dichloromethane in a small glass vial. 
ii. Dichloromethane should only be pipetted with a glass pipette. 
iii. Use parafilm to seal the lid while dissolving and while not using. 
20 mm PCL blocks, 6 mm 
in diameter 
20 mm PCL nanofiber bundles, 4 mm in 
diameter 




iv. To dissolve, tape to rotator and allow to dissolve overnight. 
b. Cast 70% PCL into a piece of silicone tubing with inner diameter of 6 mm cut to ~30 mm 
in length. 
i. Cover one end of the silicone tubing with a small square of aluminum foil. 
ii. Use plastic transfer pipettes to pipette the dissolved PCL into the tubing. 
 
iii. Allow to set overnight until dichloromethane has all evaporated, leaving just 
solidified PCL. 
iv. When all dichloromethane is used, allow glass vial to “dry” on its side overnight 
before removing the remaining PCL. 
c. Use Dremel with thin flat cutoff wheel attachment to cut PCL block in half (to 15 mm). 
1. The lower half should have significantly less bubbles; the upper half can 
be discarded.  
 
3. Attach NFBs to PCL end blocks, one end at a time 
a. Insert the 15 mm PCL block into a piece of silicone tubing cut to ~20 mm in length. 
i. Bottom of the PCL block should be at the bottom of the silicone tube. 
ii. Similar to above, the bottom end of the tubing should be covered with a small 









b. Pipette a small additional 70% PCL into the 20 mm piece of silicone tubing to fill it up to 
the top. 
c. Gently insert one end of a cut NFB segment into the liquid PCL. 
 
d. Secure upright and allow it to set overnight until dichloromethane has all evaporated, 
leaving just solidified PCL. 
e. Repeat steps a-d to create a solid PCL block on the other end of the NFB segment. 
 




A.1.4 Growth Factor Conjugation to Nanofiber Bundles 
Chemical Source Product number Amount 
Connective tissue growth factor Sigma-Aldrich SRP4702 20 μg 
Basic fibroblastic growth factor Sigma-Aldrich F0291 25 μg 
Polyallamine Sigma-Aldrich 227056 1 g (20 wt% in H20) 
N,N-dimethylformamide Sigma-Aldrich 227056 100 ml 
N-succinimidyl-3-maleimidoproprionate TCI America S0427 100 mg 
 
1. Incubate fibers in a 5% solution of polyallamine with simultaneous UV radiation for 25 minutes. 
2. Rinse fibers 
a. Rinse 3 times in dH2O. 
b. Soak in dH2O for 2 hours. 
c. Rinse 3 times in dH2O. 
3. Incubate fibers in a solution of 25mg N-succinimidyl-3-maleimidoproprionate in 3.3ml N,N-
dimethylformamide for 1 hour.  
4. Rinse fibers 
a. Rinse 3 times in dH2O. 
b. Soak in dH2O for 2 hours. 
c. Rinse 3 times in dH2O. 
5. Incubate fibers in a 50ng/ml solution of CTGF for 2 hours. 
6. Rinse fibers 
a. Rinse 3 times in dH2O. 
b. Soak in dH2O for 2 hours. 
c. Rinse 3 times in dH2O. 




A.2 Cell Culture  
 
A.2.1 General Cell Culture Media 
Item Location 
500ml bottle DMEM Fridge 
50ml FBS aliquot Freezer 
5ml pen/strep aliquot Freezer 
0.5 ml amphotericin-B aliquot Freezer 
60ml plastic syringe Cell culture supply drawer 
0.25um filter tip Cell culture supply drawer 
 
1. Thaw FBS, pen/strep, and amphotericin-B in water bath. 
2. Discard 55ml of DMEM from the bottle. 
3. If FBS and pen/strep are not already sterilized, sterile filter both into the DMEM bottle. 
4. Pipette amphotericin-B into bottle. 
5. Cap the bottle and mix gently by inverting. 




A.2.2 Adipose Derived Stem Cell Culture Media 
Item Location 
Sterile 500ml glass bottle  Middle shelf 
500ml bottle ADSC DMEM Fridge 
50ml FBS Freezer 
5ml Pen/strep Freezer 
60ml plastic syringe Cell culture supply drawer 
0.25um filter tip Cell culture supply drawer 
 
7. Thaw FBS and Pen/strep in water bath. 
8. Discard 55ml of ADSC DMEM from the bottle; pour the remainder in the glass bottle. 
9. Sterile filter the FBS and Pen/strep into the glass bottle. 
10. Cap the glass bottle and mix gently by inverting. 




A.2.3 Freezing Cells 
Item Location 
ADSC Media (warmed) Fridge 
Sterile 1x PBS (warmed) Middle shelf 
4ml 0.25% trypsin (per flask, warmed) Freezer 
FBS for freeze media Freezer 
DMSO Flammables cabinet 
15ml tubes Top of incubator 
20ml syringe Cell culture supplies drawer 
0.25um filter tip Cell culture supplies drawer 
Sterilized 2ml tubes Cell culture supplies drawer 
Cryogenic storage tubes Cell culture supplies drawer 
Mr. Frosty Cell culture supplies drawer 
Isopropyl alcohol Flammables cabinet 
 
1. Check with the cell culture microscope to ensure cells are ~80% confluent. 
2. Aspirate media from flasks. 
3. Add 13ml PBS to each flask, aspirate off. 
a. Make sure to add PBS to the NON-growing side of the flasks. 
b. Trypsin is inactivated by media so the PBS ensure that all media is removed before 
adding the trypsin. 
4. Add 1ml of trypsin to each flask, aspirate off. 
5. Add remaining 3ml of trypsin to each flask, incubate for 7-10 minutes. 
6. Check flasks with cell culture microscope to ensure that nearly all the cell have come unattached 
from the surface of the flasks. 
a. It may be necessary to gently tap the side of the flasks to release any stuck on cells. 
b. If cells are NOT detached allow to incubate for another few minutes. 
c. Do not incubate cells for longer than 10 minutes, the trypsin could start to kills them. 
7. Add 10ml of media to each flask to inactivate the trypsin. 
8. Pour the mixture of media/trypsin/cells from each flask into a 15ml tube. 
9. Centrifuge the 15ml tubes at 280G for 5 minutes 
10. CAREFULLY aspirate off the supernatant, making sure not to disturb the pellet. 
11. Pick 1 tube of cells to count. 
a. Add 1ml of PBS to the tube and gently pipette up and down to resuspend the cells. 
b. Add an additional 4ml of PBS to the tube and pipette to mix. 
c. Take 100ul of PBS/cell mixture from the 5ml PBS/cell mixture and pipette into a sterile 
2ml tube. 
d. Using the cell counter, count the number of cells in the 100ul sample. 
i. Cell counter will return a count of cells/ml. 
ii. Multiply the returned number by 5 to determine the total number of cells in 5mls 
of PBS. 
e. Centrifuge the tube that was counted at 280G for 5 minutes 
f. Aspirate off supernatant. 
12. Make freeze media 
a. Need 1ml per tube of cells to freeze. 
b. 90% FBS and 10% DMSO. 
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c. Sterile filter into a 15ml conical tube. 
13. Resuspend all tubes of cells in 1ml freeze media. 
14. Pipette each 1ml cell/freeze media mixture into cryogenic storage tubes and label all tubes with 
type of cell, passage number, initials, and date. 
15. Fill Mr. Frosty with isopropyl alcohol and plastic inserts. 
16. Add vials of cells and put in -80C freezer for at least four hours. 




A.2.4 Plating and Expanding Frozen Cells 
Item Location 
Vial of frozen cells Liquid nitrogen storage tank 
ADSC media (warmed) Fridge 
15ml conical tube On top of incubator 
50ml conical tube On top of incubator 
T75 flasks Cell culture supplies cabinet 
Sterile 1x PBS Middle shelf 
 
1. Thaw 1ml vial of cells by swirling gently in water bath. 
2. Fill 15ml tube with 4ml of media.  
3. Gently pipette 1ml of cells into tube of media. 
4. Centrifuge at 280G for 5 minutes. 
5. Fill 50ml conical tube with the amount of media necessary to seed the desired number of T75 
flasks (13ml per flask) MINUS 1ml 
6. When centrifuge has finished, aspirate off the supernatant and re-suspend the cells in 1ml media. 
7. Add the 1ml of media with cells to the 50ml conical tube with media. 
a. Pipette gently up and down to mix cells in with larger volume of media. 
b. If desired triturate the cells from the 50ml conical tube. 
8. Pipette ~2ml PBS into each flask and agitate to ensure the entire growing surface is coated with 
fluid. Aspirate off PBS. 
9. Pipette 13ml of cell/media mixture into each T75 flask. Lay flak down and make sure there are no 
bubbles and the entire growing surface is coated. Also make sure to vent the lid. 
10. Check that cells are present in the flas by using the light microscope at 10x on the middle contrast 
setting. 




A.2.5 Splitting Cells 
Item Location 
ADSC Media (warmed) Fridge 
Sterile 1x PBS (warmed) Middle shelf 
4ml 0.25% trypsin (per flask, warmed) Freezer 
15ml tubes Top of incubator 
50ml tubes Top of incubator 
Sterilized 2ml tubes Cell culture supplies drawer 
T75 flasks Cell culture supplies cabinet 
 
1. Check with the cell culture microscope to ensure cells are ~80% confluent. 
2. Aspirate media from flasks. 
3. Add 13ml PBS to each flask, aspirate off. 
a. Make sure to add PBS to the NON-growing side of the flasks. 
b. Trypsin is inactivated by media so the PBS ensure that all media is removed before 
adding the trypsin. 
4. Add 1ml of trypsin to each flask, aspirate off. 
5. Add remaining 3ml of trypsin to each flask, incubate for 7-10 minutes. 
6. Check flasks with cell culture microscope to ensure that nearly all the cell have come unattached 
from the surface of the flasks. 
a. It may be necessary to gently tap the side of the flasks to release any stuck on cells. 
b. If cells are NOT detached allow to incubate for another few minutes. 
c. Do not incubate cells for longer than 10 minutes, the trypsin could start to kills them. 
7. Add 10ml of media to each flask to inactivate the trypsin. 
8. Pour the mixture of media/trypsin/cells from each flask into a 15ml tube. 
9. Centrifuge the 15ml tubes at 280G for 5 minutes 
10. CAREFULLY aspirate off the supernatant, making sure not to disturb the pellet.  
11. Pick 1 tube of cells to count. 
a. Add 1ml of PBS to the tube and gently pipette up and down to resuspend the cells. 
b. Add an additional 4ml of PBS to the tube and pipette to mix. 
c. Take 100ul of PBS/cell mixture from the 5ml PBS/cell mixture and pipette into a sterile 
2ml tube. 
d. Using the cell counter, count the number of cells in the 100ul sample. 
i. Cell counter will return a count of cells/ml. 
ii. Multiply the returned number by 5 to determine the total number of cells in 5mls 
of PBS. 
e. Centrifuge the tube that was counted at 280G for 5 minutes 
f. Aspirate off supernatant. 
12. Resuspend the cells in 1ml new media. 
13. Fill a 50ml tube with the total amount of media needed to fill the desired number of flasks (13ml 
per flask) MINUS the media that the cells are already suspended in.  
14. Add the resuspended cell to the 50ml tube of media. Pipette up and down gently to mix. 
15. Pipette ~2ml PBS into each flask, agitate to ensure that the growing surface is coated with fluid, 
aspirate off PBS. 
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16. Pipette 13ml of cell & media mixture into each T75 flask, lay flask down and make sure entire 
growing surface is coated, avoid bubbles, make sure lid is vented. 
17. Check that cells are present by using the light microscope at 10x on the middle contrast setting. 




A.2.6 Electrospinning Sterilization and Cell Culture 
Item Location 
Flat sheets of electrospinning Electrospinning cabinet, bottom shelf 
8mm biopsy punch Cell culture supplies drawer 
48 well plate Cell culture supplies drawer 
Methanol Flammables cabinet 
70% ethanol Flammables cabinet 
Sterile 1x PBS Middle shelf 
Cell culture media Fridge 
50ml conical tube Top of incubator 
Cells 2ml tube 
 
1. Punch out flat electrospinning samples with 8mm biopsy punch. Use a cutting board under the 
electrospinning to prevent the biopsy punch blade from becoming dull. 
2. In the cell culture hood peel the electrospinning off the aluminum foil and transfer to wells of a 
48 well plate. 
3. Soak each sample in methanol (500μl per well) for 24 hours to ensure that all OLA has been 
leached out. 
4. Soak each sample in 70% ethanol for 30 minutes. 
5. Rinse each sample three times in sterile 1x PBS. 
6. Expose samples to UV light for 30 minutes with lid off the 48 well plate. 
7. Determine the number of cells necessary for seeding the desired number of samples. 
a. Seed at a density of 10,000 cells/cm2 
b. 48 well plate area = .95cm2 
c. ~9500 cells in 500ul of media per well 
d. Make sure to calculate for ~4-5 extra wells worth of cells to account for any cell/media 
mixture that gets lost. 
8. Follow procedures for splitting cells up until cell 12. 
9. Aliquot out the amount of media necessary to seed the desired number of wells, subtracting the 
amount that will be added with the cells. 
10. Remove the necessary number of cells/media solution in order to get the desired number of cells.  
11. Add the cell/media mixture to the larger volume of media, pipette up and down gently to mix. 
12.  Pipette 500ul of cell/media mixture at the final necessary cell count onto each sample, taking 
care to keep each sample as flat as possible. 




A.2.7 Nanofiber Bundle Sterilization and Cell Culture 
1. Prepare scaffolds and culture dish 
a. Autoclave specially made plastic cell culture dish and glass petri dishes 
b. Cut nanofiber bundles to 20mm in length 
c. Place one scaffold in each well of cell culture dish 
2. Sterilize scaffolds 
a. Soak samples in methanol for 24 hours to ensure that all OLA has been leached out 
b. Soak each samples in 70% ethanol for 30 minutes 
c. Rinse each sample three times in sterile 1x PBS 
d. Expose samples to UV light for 30 minutes 
e. Store samples in DI water until ready for use 
3. Determine number of necessary cells for seeding the desired number of samples 
a. Seed at a density of 65,000 cells/cm2 based on the exposed bottom surface area of each 
well in the culture plate 




c. ~40,000 cells in 200 µl of media per well 
i. This is ~40,000 cells per scaffold (area of ~0.32cm2) 
d. Make sure to account for ~4-5 extra wells work of cells to account for any cell/media 
mixture lost during pipetting. 
4. Seed cells on scaffolds  
a. Follow previously established procedures for trypsanizing and counting cells. 
b. Re-suspend cells in 1ml of cell culture media. 
c. Calculate the necessary amount of cell/media solution of obtain the desired number of 
cells 
d. Aliquot out the amount of media necessary to seed the desired number of wells, 
subtracting the amount that will be added with the cells. 
e. Add the cell/media mixture to the larger volume of plain media; pipette up and down 
gently to mix. 
f. Pipette 200 µl of cell/media mixture at the necessary final cell count onto each scaffold. 





A.3 Cell Culture Analysis 
 
A.3.1 Cell Titer-Blue Assay 
*** STAIN IS LIGHT SENSITIVE. PROCEDURE SHOULD BE CARRIED OUT IN THE 
DARK*** 
Item Location 
CellTiter-Blue reagent Freezer 
 
1. Add CellTiter-Blue reagent to cells in culture, shake for 10 seconds, and incubate for 4 hours in 
incubator. 
a. Use 20ul of reagent to each 100ul of cell culture media 
b. If possible include a control sample (no cells) and a blank (just media, no sample) 
2. Shake for 10 seconds and add 100ul from each sample to a 96-well plate 
a. If possible put samples in the 96-well plate in duplicate or triplicate 





A.3.2 SEM Fixation 
***DOES NOT NEED TO BE STERILE. PROCEDURE SHOULD BE CARRIED OUT IN FUME 
HOOD*** 
Item Location 
Sterile 1x PBS Counter 
Sucrose Shelf 
Sodium cacodylate Shelf 
Millipore water Counter 
Gluderaldehyde Fridge 
Primary fixative (3% gluderaldehye in 0.1M sodium cacodylate & 
0.1M sucrose) 
Make new  
Buffer solution (0.1M sodium cacodylate & 0.1M sucrose) Make new 
35% ethanol Flammables cabinet 
50% ethanol Flammables cabinet 
70% ethanol Flammables cabinet 
100% ethanol Flammables cabinet 
Hexamethyl disilisone  Flammables cabinet 
 
 Primary fixative and buffer solution 
o Dissolve 0.68g sucrose and 0.43g sodium cacodylate in 19.4ml dH2O 
o Buffer solution: 10ml of the solution 
o Primary fixative: remaining solution plus 0.3ml gluderaldehyde 
1. Aspirate cell culture media from samples 
2. Rinse samples 2x in PBS. 
3. Place the samples in following solutions for the designated times: 
a. Primary fixative – 45 minutes 
b. Buffer solution – 10 minutes 
c. 35% ethanol – 10 minutes 
d. 50% ethanol – 10 minutes 
e. 70% ethanol – 10 minutes 
f. 100% ethanol – 10 minutes 
g. Hexamethyl disilisone – 10 minutes 




A.3.3 Fluorescence Staining 
*** STAINS ARE LIGHT SENSITIVE. PROCEDURE SHOULD BE CARRIED OUT IN THE 
DARK*** 
Item Location 
CMFDA stock solution Freezer 
CMFDA working solution (10uM concentration) Make new from stock solution 
Rhodamine stock solution Fridge 
Rhodamine working solution (1:200 dilution)  Make new from stock solution 
DAPI stock solution Freezer 
DAPI working solution (1:1000 dilution, 1ug/ml) Make new (store in freezer for up to 1 week) 
Fixative solution Middle shelf 
37% Formaldehyde Flammables cabinet 
Permeative solution Middle shelf 
Triton X Flammables cabinet 
Sterile 1x PBS (warmed) Middle shelf  
Culture media (warmed) Fridge 
15ml tubes Top of incubator 
 
 CMFDA stock solution (10mM concentration) 
o Add 10.8ul DMSO to one of the kit vials 
 Rhodamine stock solution 
o Add 500ul methanol to Rhodamine kit vial 
 DAPI stock solution (1mg/ml) 
o Add 10ml UPW to 10g powder DAPI 
 First add 2ml UPW to the container of DAPI power 
 Transfer 2ml solution to 8ml solution 
 Separate into two tubes of 5ml stock solution for storage 
 Fixative solution: 3.7% formaldehyde in PBS 
o Add 10ml 37% formaldehyde to 90ml PBS 
 Permeative solution: 1% Triton X in PBS 
o Add 1ml Triton X to 99ml PBS 
1. Aspirate cell culture media from samples 
2. Rinse samples 2x in PBS. If possible transfer samples to new wells 
3. Make CMFDA working solution 
a. Use 1ul of CMFDA stock solution for each 1ml of PBS 
4. Incubate in CMFDA working solution for 45 minutes in cell culture incubator 
5. Aspirate CMFDA working solution 
6. Incubate in warm culture media for 30 minutes in cell culture incubator 
7. Aspirate culture media and rinse 1x in PBS. If possible transfer samples to new wells 
8. Add fixative solution and incubate for 15 minutes at room temperature 
9. Aspirate fixative solution and rinse 3x in PBS for 5 minutes each 
10. Add permeative solution and incubate for 3 minutes at room temperature 
11. Aspirate permeative solution and rinse 1x in PBS. If possible transfer samples to new wells 
12. Make Rhodamine working solution 
a. Use 5ul of Rhodamine stock solution for each 1ml of PBS 
13. Add Rhodamine working solution and incubate for 20 minutes at room temperature 
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14. Make DAPI working solution (can keep for up to a week in the freezer, usually make ~10ml) 
a. Use 1ul of DAPI stock solution for each 1ml of PBS 
15. Add DAPI working solution to Rhodamine working solution and incubate for 5 minutes at room 
temperature 
a. Add DAPI working solution so that the final dilution of DAPI in PBS is 105:1000 
(105ng/ml, 300nM) 




A.3.4 Electrospinning Histological Staining 
Fixation 
Item Location 
Phosphate Buffered Saline (PBS) PBS Storage Tank 
10% formalin Flammables cabinet 
70% ethanol Flammables cabinet 
 
Methods 
1. Rinse samples in PBS. 
2. Cut in half through the center. 
3. Place in tubes with tops labeled 1-8L and sides labeled accordingly: 
a. H.Ctrl.D1 = Histology, control, day 1 
b. H.CTGF.D21 = Histology, CTGF, day 21 
4. Submerge samples in 10% formalin for 24-48 hours. 
5. Rinse samples 3 times with 70% ethanol. 
































Phosphate Buffered Saline (PBS) PBS Storage Tank 
Sucrose Chemical shelf 
Tissue Tek OCT Chemical shelf 
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Cryomolds (square, white plastic) Histology cabinet 
Liquid Nitrogen Chemistry stockroom 
Styrofoam dish Histology cabinet 
Forceps/Tweezers Drawer Beside sink 
Plastic Wrap Drawer Beside sink 
Beakers Glassware Shelf 
 
Prepared Solutions: 
 10% sucrose solution: 
1. Dissolve 10g crystalline sucrose in 100ml PBS. 
 20% sucrose solution: 
1. Dissolve 20g crystalline sucrose in 100ml PBS. 
 30% sucrose solution: 
1. Dissolve 30g crystalline sucrose in 100ml PBS. 
Methods 
1. Fill 100 mL glass beakers approximately half or ¾ full with 10% 20% and 30% sucrose solutions 
respectively. 
2. Place specimen into 10% sucrose solution, the tissue should float. 
3. Once the tissue drops to the bottom of the vial tissue has been infiltrated, move tissue to 20% 
sucrose solution 
4. Once the tissue drops to the bottom of the vial, transfer tissue to 30% sucrose solution  
5. Once the tissue drops to the bottom of the vial, remove tissue from vial and blot with Kimwipes. 
6. Put a small amount of OCT in the bottom of the mold 
7. Cut tissue if necessary to attain a flat cross section and orient appropriately in cryo mold with the 
cut face lying flat on the bottom of the mold 
8. Fill mold with enough OCT. 
9. Pour liquid nitrogen into Styrofoam dish. 
10. Carefully submerge tissue/mold in liquid nitrogen so as not to disrupt orientation of tissue in the 
mold. 
11. Once the sample sinks to the bottom of the dish, remove and place on absorbent towel (slows 
down thawing of frozen specimen/OCT). Either let rest at room temperature for a minute to bring 
up to a temperature that is safe to handle and then remove from mold and wrap immediately with 
plastic wrap, label and store at -20°C. 
Cryosectioning 
Item Location 
Cryostat Histology room 103 
Tissue Tek OCT Chemicals shelf 
Subbed Slides Shelf 
dH2O in Spray Bottle Counter top 
 
Procedure: 
1. Inside the microtome, place the chuck (grooved platform) in one of the first four holes in the “fast 
freeze rail” (2 columns of 6 holes each located on the far left inside the microtome).  These 
chucks can be left in the cryostat during cool-down time as well.  
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o `The slots are NOT numbered – make sure to label the order of your samples if you are 
prepping more than one sample at a time.  
 
 
2. Remove a blade from the blade container, or reuse one designated for your tissue, and grip it by 
the flat edge.  Raise the clamp on the right hand side of the blade holder and slide the blade in 
along the left hand side of the blade holder.  If it won’t go in, push gently on the bottom edge of 
the blade holder (the side closest to you).  Push the clamp back up to lock the blade in place. 
o Do not over-tighten blade 
o Inspect the blade before putting it into the blade holder. Do not reuse the blade if there 
are any cosmetic defects, cracks, or chips taken from the blade. 
3. Wearing gloves remove the chuck and hold the post in your hand, letting it warm up slightly.  
Spread embedding medium on the face of the chuck (over the grooved surface, making sure it 
goes down into the grooves).  NOTE: if the chuck is too cold when you put the medium on the 
grooved face, the medium will not go down into the grooves. You will have to pop off the frozen 
medium, wait for the chuck to warm up a bit more, and try again.   
4. As soon as crystals start to appear on the outside edges of the embedding medium on the chuck 
face (this will happen quickly, and the medium will turn white near the chuck), push your 
embedded specimen into the center.  The cutting surface (flat surface) should be exposed and 
parallel with the chuck surface.  
5. Allow the entire chuck/specimen combination to freeze inside the cryostat.  
6. Insert the post of the chuck into the chuck holder.  The small metal knob behind the chuck holder 
secures the chuck in the holder, and the black lever to the right of the chuck allows the chuck to 
rotate once it has been loosened. 
7. Adjust the vertical position of the sample with the knob on top of chuck so that it is centered 
vertically with respect to the blade. Adjust side to side alignment with knob on left side.  
8. Use the retract/advance buttons on main screen of the cryostat to move chuck and holder to/away 
from blade. Make sure the notch needle on the displacement wheel is up when this is done. 
9. Using the handwheel on the right hand side of the cryostat, raise and lower the embedded sample 
to trim through the frozen medium until you start to see the sample appear. Continue trimming 
until a good cross-section appears.  Adjust the angle of the chuck if the sample appears to be 
cutting unevenly (i.e., if sections appear to be thicker on one side, if they appear angled, etc.). 
There is no blade guard, so MAKE SURE TO BE CAREFUL TO NOT CUT YOURSELF WITH 
THE BLADE when you do this.  
10. Flip the “glass anti-curl plate” down so that any sections cut will slide into it underneath the 
glass; this will prevent sections from curling. 
11. Start with 6um sections and increase to 8um if 6um does not yield good sections. Raise the glass 
plate periodically to clean out any “junk sections” with the brush kept inside the microtome 
12. When your first good (even thickness, longitudinal appearance) section is cut, transfer it to a 
piece of slide glass by raising the anti-curl plate and pressing a piece of slide glass against the 
specimen.  
13. Cut at least 2 more sections that you’ll dispose of before the next section you plan to transfer to a 
slide (so that they’ll be separated through the depth of the core).  Do not place more than 3-4 
sections per slide or the cover glass will not fit.  Be careful of their placement when transferring 
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to the slide glass – you won’t be able to move them once they’ve been stuck to the slide, so make 
sure they’re close enough together so that one coverglass will cover all 3.  Obtain a total of 9 
sections (2-3 per slide; 3-4 slides) per sample.  
14. The remaining specimen can be refrozen by carefully melting the OCT medium from the 
underside the chuck with your fingers. DO NOT let the sample melt. Refold the sample in saran 
wrap and place in -20˚C non-frost free freezer. 
15. Remove the blade from the cryostat; raise the blade clamp to unlock it and use forceps to gently 
push along the right hand side of the blade, pushing the blade out the left side of the holder. Place 
the used blade in the disposal side of the blade container. 
16. Pull up the notch needle on the displacement wheel and push the “RETRACT” button to the left 
of the cryostat menu panel to retract the chuck and holder away from the blade holder.  
17. Clean out any remaining junk by pushing it down to the side/bottom of the cryostat, but wipe out 
the junk while it is frozen before turning off the cryostat for an extended period of time. 
18. Lay slides on a flat surface. 
19. Using a spray bottle, spray 60˚C (warm in microwave in northeast lab by liquid nitrogen tank) 
distilled water on slides to remove bubbles and promote the section adherence to the slide. Do not 
dip slides in water or saturate the slides. Allow to dry overnight. 
Troubleshooting: 
1. If sectioning becomes inconsistent and slices appear shredded, one of these methods may 
alleviate the problem: 
a. Adjust roll plate  
b. Change blade angle 
c. Slice using another section of the blade 
d. Flip blade over or try new blade 
e. Try the sample later! – seriously it works 
f. The sample may not have been embedded correctly 
g. The blade may not be cold enough! Allow the cryostat to drop in temperature. 
h. Try a thinner or thicker sectioning depth. 
 
Safranin O Staining – GAGs 
Item Location 
Slide Holder Histology cabinet 
Histology staining boxes Histology cabinet 
dH2O dH2O storage tank 
Tap Water Sink 
Weigert’s Hematoxylin A Under fume hood 
Weigert’s Hematoxylin B Under fume hood 
Fast green FCFR Chemical shelf 
Glacial acetic acid Under fume hood 
Safranin O Chemical shelf 
95% Ethanol Flammables cabinet 
100% Ethanol Flammables cabinet 
Xylene Flammables cabinet 
 




 Weigert’s Hematoxylin (filter after use, can be used for 3 months) 
1. Create 1:1 mixture Weigert’s Hematoxylin A and Weigert’s Hematoxylin B straight out 
of the bottle.  
2. 150mL Hematoxylin A + 150mL Hematoxylin B is sufficient for 250mL slide boxes. 
 Fast Green FCF Solution 
1. Dissolve 0.1g fast green FCFR in 1000mL dH20 
 1% Acetic Acid Solution 
1. Mix 10mL glacial acetic acid with 990mL dH20 
 0.1% Safranin O Solution 
1. Mix 40ml 1% Safranin O in 360 mL dH20 
Procedure: 
1. Place the slides in the slide holder. 
2. Stain with Weigert’s iron Hematoxylin working solution for 10 minutes 
3. Wash in running tap water for 10 minutes – take care not to run faucet open too far, 
pressure/agitation will cause samples to come off slide  
4. Stain with fast green (FGF) solution for 5 minutes 
5. Rinse quickly with 1% acetic acid solution for no more than 10 – 15 seconds 
6. Stain in 0.1% Safranin O solution for 10 minutes 
7. Dehydrate and clear with 95% ethanol, absolute ethanol and xylene, using 2 changes each, for 2 
minutes each 
8. Allow to dry for ~3minutes, cover samples in Clearmount Mounting  
Cleanup: 
 Filter Weigert’s, Safranin O and Fast green using funnel and filter paper back into their containers 
 Weigert’s must be placed in used container as it comes separated and is mixed to activate 
 Acetic acid, ethanol and xylene washes are disposed of in respective labeled waste containers. 
Troubleshooting: 
 If slides still have stain on them, plunge slide holder up and down during the acetic acid wash and 
ethanol/xylene clearings 
 Weigert’s solution once mixed will last approx. 3 month 
Alizarin Red Staining – Calcium 
Item Location 
Slide holders Histology cabinet 
Histology staining boxes Fume hood 
dH2O dH2O storage tank 
Alizarin Red Chemical shelf 
Ammonium hydroxide Under fume hood 
Glacial acetic acid Under fume hood 
Acetone Under fume hood 
Xylene Flammables cabinet 
 
Description: Alizarin Red S, an anthraquinone derivative, may be used to identify calcium in tissue 
sections. The reaction is not strictly specific for calcium, since magnesium, manganese, barium, 
strontium, and iron may interfere, but these elements usually do not occur in sufficient concentration to 
interfere with the staining. Calcium forms an Alizarin Red S-calcium complex in a chelation process, and 




 Alizarin Red Solution: 
1. Mix 2g Alizarin Red in 100mL distilled water (mix thoroughly, may take excess of 1 
hour stirring to remove all clumps). 
 Start with 1g Alizarin Red and check particulate content. Increase to 2g Alizarin Red 
if solution is transparent/ particulate content not extreme 
2. Adjust pH to 4.1~4.3 with 10% Ammonium Hydroxide (only will take a few drops). The 
pH is critical, so make fresh or check pH if the solution is more than one month old. 
 Increase pH with 10% Ammonium Hydroxide 
 Decrease pH with 10% Glacial Acetic Acid 
 Acetone-Xylene: 
1. Mix equal parts acetone to xylene in the fume hood.  
Procedure:  
1. Stain slides with the Alizarin Red Solution for 30 seconds to 5 minutes, and observe the reaction 
microscopically. Usually 2 minutes will produce nice red-orange staining of calcium. 
2. Shake off excess dye and blot sections. 
3. Dehydrate in acetone, 20 dips. Then in acetone-xylene solution, 20 dips. (Increase to 30 dips each 
for clearer slides) 
4. Clear in xylene (2 changes, 2 minutes each) and mount in a synthetic mounting medium.  
 
Picro-sirius Red Staining – Collagen 
Item Location 
Slide holders Histology cabinet 
Histology staining boxes Fume hood 
Sirius red F3B Chemical shelf 
Saturated aqueous solution of picric acid Under fume hood 
Glacial acetic acid Under fume hood 
Tap water Sink 
Weigert’s hematoxylin A  Under fume hood 
Weigert’s hematoxylin B Under fume hood 
 
Description: In bright-field microscopy collagen is red on a pale yellow background. (Nuclei, if stained, 
are ideally black but may often be grey or brown. The long time in picro-sirius red causes appreciable de-
staining of the nuclei 
Prepared Solutions: 
 Weigert’s Hematoxylin 
1. Create 1:1 mixture Weigert’s Hematoxylin A and Weigert’s Hematoxylin B 
 ~150mL Hematoxylin A + ~150mL Hematoxylin B 
2. Filter after use and can be used many times (lasts ~3 months) 
 Picro-sirius red solution 
1. Dissolve 0.5 g Sirius red F3B in 500ml saturated aqueous solution of picric acid 
2. Keeps for at least 3 years and can be reused many times 
 1% acetic acid 
1. Mix 5ml glacial acetic acid with 495ml dH2O 
Procedure 
1. Place slides in a rack 
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2. Immerse the rack in solutions as defined below 
Solution Time 
Picro-sirius red 1 hr 
1% acetic acid 30 sec 
1% acetic acid 30 sec 
dH2O 30 sec 
dH2O 30 sec 
95% ethanol 30 sec 
95% ethanol 30 sec 
Xylene 3 min 
Xylene 3 min 
 




A.3.5 Electrospinning Biochemical Assays 
Freezing Samples 
Methods 
7. Rinse samples in PBS. 
8. Cut in half through the center. 
9. Blot away excess liquid using a Kimwipe. 
10. Place in tubes with tops labeled 5-12R and sides labeled accordingly: 
a. B.Ctrl.D1 = Biochemical assay, control, day 1 
b. B.CTGF.D21 = Biochemical assay, CTGF, day 21 





























Papain Digestion of Scaffolds 
Item Source Location 
NaOH Sigma S8045 Chemical shelf 
Na2EDTA2H2O Sigma E5134 Chemical shelf 
Sodium phosphate dibasic anhydrous Sigma S3264 Chemical shelf 
Sodium phosphate monobasic 
anhydrous 
Sigma S3139 Chemical shelf 
Hydrochloric acid (HCL)  Under fume hood 
L-cysteine hydrochloride hydrate Sigma C7477 Chemical shelf 
Papain stock solution Sigma P3125 Fridge 
Prepared Solutions: 
 10 M NaOH (for pH adjustment of EDTA) 
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1. Add 20 g NaOH to 50ml dH2O 
 500mM Na2EDTA2H2O (aka EDTA) 
1. Add 18.6 g Na2EDTA2H2O to 70 ml dH2O 
2. pH up to 8 with 10M NaOH (~3  ml, takes 30 min-1 hr) 
3. Add dH2O to make up to a final volume of 100 ml (use a graduated cylinder) 
4. Autoclave and sterile filter to remove dust particles 
 Papain buffer extract (PBE) 
1. Add 0.7098 g sodium phosphate dibasic anhydrous (Na2HPO4) and 0.5998 g sodium 
phosphate monobasic anhydrous (NaH2PO4) to 90 ml dH2O 
2. Add 1ml 500 mM EDTA 
3. Adjust pH to 6.5 while using magnetic stirrer (~200 µl of 38% HCL) 
4. Add dH2O to make up to a final volume of 100ml (use a graduated cylinder) 
5. Sterile filter to remove dust particles, store at 4°C 
 Activated papain enzyme digest solution (APEDS) 
1. Add 63 mg of L-cysteine hydrochloride hydrate to 40 ml of PBE 
2. Remove papain stock solution from fridge, vortex to dissolve, swab rubber stopper with 
70% ethanol 
3. Remove required papain stock solution with syringe and needle and transfer to a sterile 
microcentrifuge tube 
4. Add 3.88 units/ml of papain stock solution to L-cysteine/PBE solution 
 Papain enzyme stock is 24 mg/ml and 16 units/ml  384 units/ml  
3.88*1000 = 10.1 μl 
           384 
 For 40ml of activated papain enzyme digest solution 
 10.1 * 40 = ADD 404 µl of papain stock solution to L-cysteine/PBE 
solution 
Procedure 
1. Remove scaffolds from storage in -80°C freezer. Excess fluid should have been previously 
removed 
2. Add 0.5 ml APEDS to each microcentrifuge tube to cover the sample 
3. Set cell culture incubator to 0% CO2 and 50°C. Place tubes in rotator at 10 rpm and incubate 
overnight or for 18 hr. 
4. Vortex and shake tubes to free anything that might be trapped within the fibers 
5. Remove fibers from papain solution and proceed immediately to Pico-green DNA assay to avoid 
degradation. 
PicoGreen DNA Content Assay 
Item Source Location 
Quant-iT PicoGreen dsDNA Reagent Fisher P7589 Fridge, desiccate and protect from 
light 
20x TE buffer Fisher P7589 Chemical shelf 




 1x TE buffer (for one 96 well plate) 
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1. 1.25 ml of 20x TE stock buffer in 23.75 ml of dH2O 
 PicoGreen working reagent (for one 96 well plate, prepare in plastic tube) 
1. Remove 55 μl from 22ml of 1x TE buffer 
2. Add 55 μl of PicoGreen stock solution 
3. Protect from light and use within a few hours 
 40 ug/ml DNA solution (for one 96 well plate) 
1. Add 40 μl of DNA standard to 60 μl of 1x TE buffer 
2. Vortex and briefly centrifuge 
 20 ug/ml DNA solution 
1. Add 2 μl of DNA standard to 38 μl of 1x TE buffer 
2. Vortex and briefly centrifuge 
Procedure 
1. Prepare DNA standards as follows: 
Standard ng/well 
4 x -scale 
mix 




Volume PBE to 
40µl 
STD0 0 0 0  40 
STD1 2.5 10 5  35 
STD2 5 20 10  30 
STD3 10 40 20  20 
STD4 50 200  5 35 
STD5 100 400  10 30 
STD6 150 600  15 25 
STD7 200 800  20 20 
2. Vortex and briefly centrifuge standards 
3. Place 10 μl of each standard and sample into individual wells in triplicate in a 96 well plate 
4. Add 190 μl of PicoGreen working reagent to each well (mix well) 
5. Cover plate with tin foil and allow to incubate for 5 minutes in the dark at room temperature 
6. Read in plate reader at 480 nm excitation and 520 nm emission. 
7. Using standard curve and taking into account dilution extrapolate DNA content for each sample. 
Standard Curve 
 






















Item Source Location 
Sodium chloride Fisher S271 Chemical shelf 
Glycine Fisher G48 Chemical shelf 
Dimethylmethylene salt Sigma 341088 Chemical shelf 
38% hydrochloric acid  Under fume hood 
Shark chondroitin sulfate Sigma C4384 Chemical shelf 
 
Prepared Solutions: 
 DMMB dye (200 ml) 
1. Add 150 ml of dH2O to a beaker 
2. Add 0.468 g NaCl 
3. Add 0.6 g glycine 
4. Add 3.83 mg (0.00383 g) DMMB salt  
5. Adjust the pH to 3.0 with 38% HCl (add 5 µl at a time) 
6. Bring solution to 200 ml with dH2O 
7. Filter solution through Whattman filter paper 
8. Protect from light!  DMMB dye solution is light sensitive.  DMMB dye may be covered 
in aluminum foil and stored at room temperature for approximately one month.  Do not 
use if the solution begins to precipitate. 
 GAG standard solution (200 µg/ml) 
1. Add 2.0 mg (0.002 g) of shark chondroitin sulfate to 10 ml of dH2O 
Procedure: 





GAG Standard [µL] 
Volume PBE 
[µL] 
STD0 0 0 90 
STD1 0.5 7.5 82.5 
STD2 1 15 75 
STD3 2 30 60 
STD4 3 45 45 
STD5 4 60 30 
STD6 5 75 15 
STD7 6 90 0 
2. Add 30 µl of each standard in triplicate 10 a 96 well plate 
3. Add 10 µl of each sample in triplicate to a 96 well plate 
4. Add 20 µl of PBE to each sample well 
5. Prepare plate reader to measure the absorbance wavelength at 525 nm 
6. Add 300 µl of the DMMB dye to each standard and sample well 





Determination of Collagen Content with a Hydroxyproline Assay 
Item Source Location 
Trans-4-hydroxy-L-proline Acros Organics 121780100 Chemical shelf 
Hydrochloric acid (HCL)  Under fume hood 
Citric acid monohydrate Macron Chemicals 0627-12 Chemical shelf 
Sodium acetate tryhidrate Sigma S209 Chemical shelf 
Sodium hydroxide Sigma S318 Chemical shelf 
Acetic acid  Under fume hood 
n-propanol Macron  Chemicals 7169-04 Flammable cabinet 
Chloramine T Sigma 857319 Chemical shelf 
70% perchloric acid Sigma 244252 Chemical shelf 
4-(Dimethylamino)benzaldehyde Fluka 39070 Chemical shelf 
 
Prepared Solutions: 
 Hydroxyproline stock solution (1 mg/ml) 
1. Add 40 mg of trans-4-hydroxy-L-proline to 40 ml of dH2O 
2. Store in fridge, expires after 3 months 
 Citrate stock buffer (prepare 100 ml solution, use fresh batch for each experiment) 
1. Add 5.04 g citric acid monohydrate to 80 ml dH2O 
2. Add 11.98 g sodium acetate trihydrate 
3. Add 3.4 g sodium hydroxide 
4. Add 1.26 ml acetic acid 
5. Adjust pH to 6.1 (use 38% HCL, takes ~100 µl) 
6. Add dH2O to bring total volume to 100 ml 
7. Filter with Whatman paper 
8. Store in fridge 
 Assay buffer (prepare in 15ml tube, enough for two plates) 
1. 1.5 ml n-propanol 
2. 1 ml dH2O 
3. 5 ml citrate stock buffer 
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 Chloramine-T reagent prepare in 15 ml tube (enough for one plate) 
1. Add 141 mg Chloramine T to 0.5 ml dH2O 
2. Place in oven at 60C for 10 min to dissolve 
3. Add 0.5 ml n-propanol 
4. Add 4 ml citrate stock buffer 
5. Wrap tube in tinfoil until use 
 DMBA reagent 
1. 6 ml n-propanol 
2. 3 ml 70%perchloric acid 
3. 4.5 g 4-(Dimethylamino)benzaldehyde 
4. Wrap tube in tinfoil until use 
Procedure: 
1. Sample preparation 
2. Standard preparation 
a. Create a 50 ug/ml hydroxyproline solution (1 in 20 dilution) from the 1 mg/ml stock 
solution 
i. Take 50 ul of hydroxyproline stock solution 
ii. Add 950 ul PBE 
iii. Vortex and briefly spin 
b. Prepare standards as described below, vortex and briefly spin 
Standard ID Vol 50µg/ml HYP (µl) Vol PBE to 1000µl Add 60 µl to each well (ng/well) 
STD0 0 1000 0 
STD1 5 995 15 
STD2 20 980 60 
STD3 40 960 120 
STD4 70 930 210 
STD5 100 900 300 
STD6 125 875 375 
STD7 150 850 450 
TOTAL 510 μL 7490 μL  
 
3. Assay procedure 
a. Add 60 ul (in triplicate) of standards and samples to wells 
b. With a multichannel pipette add: 
i. 20 ul of assay buffer 
ii. 40 ul of chloramine-T reagent 
c. Cover the plate with tinfoil and incubate at 20 min at room temperature to allow 
hydoxyproline oxidation to complete 
d. Add 80 ul of DMBA reagent. Solution will become cloudy. It is essential to mix the 
contents using the pipet until the solution becomes clear 
e. Cover with SealPlate and incubate in an oven at 60C for 20 min 
f. Cover plate with tinfoil and allow to cool for 25 min 
g. Remove SealPlate carefully after cooling 
h. Read in a plate reader at 570 nm. Hdryoxyproline levels in samples can be estimated 





Relationship between hydroxyproline and collagen: 
 
Hydroxyproline is an amino acid that is only found in collagen and elastin. Hydroxyproline is formed via 
the costranslational hydroxylation of the amino acid proline. During the hydroxyproline assay the 
pyrrolidine ring of the hydroxyproline amino acid undergoes oxidative dehydrogenation to a pyrrole ring 
in the presence of  4-(dimethylamino)benzaldehyde with chloramine-T used as an oxidizing agent. 
Spectrophotometric analysis is then used to assess color change as an indication of the amount of 
hydroxyproline present. The hydroxyproline content of soluble collagen Type 1 was found to be 13%, 
which corresponds to a hydroxyproline-to-collagen ratio of 1:7.69. This ratio can be used to estimate the 
collagen content. Thus when a well of a 96 well plate is found to have 100 ng of hydroxyproline present 
the amount of collagen Type 1 present can be calculated to be 794 ng. 
 
Ref: Ignat'eva, N. Y., N. A. Danilov, et al. (2007). "Determination of hydroxyproline in tissues and the 




A.4 Mechanical Testing 
 
A.4.1 Electrospinning Tensile Test 
Item Location 
Flat sheets of electrospinning Cabinet under espin setup 
Spray gun MTS cabinet 
India ink Shelf over scale 
Cardboard enclosure Top of fridge 
Dogbone punch Hannah’s drawer 
Cutting board Hannah’s drawer 
Press Bolted to tabletop 
Divided box Tupperware cabinet 
Thin film grips with sandpaper Tooling cabinet 
Thin film grip adapter plate and screws Tooling cabinet 
Thin film grip to adapter plate adapter Tooling cabinet 
2lb Futek load cell Tooling cabinet 
2 and 10lb load cell adapter plate and screws Tooling cabinet 
Thin film grip to load cell adapter Tooling cabinet 
Flea3 camera Tooling cabinet 
 
Preparation of samples 
1. Electrospin flat sheets (see protocol on T DriveElectrospinning_HP) 
2. Speckle coat sheets 
a. Attach the top pin piece to the compressed air can. Make sure the pin is fully unscrewed 
while attaching. 
b. Connect the air cable to the sprayer and the can of compressed air.  
 
c. Fill the bottle with India ink and attach to the sprayer. To release air screw down the pin 
on the compressed air can. 
d. Tape sheets of electrospinning to the cardboard enclosure and spray from ~1ft away by 
depressing the button on the sprayer. It usually helps to practice first on white paper to 
ensure a desirable speckle pattern. Aim for a light even coating of ink with individual 
dots visible. Avoid spraying large, thick drops of ink or the electrospinning will stick to 




3. Cut out samples using dogbone punch 
a. Tape a few sheets of paper to the cutting board to help avoid dulling the blade.  
b. Place the sheet of speckle coated electrospinning on the cutting board and position the 
dogbone cutter lengthwise in the center of the electrospun sheet where the 
electrospinning is the thickest. 
 
c. Three punches can usually be made from each sheet. 
d. Place the samples in labeled containers, keeping track of the sheet alignment and number.  
MTS Setup 
1. Setup adapters to accommodate thin film grips and 2lb load cell 
a. Attach thin film grip adapter plate to lower load cell 
b. Attach thin film grip to adapter plate adapter. Tape sandpaper to both thin film grips. 
c. Attach bottom thin film grip. Make sure that the grip face will be exactly parallel to the 




d. Attach the 2 and 10lb load cell adapter plate to the actuator 
e. Attach the 2lb load cell adapter to the load cell adapter plate and attach the load cell to 
the adapter. 
 
f. Connect the 2lb load cell to the axial force 2 cable being sure to match up the pins 
correctly. 
2. Turn on and warm up the MTS (see protocol on T 
driveMTS_Bionic370.02Landmark_Setup_KMF 
3. After the 20 minute warmup cycle attach the thin film grip to load cell adapter to the thin film 
grip and the 2lb load cell. 
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4. Manually displace the actuator to the maximum negative displacement. Move the crosshead down 
until the grips are very close together but NOT touching. The two grips should still be separated 
by at least 10cm. 
5. Switch the manual control to torsional displacement (angle controlled) and align the top grip with 
the bottom grip. 
6. Switch manual control back to axial displacement and move the actuator up to a working 
displacement. 
 
7. Setup the camera stand on the MTS and attach the Flea3 camera. The camera should be ~1ft away 
from the thin film grips. Adjust the height of the camera stand so that the top of the lower thin 
film grip is just visible at the bottom of the camera image. Note that if the camera is positioned as 
shown in figure X the recording will be upside down. 
 
8. Setup the Flycap software and Labview to run the camera triggering program (see protocol on the 




1. Open the test file Espin_Tensile 
2. Insert a dogbone shaped specimen into the thin film grips. Name each specimen  
a. I have found the easiest was to do this is to first use tweezers to carefully peel the 
electrospinning. 
b. With the top tab of the dogbone gripped in the tweezers place in the top grip and tighten 
it. After the grip has been tightened remove the tweezers. 
c. Lower the top grip until the bottom tab of the dogbone can be gripped by the bottom grip, 
then tighten the bottom grip. 
 
3. Zero the axial force 2 meter and manually displace the actuator upwards until a pre-load of 0.01N 
has been applied 
4. Take a picture of the entire specimen using the Flycap software. For the first specimen of each 




5. In ImageJ (or FIJI) open the image and measure the gauge length of the specimen. For the first 
specimen of each day of testing first set the scale using the ruler in the image. Make sure to click 
“Make Global” so the same scale will be applied to all subsequent images. 
6. In the MTS test file adjust displacement rate based on the gauge length and desired strain rate. 
7. Continue the camera triggering procedure on step 7 of the MTS_Camera_Trigger_BBW protocol. 
8. Once the specimen fails stop the test procedure as well as the Flycap recording. 




A.4.2 Electrospinning Tensile Test Analysis 
1. Determine the image failure number. 
a. Open the images from the test in ImageJ via FileImportImage Sequence and 
navigate to the file where the test images are stored. If there are a large number of images 
(0.1% strain rate typically results in 8000 images) only open the final ~1000 images. 
b. Scroll through the image sequence and note the first image where the specimen is no 
longer intact. 
 
2. Run the Matlab program Flat_Sheet_Espin.m to determine the true image collection rate. 
a. Will ask you to input the strain rate, the gauge length, and the failure image number. 
When the new ‘Choose file’ window opens click cancel to exit the program.  
b. Assess the resulting variable ‘dic_images’ to determine how many images to include in 
the DIC analysis 
i. This number is determined based on the image rate and the amount of the test 
that will be analyzed. DIC analysis will be run on the first 150 seconds of testing 
(0.1% strain rate), the first 15 seconds of testing (1% strain rate), the first 4 
seconds of testing (5% strain rate), or the first second of testing (25% strain rate). 
3. Prepare the test images for the DIC analysis program 
a. Create a subfolder within the folder of test images that includes the number of images 
specified in the ‘dic_images’ variable. 
b. Crop these images to include only the specimen and a small portion of each grip. Make 
sure that the cropped region will include the specimen for all of the images by checking 




i. The files in the “Cropped” subfolder should be saved sequentially starting with 
the first image. 
4. Run the DIC analysis program in Matlab 
a. Ensure the folder with the Kevin_DIC program files has been added to the working path.  
b. Open Matlab and set the directory to be the “Cropped” folder for the desired specimen. 
File names should be number sequentially. 
c. In the Matlab terminal type “image_setup_GUI” and press Enter. Select the appropriate 
file extension, typically .tif. For the specimens tested at 0.01%strain/sec set the skip to 
10. 
 
d. In the Matlab terminal type “correlate_images_GUI. Set the type of loop to serial, with 
the reference image set to preceding image. Choose all the other settings as shown and 




e. Now a grid must be generated on the reference image. When the window appears select 
the reference image (the first sequentially labeled image with no displacement). Using the 
crosshairs select the area to be analyze as directed. It’s best to choose a region in center 
of the specimen to avoid edge effects. Also make sure the entire rectangular region of 
interest is within the center rectangular area of the dogbone. 
 




g. All windows will close when the correlation is compute. 
h. In the Matlab terminal type “visualize_data_GUI”. Select full data from the drop down 
menu and click “Filled Contour Plot” 
 
i. Select the follow settings and click “View Contour plot” 
 
j. Advance through the test images and observe the contour plot for the entire test. There 




k. Run the “correlate_images_GUI” step again keeping all settings the same except 
changing the step size to 2 pixels. This will produce a finer, more accurate grid. 
 





m. In the Matlab terminal type “compute_data_GUI” and choose the settings shown. 
 
n. Run the “visualize_data_GUI” step again. Still select full data from the drop down menu 




o. Use the settings shown to view the computed strains. When prompted save the resulting 
strains in an Excel file. 
 





5. Combine the MTS data and image data to calculate results of interest 
a. Run the Matlab program Flat_Sheet_Espin.m again. This time when promted to select the 
second file, choose the “gradient” Excel file that was saved at the end of the DIC 
analysis.  
b. After the code runs it will several from the data the “results” variable will contain (in 
order) the short range modulus (MPa), the r-squared of the short range modulus, the yield 
range modulus (MPa), the r-squared of the yield range modulus, the yield stress (MPa), 













A.4.3 Nanofiber Bundle Tensile Test 
Item Location 
Nanofiber bundles Cabinet under espin setup 
Thin film grip plate and screw Tooling cabinet 
Thin film grip to plate adapter Tooling cabinet 
Tensile rod fixture Tooling cabinet 
Thin film grip to load cell adapter Tooling cabinet 
10lb Futek load cell Tooling cabinet 
10lb load cell plate and screws Tooling cabinet 
Flea3 camera Tooling cabinet 
 
1. Setup MTS to accommodate the 10lb load cell and tensile rod fixture 
 
2. Setup the camera stand on the MTS and attach the Flea3 camera. The forward/backward position 
of the camera and the height should be adjusted so that the entire sample will be visible in the 
camera shot. 
3. Set up sample for test 





10lb load cell 
Thin film grip to 
load cell adapter 
Thin film grip 
to plate adapter 




i. Loosen screws on rod of upper fixture and insert one end of the nanofiber bundle 
through the cut center of the rods. End of the nanofiber bundle should be close to 
center tapped hole of the fixture. 
ii. Tighten down screws on rod to sandwich the nanofiber bundle between the 
halves of the rod. 
iii. Wrap the nanofiber bundle around the upper half of the rod, making sure that it is 
seated in the groove in the upper half of the rod to avoid stress concentrations. 
iv. Lower the upper actuator down until the lower end of the nanofiber bundle is 
close to the lower fixture. 
v. Repeat i-iii to secure lower end of nanofiber bundle into lower fixture. 
vi. The long axis nanofiber bundle should be centered on the tapped holes of the  
fixture, as shown in the side-view schematic: 
 
b. Apply a 0.1 N pre-load by manually moving the actuator upwards to ensure fixture 
alignment. 
c. Measure gauge length 
i. After preloading take a picture of the entire specimen using the Flycap software. 
For the first specimen of each day include a ruler for scale. 
ii. In ImageJ (or FIJI) open the image and measure the gauge length of the 













to the center of the lower rod (points where the nanofiber bundle contacts the 
rods). 
 
iii. For the first specimen of each day of testing first set the scale using the ruler in 
the image. Make sure to click “Make Global” so the same scale will be applied to 
all subsequent images. 
iv. Gauge length should be ~15-20mm 
4. Run the test 
a. In the appropriate MTS test file adjust displacement rate based on the gauge length and 
desired strain rate. 






A.4.4 Scaffold Stress Relaxation and Pull to Failure 
Item Location 
Electrospun scaffold Hannah’s drawer 
Hydraulic grip screws Tooling cabinet 
Hydraulic grip plate and screws Tooling cabinet 
100lb load cell Tooling cabinet 
100lb load cell plate and screws Tooling cabinet 
Flea3 camera Tooling cabinet 
 
1. Setup MTS to accommodate the 100lb load cell with the hydraulic grips.
 
2. Setup the camera stand on the MTS and attach the Flea3 camera. The forward/backward position 
of the camera and the height should be adjusted so that the entire sample will be visible in the 
camera shot. 







Hydraulic grip plate 





a. Secure the scaffold in the hydraulic grips 
i. Insert one PCL block into the upper hydraulic grip and close the grip. 
1. PCL block should not be visible since it is completely within the grip. 
ii. Lower the actuator until the lower PCL block drops into the lower hydraulic grip 
and then close the grip. 
b. Apply a 5N pre-load by manually moving the actuator upwards to ensure fixture 
alignment. 
c. Measure gauge length 
i. After preloading take a picture of the entire specimen using the Flycap software. 
For the first specimen of each day include a ruler for scale. 
ii. In ImageJ (or FIJI) open the image and measure the gauge length of the 
specimen. The gauge length should be measured grip to grip. 
iii. For the first specimen of each day of testing first set the scale using the ruler in 
the image. Make sure to click “Make Global” so the same scale will be applied to 
all subsequent images. 
iv. Gauge length should be ~15-20mm 
 
4. Stress relaxation test 
a. Preload sample to 10N 
b. Strain to 3% of gauge length at a strain rate of 2 mm/s 
c. Allow to relax for 20 minutes 
5. Pull to failure test 
a. Preload to 5N 













A.4.5 Ovine Stifle Anterior Drawer 
1. Prepare joint 
a. If knee has not been previously used: 
i. Cut both bones to 135mm from the joint line. Make sure that the proximal 70mm 
of the femur and the distal 70mm of the tibia are free from all soft tissue to 
accommodate the cardboard tube for potting. 
ii. Drill 3 wood screw into the proximal end of the femur and 3 into the distal end of 
the tibia. It may be necessary to use a small drill bit to drill pilot holes. 
 
iii. Pot femur and tibia in Smoothcast. 
1. Cut a piece of cardboard tubing to 70 mm in length. 
a. Outer diameter: 55 mm, inner diameter 50 mm 
b. Peel layers of cardboard off the outside of the tube until it slides 
easily into and out of the cup of the lower MTS fixture. 
c. Cover base and sides of the tube with duct tape to ensure that 
resin does not leak out. 
2. Mix together equal parts of the clear and amber Smooth-Cast 321 Resin 
a. Measure out each component in the sample cup with the yellow 
lid, mix together in a plastic cup. 
b. Stir aggressively and incorporate air. 
c. Continue stirring until the mixture warms slightly and small 
bubbles have formed. 
3. Prop up knee so tibia hangs straight into one of the cardboard tubes. 
4. When Smooth-Cast is ready (when it is slightly warm) pour into the 
cardboard tubing. Leave some space at the top of the tube to allow for 
expansion during hardening. 
5. Allow to set until transparent and completely hardened, ~20 minutes. 







iv. Dissect to a state that would enable insertion of Tekscan sensors below the 
menisci. 
1. Dissect back the patella/patella tendon/quadriceps complex to expose the 
joint space. 
2. Remove any excess tissue to expose the lower edge of the menisci, both 
anteriorly and posteriorly. 
3. Lateral anterior: separate the long digital extensor (LDE) ligament from 
the lateral anterior meniscus by using a scalpel to gently cut underneath 
the ligament. 
4. Lateral posterior: remove the fat pad and dissect the muscle down from 
the femoral condyle towards the tibial plateau. 
5. It is necessary to sever the small attachment lateral posterior meniscal 
attachments that connects to the tibial plateau. The more prominent 











6. Use fishing line to secure the patella/patella tendon/quadriceps complex 
up to the femur 
 
b. If the knee has already been tested with Tekscan sensors: 
i. Cut the femur to 135mm from the joint line. Make sure that the proximal 70mm 
of the femur is free from all soft tissue to accommodate the cardboard tube for 





ii. Drill 3 wood screws into the distal femur shaft. 
iii. Pot the femur in Smooth cast (see step 1.a.iii above) 
iv. Use fishing line to secure the patella/patella tendon/quadriceps complex up to the 
femur (see image above). 
2. Prepare the MTS 
a. Attach 2000 lb load cell to upper actuator 
b. Turn on and warm up 
c. Upper fixture: Thread cup into 2000 lb load cell 
i. After cup is threaded in, zero the load cell. This only needs to be done once! 
d. Lower fixture: Set up parallel cross-bars with rotating angle uniaxial fixture. Insert potted 
bones into fixtures, femur in upper fixture and tibia in lower fixture.  
e. Adjust the angle of the lower fixture so that the tibia is at 90º of flexion relative to the 
femur.  
f. Tighten down all fixtures (including the screws of the cup) and ensure that the load cell 
reads zero (indicating the knee is not being tensioned or compressed). 
 
3. Anterior drawer test 
a. Open MTS program: Ovine whole knee_AD. 
b. Apply a 5 N preload by manually moving the actuator upwards to ensure fixture 
alignment. 
c. Hit run on the MTS program. 














ii. When the load cell reads 50 N the displacement wills top and the program will 
hold for 10 seconds. 
1. Expect ~2mm of displacement if the ACL is intact or ~5mm of 
displacement if the ACL is transected. 
iii. Then the femur will displace downwards 10mm. 
d. When complete stop the program immediately and return the load to zero so no excess 




A.4.6 Ovine Stifle Stress Relaxation and Pull to Failure 
1. Prepare joint 
a. If knee has not been previously used: 
i. Cut both bones to 135mm from the joint line. Make sure that the proximal 
70mm of the femur and the distal 70mm of the tibia are free from all soft 
tissue to accommodate the cardboard tube for potting. 
ii. Drill 3 wood screw into the proximal end of the femur and 3 into the distal 
end of the tibia. It may be necessary to use a small drill bit to drill pilot 
holes. 
 
iii. Pot femur and tibia in Smoothcast. 
1. Cut a piece of cardboard tubing to 70 mm in length. 
a. Outer diameter: 55 mm, inner diameter 50 mm 
b. Peel layers of cardboard off the outside of the tube until it 
slides easily into and out of the cup of the lower MTS 
fixture. 
c. Cover base and sides of the tube with duct tape to ensure 
that resin does not leak out. 
2. Mix together equal parts of the clear and amber Smooth-Cast 321 
Resin 
a. Measure out each component in the sample cup with the 
yellow lid, mix together in a plastic cup. 
b. Stir aggressively and incorporate air. 
c. Continue stirring until the mixture warms slightly and small 
bubbles have formed. 




4. When Smooth-Cast is ready (when it is slightly warm) pour into 
the cardboard tubing. Leave some space at the top of the tube to 
allow for expansion during hardening. 
5. Allow to set until transparent and completely hardened, ~20 
minutes. 
6. Repeat steps 1-5 for femur. 
 
iv. Dissect knee of all tissue that connects the femur and the tibia except the 
ACL. 
1. Notably transect: PCL, MCL, LCL, all muscle, the lateral posterior 
meniscal attachment (connects to the femur) 
2. Menisci should remain intact if desired. 
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v. Determine length of the ACL (gauge length) by measuring from the 
posterior view of the knee in full extension. 
1. Use calibers. 
2. Measure from the top of the femoral attachment to the center of the 
tibial attachment. 
 
2. Prepare the MTS 




b. Turn on and warm up 
c. Upper fixture: Thread cup into 2000 lb load cell 
i. After cup is threaded in, zero the load cell. This only needs to be done 
once! 
d. Lower fixture: Set up parallel cross-bars with rotating angle uniaxial fixture. 
Insert potted bones into fixtures, tibia in upper fixture and femur in lower fixture.  
e. Adjust the angle of the lower fixture so that the tibia is at 60º of flexion relative to 
the femur. This ensures that the ACL is roughly vertical, aligned with the tibia 
and the axis of applied load. 
f. Tighten down all fixtures (including the screws of the cup) and ensure that the 
load cell reads zero (indicating the knee is not being tensioned or compressed). 
 
3. Stress relaxation test 
a. Open the MTS program: Ovine whole knee_SR 
i. Edit the program so that the relative end level of the ramp is equal to 3% 
of the gauge length. 
b. Apply a 5 N preload by manually moving the actuator upwards to ensure fixture 
alignment. 
c. Hit run on the MTS program. 










i. Program will strain to 3% strain at a rate of 2 mm/s and hold for 20 
minutes 
ii. When program is complete return to zero load and wait 10 minutes 
(recovery) before proceeding to pull to failure test. 
4. Pull to failure test 
a. Open the MTS program: Ovine whole knee_PTF 
i. Edit the program so that the strain rate is 1%/s based on the gauge length 
b. Hit run. 




A.4.7 Tekscan Equilibration and Calibration 
1. Turn on and warm up MTS. 
a. Refer to SOP: MTS – Bionix Model 370.02 Landmark Setup 
b. The built-in bottom load cell will be used to take readings. 
2. Setup calibration fixturing as shown: 
 
a. Use double sided tape to attach aluminum plates to the load cell and adapter. 
3. Connect the Tekscan sensor to the Tekscan handle 
a. Make sure the green light comes on to indicate a successful connection. 
 
4. Initiate the Tekscan software 
a. Open Iscan from the desktop. 
MTS to bath plate 
Extra wide 
Actuator 
Bottom load cell 
Aluminum 
plates with faux 
Green light 
MTS plate to bath plate 
233 
 
b. Press on sensors with your finger to make sure all the sensor rows and sensels 
light up. 
c. If an entire row or column of sensels is unlit, try reinserting the sensor into the 
handle. If the row or column still remains out the sensor may be damaged. 
5. Adjust sensitivity of Tekscan pressure sensors 
a. Sandwich Tekscan sensors one on top of the other between the faux leather on the 
aluminum plates. 
i. Make sure that the sensors are centered (as much as possible) between the 
plates 
 
b. Load the sensor to max pressure and adjust sensitivity. 
i. Load the Tekscan sensor to 2560 lbs (according to the load cell) which is 
the max allowable pressure for the sensors. 
ii. Click Tools  Adjust sensitivity and drag the slider bar up so the 
sensitivity is as high as possible without triggering one of the errors. Click 
OK. 
iii. Note the sensitivity value, it should be used for all subsequent tests with 
the sensor. 






6. Calibrate Tekscan pressure sensors. 
a. Load the Tekscan prong to the lowest load possible where all the sensels are 
loaded. 
 
i. Click Movie  Snapshot (or CTRL+H) to save the raw value readings. 
ii. Take note of the load (according to the load cell). 
iii. Save as a .fsx file (can open only in iScan software) 
1. Click File  Save movie as… 
2. Save the file in the subfolder “SxPy” where x corresponds to the 
appropriate sensor number and y corresponds to the appropriate 
prong number. 
3. Save as “SxPy_#” where # corresponds to the applied load. 
iv. Save as a .csv file (to process in Matlab or Excel) 
Drag this slider bar as high as 
possible without triggering an 
These two metrics should have 




1. Click File  Save ASCII… Then click OK button 
2. Save the file in the subfolder “SxPy” where x corresponds to the 
appropriate sensor number and y corresponds to the appropriate 
prong number. 
3. Save as “SxPy_#” where # corresponds to the applied load. 
v. Click File  New Recording (or CTRL+N) to start a new live session. 
b. Load the Tekscan prong sequentially to 100, 300, 500, 700, 900, 1100, 1300, 
1500, 1700, 1900, 2100, 2300, and 2500lbs (according to the load cell). For each 
load: 
i. Click Movie  Snapshot (or CTRL+H) to save the raw value readings. 
ii. Save as a .fsx file (can open only in iScan software) 
1. Click File  Save movie as… 
2. Save the file in the subfolder “SxPy” where x corresponds to the 
appropriate sensor number and y corresponds to the appropriate 
prong number. 
3. Save as “SxPy_#” where # corresponds to the applied load. 
iii. Save as a .csv file (to process in Matlab or Excel) 
1. Click File  Save ASCII… Then click OK button 
2. Save the file in the subfolder “SxPy” where x corresponds to the 
appropriate sensor number and y corresponds to the appropriate 
prong number. 
3. Save as “SxPy_#” where # corresponds to the applied load. 
iv. Click File  New Recording (or CTRL+N) to start a new live session. 
c. Process the .csv files using the Matlab code “Tekscan_calibration” to generate a 
calibration curve via linear interpolation fitting. 
i. Make sure that the “Current folder” in Matlab contains all 14 .csv files. 
ii. Take note of the graphs produced to ensure that the fitted calibration curve 





iii. Save the fitted calibration curve as a .mat file. 
1. In the Matlab workspace there should be a file name 
“calibration_fit”. 
2. Select the file, right click, then click Save as. 
3. Save in the subfolder “Calibration Fits” 
4. Save as “SxPy” where x corresponds to the appropriate sensor 




A.4.8 Ovine Stifle Joint Preparation for Tekscan 
7. Thaw frozen knee overnight at room temperature or for ~3 hours with limb in bag submerged in 
water. 
a. Knee should already be dissected of all excess skin and soft tissue, with knee capsule 
remaining intact. 
b. Make sure to note whether the limb is a right or left. 
i. The bulk of the calf muscle will be visible on the lateral side of the tibia. 
8. Prepare tibia for potting (NOTE: This step is only necessary if the limb will later be used for a 
tension test, such as stress relaxation or pull to failure). 
a. Cut the tibia to ~135 mm from the joint line. 
i. ~70 mm of the distal tibia should be free of all soft tissue 
ii. Drill screws into distal tibia so that they extend outward from the bone. 
1. May be necessary to drill a small pilot hole first. 
2. Stop when the tip of the screw is in the bone marrow canal. 
 
9. Drill fixture holes in femur. (NOTE: it is typically easier to drill the holes when the femur is 
cleaned of all soft tissue, as described in Step 5). 
a. Drill a 105 mm diameter hole just above the proximal attachment of the lateral collateral 
ligament (LCL).  
i. It may be necessary to remove some muscle tissue to expose the LCL attachment. 





ii. Place cardboard below the limb to catch the drill bit after it goes through the 
joint. 
iii. Place the knee on its side and make sure it is at an angle of near full extension (as 
much as possible, usually ~60º) 
iv. Use a small drill bit to create a pilot hole at the marked spot, and then use 
incrementally larger drill bits to enlarge the hole to its final size. 
1. Approximate drill bit size order (in mm): small pilot hole, 65, 85, 105 
2. Do not drill with a blue drop cloth under the limb it may get caught on 
the drill. 
v. The path of the hole should be parallel to the tibial plateau. 
1. The edge of the tibial plateau can be felt through the capsule to serve as a 
general guide. 
2. To keep the tibial plateau horizontal and prevent rotation of the condyles 
slightly elevate the proximal femur. 




b. Drill a second 85 mm diameter hole in the proximal femur 75 mm from the first hole. 
i. To guide the position of the second hole, insert the 10 mm bar through the first 
hole and hang the knee in in the upper MTS fixture and use the second hole array 




ii. It may be necessary to dissect some soft tissue from the bone at the place where 
the hole will be drilled. 
iii. During drilling a second person should brace the limb from below (“inside” the 
fixture). 
iv. Use a small drill bit to create a pilot hole at the marked spot and then use 
incrementally larger drill bits to enlarge the hole to its final size. 
1. Approximate drill bit size order (in mm): small pilot hole, 65, 85 
v. The second hole should be parallel (as much as possible) to the first hole. 
 
c. Position the knee in the upper MTS fixture to ensure the two holes enable insertion into 
the fixture. 
d. If the bars will not insert both insert in the fixture, it may be necessary to slightly enlarge 
the second hole further 
10. Pot tibia in SmoothCast 
a. Cut a piece of cardboard tubing to 70 mm in length. 
i. Outer diameter: 55 mm, inner diameter 50 mm 
ii. Cover base and sides of the tube with duct tape to ensure that resin does not leak 
out. 
b. Mix together equal parts of the clear and amber Smooth-Cast 321 Resin 
i. Measure out each component in the sample cup with the yellow lid, mix together 
in a plastic cup. 
ii. Stir aggressively and incorporate air. 
iii. Continue stirring until the mixture warms slightly and small bubbles have 
formed. 
c. Suspend knee so that tibia hangs straight into the cardboard tubing. 
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i. Use a hole in the array that is similar to one which would be used during testing 
and hang between two plastic bins. 
 
ii. When Smooth-Cast is ready (when it is slightly warm) pour into the cardboard 
tubing. Leave some space at the top of the tube to allow for expansion during 
hardening. 
iii. Allow to set until transparent and completely hardened, ~20 minutes. 
iv. Once the Smooth-Cast is hardened peel layers of duct tape and cardboard off the 
outside of the tube until it slides easily into and out of the cup of the lower MTS 
fixture. 
11. Dissect knee to gain access to medial and lateral hemijoints of the tibia. 
a. To hold the knee during dissection it may be helpful to put the potted tibia into the lower 
fixture and place the fixture on the benchtop 
b. Dissect back the patella-patella tendon-quadriceps complex to expose the joint space. 




c. Remove any excess tissue to expose the lower edge of the menisci, both anteriorly and 
posteriorly. 
i. Make sure to keep all major ligaments intact and to not damage the menisci. 
ii. Lateral anterior: Cut and remove the LDE tendon. 
iii. Lateral posterior: remove the fat pad and dissect the muscle down from the 
femoral condyle towards the tibial plateau. 
iv. It is necessary to sever the small attachment lateral posterior meniscal 
attachments that connects to the tibial plateau. The more prominent lateral 




12. Insert Tekscan pressure sensors 
a. Insert the Tekscan pressure sensor into the medial hemijoint. 
i. The sensor insertion is easiest to do when the rods are removed from the femur 
and the tibia is in the universal cup which is free to rotate, making it easy to 
move the joint as necessary for visualization. 
ii. Thread a green needle threader through the medial hemijoint, starting from the 
posterior aspect of the joint.  
 
1. Make sure to “aim” the needle threader under the medial meniscus. 
2. If necessary, when the needle threader emerges on the anterior aspect of 
the joint, use curved tweezers to guide the needle under the medial 





iii. Us the needle threader to pull a long piece of fishing line through the joint space 
and make sure it can be slid entirely under the meniscus. 
iv. Using a curved needle create a hole in the pressure sensor tab and tie it to the 
piece of fishing line that extends from the anterior aspect of the joint. 
1. Tie the knot tightly and make sure that it will not slip and over tighten. 
v. Use the fishing line to guide the sensor into the joint, pulling firmly but slowly. 
1. The best approach is to have the sensor enter the joint aimed slightly 
laterally (not straight posteriorly) and then rotate it so it exits the joint 
aimed slightly medially, so it follows the normal curve of the tibial 
plateau.  
b. Repeat sensor insertion process to insert Tekscan sensor into the lateral hemijoint. 
c. Once the sensors are inserted attach hemostats to the fishing line to prevent them from 
being pulled out of the joint. 
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13. Tie extra strength fishing line around the patella-patella tendon-quadriceps complex so it can be 
held up during testing. 







A.4.9 Ovine Stifle Tekscan Testing 
1. Turn on and warm up MTS 
a. Refer to SOP: MTS – Bionix Model 370.02 Landmark Setup  
b. Attach the 2000lb load cell to the upper actuator. 
2. Set up the MTS fixturing. 
a. Attach the lower universal (3 axes of rotation) cup fixture to the 8020 bars that extend 
over the top of the bottom load cell. 
b. Screw the threaded rod into the two pound load cell, and then screw the upper fixture 
onto the other end of the threaded rod. 
 
3. Position knee (with the Tekscan sensors in place) into the MTS fixturing 
a. Remove the tibia from the lower universal cup fixture. 
b. Insert the two steel rods through the holes in one side of the upper MTS fixture, then 
through the femur, then through the holes on the second side of the upper MTS fixture. 
i. May be necessary to rotate the fixture so the steel rods can be slid through, just 
make sure to rotate straight again one positioned. 
ii. This is where it is important to decide the angle of interest, and choose the array 
hole accordingly. 
iii. At this point, zero the load cell. 
Upper fixture 
Lower universal cup 
fixture 
8020 bars 




c. Lower the MTS actuator and gradually lower the potted tibia into the lower universal cup 
fixture. 
i. Stop lowering when a small negative load is read. 
d. It may be necessary to slide the plate attached to the universal cup fixture to the side to 






































i. Stop when the potted tibia is completely inside the fixture. 
ii. This allows the tibia to “settle” naturally into place. 
iii. At this point note the lateral position of the fixture using the ruler on the parallel 
bar stand. This same position should be maintained whenever the knee is tested 
(including in the destabilized position). 
Lower universal cup 
fixture slid to the right to 






e. Tighten down the bolts of the lower universal cup fixture to lock it into position 
i. Should see a small positive force, indicative of slight tension on the joint. 





iii. On the cardboard potting tube make a vertical mark with a marker. Note the 
position of the mark at each angle using the ruler on the cup. This position should 
be the same any other testing with the joint (such as in the destabilized 
condition). 
 
f. Zero the load on the load cell again. 
2. Tension the patella-patella tendon-quadriceps complex. 
a. Insert a 6mm rod (aluminum or steel) into the outer hole array, just above the distal femur 
rod. 




b. Insert another 6mm rod (aluminum or steel) into one of the holes in the column toward 
the front of the fixture. 
c. Attach a nylon strap to the washer on the patella-patella tendon-quadriceps complex and 
thread the nylon strap over the rods (as shown in the side-view schematic). 
 
d. Use a carabiner to hang a 10lb weight from the nylon strap. 
e. Make sure that the sensors are above the 10lb weight, so that if the weight accidentally 





f. Should see a 10-13lb positive load on the load cell. 
g. Load the joint until the load cell reads zero- this the “unloaded” joint condition. 
3. Initiate the Tekscan software 
a. Open Iscan from the desktop. 
b. Load the appropriate equilibration file.  
i. Click Tools  Load Equilibration 
ii. Select the equilibration file that corresponds to the correct sensor and prong. 
4. Load the knee and record the resulting raw value readings. 
a. Gradually load the knee to a set load (according to the load cell). 
b. Click Movie  Snapshot (or CTRL+H) to save the raw value readings. 
c. Save as a .fsx file (can open only in iScan software) 
i. Click File  Save movie as… 
ii. The file name should include the sensor number (and prong number if only 1 
prong is used), sheep number (O#), the limb (left or right), and the angle. 
d. Save as a .csv file (to process in Matlab or Excel) 
i. Click File  Save ASCII… Then click OK button 
e. Click File  New Recording (or CTRL+N) to start a new live session. 
5. Process the .csv files using the Matlab code “Tekscan_HP” to obtain pressure values. 
a. Make sure the “Current folder” in Matlab contains the .csv files to be analyzed.  








i. Mean and peak pressure, location of peak pressure, and the contact area from 
each prong. 
ii. Pressure map (in PSI) 
 
 
 
 
 
